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Opioid dependence has reached epidemic levels in the United States and around the world. With 
the increased prescribing of opioid pharmaceuticals and the influx of inexpensive heroin, the 
health care cost to society has topped $72.5 billion annually (Murphy et al., 2016). Opioid 
overdose deaths have now surpassed motor vehicle deaths and have tripled since 1990. In some 
age groups opioid overdose is the leading cause of death. This study seeks to analyze the only 
field that directly treats this primary brain disease: medication assisted treatment for opioid 
dependence. The three primary participants in this partnership include: (a) doctors and allied 
medical providers; (b) substance abuse counselors known in Washington State as Chemical 
Dependency Professionals (CDPs); and (c) clients affected by opioid dependence. Together they 
combine medical approaches and psychosocial counseling with clients to attain the goal of 
recovery. Attitudes and beliefs of these three groups of individuals vary, as do their views toward 
the medications currently being utilized in the treatment field. This study measures these 
differences and discusses the implications for clients, medical providers, and CDPs. It was 
hypothesized that differences in opinions across the three groups about medication assisted 
treatment, length of time clients should be on medications, and recovery limit positive outcomes.  
Data were collected via survey from more than 250 clients being treated for opioid dependency 
and from over 200 professionals (medical and counseling). Descriptive and comparative 
ANOVA and t-test statistics were used in the analysis.  Results indicate that there remain large 
differences in beliefs and attitudes among the medical providers, CDPs, and clients on key issues 
related to medication assisted treatment.  The gap appears to be especially evident when 
comparing the two professional groups who treat clients with opioid use disorder. CDPs and 




related to their beliefs about the use of medications. CDPs are generally less supportive of 
medication assisted treatment. Medical providers and CDPs disagree about the length of time 
clients should be on medications and the long term goals of opioid dependence treatments. In 
addition clients in opioid treatment programs that use methadone have significantly different 
views on many issues from those who use buprenorphine/naloxone (Suboxone®). Findings from 
this study can be used to improve the services provided to clients to increase provider awareness 
of the ways that attitudes and perceptions impact treatment outcomes.  The electronic version of 
this dissertation is at AURA: Antioch University Repository and Archive, 
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Medication assisted treatment in the field of opioid dependence is a growing field of 
major importance to the health of many patients who are addicted to prescription pharmaceutical 
narcotics, and/or heroin. The incidence of impairment for those people addicted to opioids has 
continued to rise at an alarming rate, with the results being catastrophic for individuals, their 
families, and overall public health.  The focus of this dissertation project has been on analyzing 
the three important individuals involved in the complex process of treating and overcoming this 
disease process: the physicians and medical providers, the chemical dependency professionals 
(future reference will be CDPs as they are certified in Washington state, however in other states 
addiction counselors may be known by other designations), and the patient who is opioid 
dependent and most affected by this disease. Together they make up the “three legged stool” of 
recovery from this debilitating illness. The importance of these three groups working together for 
positive outcomes cannot be overstated. Problems arise when medical providers, CDPs, and 
clients have divergent attitudes toward the appropriate use of various medications used in 
medication assisted treatment for opioid dependence. This study has collected and analyzed the 
attitudes, beliefs, and experience of these individuals as they relate to opioid dependence and the 
treatment and recovery process for the purpose of identifying convergences and divergences 






Chapter I: Introduction 
There is both a national and worldwide opioid epidemic occurring today.  The record 
number of prescriptions being written for painkillers, and the influx of less expensive heroin has 
proven to be a deadly combination.  Drug overdose deaths have more than tripled in the United 
States since 1990, and studies by the Centers for Disease Control and Prevention attribute more 
than half of those deaths to prescription painkillers (Paulozzi, Budnitz, & Xi, 2006). Many of 
these people are our nation’s most precious resource.  Our future leaders in the 15 to 24 age 
group remain the highest risk group for death due to overdose.  Treatment admission for opioid 
dependence has risen in some areas of the country to account for over 50% of all admissions 
(Volkow, Frieden, Hyde, & Cha, 2014a). 
The problem often begins with easy access to pharmaceutical prescription medications, 
mainly opioid based pain relievers. These are easily attained through raiding their parent’s 
cabinets, their grandparent’s cabinets or getting it off the street. Opioid dependence, however, 
does not just start with unlawful acquisition of prescription painkillers. One of my current clients 
reported to me, “I never would have thought that in five years I would be injecting heroin in the 
bathroom somewhere, in a bathroom stall, or finding dirty needles off the group and using them 
because I couldn’t find any cheaper needles” (personal communication, October 2015.)  Many 
people with opioid addiction journeys begin with simple back injuries, a trip to the dentist office, 
or some physical injury that results in an opioid prescription for their pain.  Opioids relieve pain 
and fill a medical need during and after surgeries, injuries, or throughout the rehabilitative 
process of many medical conditions.  However these same opioids that are prescribed for good 
intention and aimed at positive outcomes quickly become a trap of addiction from which people 





and soon people become dependent on the opioids just to feel normal because the physical 
withdrawal from opioids is one of the worst of all drugs. “I thought for sure I was going to die, I 
was puking, had  nausea & diarrhea, was experiencing hot and cold flashes, my entire body 
ached, and I felt like I had just contracted the worse flu In the world,” Alicia told me last week 
when I visited her in detox. 
People with opioid dependence speak with certain nostalgia much like a child speaks of 
their first puppy, when referring to their use of opioids. They say that opioid dependence is the 
hardest habit they’ve had to shake, and it works its way into your soul and has a grip on you in a 
way that is difficult to put into words. “Opioid addiction is like no other and it has the ability to 
grab a hold of you, not let go, and take control over your life,” Bob, a recovering heroin addict 
told me.  
 Opioid dependence is a major public health concern and remains primarily an untreated 
or undertreated medical condition in the United States.  It is estimated that in 2012 there were 
over 560,000 individuals who used heroin, but an even more alarming 11.4 million Americans 
that had non-medical use of prescription opioids (Scheibe & Week, 2016). The economic cost 
is estimated to top $21 billion a year and the far reaching human implications are even more 
staggering. Opioid dependency is associated with several well-known health risks including 
Hepatitis B, & C, along with an increased spread of HIV infection. This appears to be only the 
tip of the iceberg from the standpoint of opioid abuse and dependence as this modern epidemic 
continues to be on the rise in 2015–2016. Worldwide the scope of the current problem is even 
more alarming. The United Nations Office on Drugs and Crime notes that opioids, especially 
heroin, are the main problem drugs globally (United Nations Office on Drugs and Crime, 





Organization (WHO) estimates that there are 12.6 million injection drug users worldwide. 
Injection drug users represent the single highest risk for HIV infection. According to the Joint 
United Nations program on HIV/AIDS, injection drug use accounts for up to 80% of HIV 
infections in Europe and Central Asia (Mann & Tarantola, 1996).  
The medical cost and implications of opioid dependence are outweighed by the 
devastating social consequences that accompany this chronic disease process. Broken families, 
divorce, parentless children, incarceration, overdose deaths, child abuse/neglect, and 
socioeconomic ruin make up but a short starter list of what the opioid dependent individual 
experiences with their impulsive and compulsive pursuits. Opioids impact the brain, leading to 
temporary feelings of intense pleasure. Dependence to opioids can develop very quickly, even 
with minimal use. This opioid dependence can be physical, in that a habitual user’s body 
craves the drug. It can also be mental, in that a user consciously desires the drug’s effects. A 
person who is dependent on opioids may do whatever it takes to get more of the drug, 
regardless of the risks or consequences. The consequences of the opioid dependence are severe 
to both the individual who suffers from the disorder and to society. For individuals these 
include increased morbidity and overdose deaths, hepatitis C, HIV, liver failure, and infections 
and more. Psychosocially the impact is even great as people with opioid addiction lose their 
jobs, their families, their homes, and become involved in the justice system because of their 
involvement in illegal behaviors in order to support their dependence to opioids. The stories, as 
told through the eyes of those who are dependent, tell the true physical, emotional, and mental 
toll that their opioid dependence have caused.  James told me, “I have no life now, where once 





lost everything. My only hope is that I will get caught ripping off people and put in jail. It may 
save my life.”  
 The relapse rate and treatment outcomes for opioid dependence are very grim. Some 
studies suggest a 95% recidivism rate for people with opioid dependence that complete 
traditional treatment programs (Center for Substance Abuse Treatment, 2005). Medical experts 
and those working in the addictions field recognize the definition for opioid dependence from the 
National Institute on Drug Abuse (NIDA)—a chronic, relapsing brain disease characterized by 
compulsive drug-seeking and use despite harmful consequences and by long-lasting structural 
and functional changes in the brain. Since the problem is so large, the recovery rates so low, and 
the lifelong consequences so dire for both the individuals and society as a whole, the importance 
of continued research in this area to improve outcomes is paramount. The purpose of this study 
was to add to the body of knowledge related to this fast growing societal problem, and work to 
identify how the three most important players in this epidemic can work together to improve 
outcomes.  
 Medication assisted treatment for opioid dependence has been around for over half a 
century since 1962 when Dole and Nyswander carried out early research with morphine as a 
replacement therapy for opioid dependence (Dole & Nyswander, 1980).  Researchers quickly 
realized that morphine was not a good choice as a medication for opioid maintenance treatment 
because of the short half-life, and the decrease in social functioning and the sedating effects to 
patients. Methadone was shown to be effective in early trials and by the early 1970s became the 
treatment of choice for opioid dependence. Methadone maintenance treatment became a major 
public health initiative to treat opioid addiction. Dr. Jerome Jaffe headed the Special Action 





Dr. Jaffe's office oversaw the creation of a nationwide, publicly funded system of treatment 
programs for opioid dependence. Buprenorphine and naltrexone then joined the FDA’s approved 
list of medications for treating opioid dependence and along with methadone these now represent 
the current “big three” medications used throughout the United States and the world in 
medication assisted treatment (Fiellin & O'Connor, 2002). 
 Even though medication assisted treatment has been around for the past several decades, 
the rise in the opioid epidemic problem coupled with the approval of new medications has 
combined to substantially increase the number of people being currently treated by private 
physicians with buprenorphine/naltrexone and in opioid treatment program clinics that 
primarily use methadone throughout the United States.  Buprenorphine/naltrexone is known to 
the general public as Suboxone®.  However, Suboxone® is a brand name.  To avoid using a 
brand name and for ease of reference and understanding the generic shortened term, bup/nal, 
will be used throughout this paper to refer to this medication.  By some estimates the number of 
clients in methadone maintenance has remained stable over the last 10 years at around 200,000 
clients in the United States whereas buprenorphine, which has only been clinically approved 
since 2002, now boasts over 650,000 clients engaging in this form of treatment nationwide. 
Medication assisted treatment, despite its popularity and efficacy, continues to be challenged by 
old attitudes and traditional paradigms of “abstinence based addiction treatment” models. In 
2015 we can use all the technology, see the clinical trials of the efficacy of  medication assisted 
treatment, and addiction counselors, CDPs, social workers, and other health care providers still 
want to know when these clients will get off their medications and become truly “drug free.” 
The treatment and recovery issues that continue to surface reflect deep-seated attitudes that 





During data collection at the opioid treatment program that administers bup/nal in October 2015 
one client reported, “I think I want to get off suboxone because even though it has changed my 
life. I keep being asked by my family and my counselor when I am going to be drug free. Just 
when I am feeling stable and having the most time clean I have had ever, it feels like it is not 
good enough. I am tired of this and just want to not take it anymore [sic].” Clients have 
reported that they still feel stigmatized by being on this accepted form of medications, and that 
they get referred to as “weak-willed” or “unmotivated” because they are receiving medication 
assisted treatment. CDPs have also made statements that reflect their resistance in supporting 
their clients who attend the clinic and are on medications. At a recent workshop with over 200 
Washington State CDPs on the pros and cons of medication assisted treatment, the sentiments 
were captured in the following questions:  Why not teach people how to use drugs safely and 
not use pharmaceuticals? What is the long term goal of medication assisted treatment and when 
should clients be weaned off the medications? How can medication ultimately end the addiction 
process? Do clients really have to stay on these medications and why can’t they be taken off of 
them after they are stable? Isn’t the goal to be totally drug-free and don’t you think some of 
these clients are just using the medication as a crutch because they are not motivated to be 
clean? [Sic] (2014 Washington State Warm Beach Counselor Retreat). 
This is only a short list of the treatment issues involved, explaining why more research 
is needed in order to bring to light the underlying issues, biases, and attitudes of providers that 
are a key link in clients’ successful recovery. The three legs of this important stool are the 
(a) medical provider or prescribing physician and mid-level medical providers, (b) CDPs, and 
(c) opioid dependent clients who suffer and are looking to overcome the disease and get into 





ones that have been impaired and are facing severe life consequences, and they deserve 
individualized and professional support to overcome this affliction. If these three parties do not 
work closely together and share the same goals then positive treatment outcomes are not 
attained. The wide variety of training, professional backgrounds, personal experiences, and 
underlying biases represent one of the largest challenges facing these medical providers, CDPs 
and  their clients.  
Positionality 
 I have been a certified CDP in the state of Washington for the past 28 years. I have also 
worked as an addiction specialist and CDP for the Lummi Nation, a Native American sovereign 
nation located in the NW corner of the United States. I am currently the program director of the 
Lummi nation’s “Healing Spirit Clinic” opioid treatment program. We are a state and federally 
certified program that has been open since January 2013. The Healing Spirit Clinic is licensed 
to serve up to 500 clients, with a current client load of 356 active participants. All participants 
are required to meet criteria for “opioid dependence” based on DSM V criteria and must be 
enrolled as a Native American in a federally recognized tribe. We treat patients with 
buprenorphine/naloxone (Suboxone®) or naloxone only.  We do not treat with methadone. We 
are one of the only programs operating this way in the United States. Most opioid treatment 
programs operate as methadone maintenance programs and offer only methadone as their 
primary medication. There are over 1,200 of these clinics nationwide, yet only three that we 
know of offer the modality that the Healing Spirit Clinic does. I am involved as a member of 
the Washington State Association for the Treatment of Opioid Dependence. This unique role 
that our clinic plays in the opioid treatment field has been recognized by our colleagues. As a 





interested in how we are dealing with the opioid problem on the Lummi Reservation. We have 
quarterly meetings with our association and all other state opioid treatment programs to discuss 
issues relating to best practice, quality improvement, diversion, overdose, DEA compliance, 
current trends, clinical issues, and all other concerns related to our practice as opioid 
replacement providers.  
 Because of this position I am also offered a unique and integral perspective of treatment 
and recovery issues as they relate to opioid dependence. My current job offers me a front seat 
view of life in the trenches of opioid dependence and treatment, and due to my experience and 
background I interact daily with prescribing physicians, dosing nurses, clients, and addiction 
professionals (CDPs) that provide the psychosocial support in order to attain the goal of 
recovery and abstinence. The issues related to both treatment and recovery are complicated. In 
surveying the experiences and attitudes of what I call the big three (medical providers, CDPs, 
and clients) and emphasizing the importance of their forming a good working team, I am 
drilling down into the deeper core issues that are, in many cases, the barriers to better outcomes 
and compassionate care for affected individuals. 
I come from a training and experiential background that was philosophically built on a 
total abstinence mindset. The foundational beliefs and ways of practicing addiction treatment 
for the first 24 years of my Chemical Dependency Professional certification were seriously 
challenged. A major paradigm shift was necessary, along with an open mind and continued 
study in order to adjust to the challenges and changes that lie ahead. I needed to address current 
best practice and adjust to the state of opioid addiction treatment practices. I saw the difficulty 





new way of thinking. Using an opioid substitute to treat the substance abuse felt like cheating 
on a test and challenged the ethical and moral foundation of what I felt “recovery” was. 
Medication assisted treatment and traditional methadone treatment carried with it a 
stereotype of failed attempts to be clean and sober, and a settled philosophy of harm reduction. 
I was challenged to continue to change with the times or face being left behind and stalled with 
old ways of thinking. Doing this critical review of literature and research in the opioid 
treatment field aided positively to my ever-changing mindset. I learned that the various 
treatments were not meant to be in opposition to each other, and that I did not need to find out 
which treatment was more effective than the next, but rather how to individualize the treatment 
approaches to better serve those affected. 
One size does not fit all. I had many personal biases as I set about reading for this 
dissertation work and I soon discovered how misdirected my thinking was. I had failed to 
realize and understand a basic foundational principle that I now will call “recovery potential.” 
Much like the concept of human potential, recovery potential encompasses all that is possible 
for individuals in their personal and private journeys on the road to wellness. Dogmatic 
approaches that only saw complete and total abstinence from all substances in order to be 
successful in recovery were missing the mark. As a result of this research process I am a better 
Chemical Dependency Professional, more open-minded and understanding of each individuals 
struggle. It has helped me to better serve those who reach out, to have a more emphatic and 
compassionate approach, and to celebrate success with individuals who seek to change. I am a 
better and more rounded clinician now and have a better grasp on both the questions and 






There were five research questions for this inquiry:   
1. What attitudes, beliefs, and practices do medical providers, chemical dependency 
professionals, and clients have related to medication assisted treatment of opioid 
dependence?    
2. To what degree are the views and practices of each of the three groups different from 
those of the other groups? 
3. In what ways are the views and practices of medical providers, chemical dependency 
professionals, and clients similar or different?   
4. What underlying beliefs and philosophies explain the similar or different views of the 
three groups? 
5. What implications do these differences and similarities have for the opioid 
dependence treatment field? 
Based on my professional experience my hypothesis is that physicians and their opioid 
dependent clients are more accepting of medication assisted treatment than are CDPs. I have 
conducted a mixed method research design that utilized surveys that included both quantitative 
data and qualitative data collection and analysis. Medical providers and Washington State CDPs 
completed voluntary and anonymous surveys on line after being properly identified and invited 
to participate. Methadone and bup/nal opioid treatment programs clients were administered paper 
and pencil surveys at two participating clinics.  
Justification for Study 
  The most important part of opioid addiction and recovery is providing supportive and 





overwhelmingly strong grip of opioid dependence. The negative impacts of opioid dependence 
on one’s life, family, and the community one resides in are well documented. From reduced life 
spans, the spreading of communicable diseases, lifelong legal problems, destruction of the 
family unit, physical, medical, and moral degradation, just to name a few, opioid dependence  
shatters and diminishes lives.  
 Positive outcomes for opioid dependence continue to be the focus of opioid treatment 
centers throughout the United States and the world. Any factors that can aid in the 
understanding of this complex addictive dynamic will further positive outcomes. The interplay 
that takes place between the medical providers (doctor, physician assistant, and nurse 
practitioner), the active opioid dependent client, and the CDPs who provide psychosocial 
support is worthy of further study. Most reviews in the opioid treatment field concern 
themselves with the “effectiveness” of the medication involved in treating active opioid 
dependent individuals and the counseling approaches applied. Studies tend to look at positive 
outcomes regarding those patients who remain engaged in treatment services and who cut down 
their negative behaviors that are associated with using heroin or other opioids. This study aims 
to go a step further to focus on the underlying attitudes, beliefs, and mindsets of the three 
groups involved in the recovery process for opioid dependence. It is important that these three 
groups of people, who are working toward the common goal of recovery for the suffering 
individual, be on the same page on important and key issues regarding opioid recovery. As a 
28-year addiction professional and the program director of an opioid treatment program, I often 
hear the disparity in approaches and attitudes between these three groups.  For instance, CDPs 
often express the belief that clients should be taken off medications when they are doing well in 





medications and do not normally urge clients to discontinue medications. The suffering 
individuals are often caught in the middle of these divergent views and ultimately have to 
negotiate their way through this labyrinth of varying viewpoints.  
 The field of addiction counseling has its roots and foundation in a paradigm that demands 
complete and total abstinence from all substances in order to be considered “in recovery” from 
active addiction. This mindset is especially prevalent when it comes to medication assisted 
treatment and opioid dependence.  My research focuses on the similarities and differences in 
perspective about medication assisted treatment.  In my role as opioid treatment program sponsor 
and addiction specialist, I hear patients relate the mixed message that they encounter when trying 
to do what works best for them. Recovering addicts expose the negative beliefs, attitudes, and 
opinions that they encounter from a wide variety of people including their families, AA/NA 
members, non-medication assisted treatment physicians, and medical providers. Those who have 
substance use disorders have lots of experience with others who discriminate against them, put 
them down, judge them, and add to their already existing sense of personal shame for “being an 
addict.” They are sensitive to how others perceive or treat them, and so when they encounter any 
similar treatment from their counselors or doctors, it just becomes one more roadblock to 
successful recovery. 
 The current study was designed to uncover and study the underlying attitudes and 
beliefs that are held by medical providers, CDPs, and most importantly recovering opioid 
dependent individuals. While much has been studied about the drugs and treatment processes, 
the research gap lies in the lack of exploration into how the interaction between medical 
providers, CDPs, and those with opioid dependence, and their potentially divergent views, 





differences across groups.  The narrative responses to the open-ended survey questions were 
analyzed to address both addicts and those who work in concert for their recovery.  
Ethical Issues 
Strict measures were employed to assure confidentially and compliance with federal 
HIPPA laws for all survey participants. This survey was designed with specific focus to do no 
harm and to not engage participants with inquiries that might be upsetting or traumatic for them. 
The research design was focused on positive outcomes, treatment approaches that have worked 
well, areas of feedback for improvement of services, and exploring the underlying attitudes and 
beliefs that these three groups have about the dynamics of medication assisted treatment.  I have 
followed all Antioch University policy and procedures on research design and implementation 
including strict review and approval by Antioch’s IRB.  
Limitations of the Study 
 This study is conducted with a small segment of opioid treatment providers and their 
clients in the NW section of the United States; demographic and geographic markers of clients 
and their providers may not be similar to other populations or other cultural settings. The 
expected sample size was relatively small in comparison to the population affected and therefore 
could limit the generalization of results.  The field of opioid replacement therapy continues to 
grow and the issues involved in the treatment of this disorder become increasingly complex.  
Thus, longitudinal and in depth quantitative and qualitative studies could potentially yield 
important findings, but these approaches to research are outside the scope of this study.   
Value of This Research 
 As stated previously, the epidemic of opioid dependence continues to spread in the 





rising tide of heroin and prescription pain killer dependence is well documented. According to 
a recent article published by the Yale school of medicine SBIRT (Screening Brief Intervention 
& Referral to Treatment), “Opioid dependence is a major public health concern and remains 
primarily an untreated medical condition in the United States” (Schwarz, Zelenev, Bruce, & 
Altice, 2012, p. 2). The economic cost is estimated to top $21 billion a year and the far reaching 
human implications are even more staggering.   Worldwide the scope of the current problem is 
even more alarming. The United Nations Office on Drugs and Crime notes that opioids, 
especially heroin, are the main problem drugs globally (United Nations Office on Drugs and 
Crime, 2010).  Any additional or continued research in this important area of public health can 
be beneficial to all concerned. Understanding how differing attitudes and beliefs about 
medication assisted treatment effects patients recovery from opioid use disorder is crucial to 
helping improve client outcomes. The primary parties that I refer to as the “big three”— 
medical providers, CDPs, and clients—working together to address and overcome opioid 
dependence, require additional information and collaboration in order to be successful and 
increase successful treatment outcomes. This research focuses on those areas of cooperation, 
collaboration, communication, and attitudes and beliefs between the providers and those they 
serve.  Information and educational implications of this study are important contributing facts 
to the body of knowledge in the opioid treatment field.  
Definition of Key Terms 
Medication assisted treatment:  Utilizing opioid replacement medications along with 
psychosocial counseling to gain abstinence and obtain recovery from opioid addiction. 
Addiction specialist: A profession who has been trained to counsel and case manage clients 





place, addiction specialists are called Chemical Dependency Professionals, or CDPs.  
Naltrexone: A drug that is an endorphin and narcotic antagonist. It is available in both oral 
tablet form and subcutaneous injections for the treatment of alcohol and drug addiction. The 
brand name of the injectable form is vivitrol and will be used as synonymous for naltrexone.   
Methadone: A potent synthetic narcotic drug, that is less addictive than morphine or heroin and 
is used as a substitute for these opioid drugs in addiction treatment programs. It is also used for 
chronic pain management.  
Buprenorphine/naloxone (Bup/nal): A prescription medication containing a combination of 
buprenorphine which is a mixed opioid agonist/antagonist, and naloxone a pure opioid 
antagonist, used in the treatment of opioid and heroin addiction treatment. Brand names 
include Suboxone® , Zubsolv®, and Bunavail®. Generic forms are also available. 
Buprenorphine: A partial agonist, partial antagonist, with a “ceiling effect” making it harder to 
overdose or abuse than other opioids. Buprenorphine is a prescription opioid used for pain 
control and for people addicted to heroin or other opioids that acts by relieving the symptoms 
of opioid withdrawal and reducing cravings. Buprenorphine is less addictive and has a lower 
risk of overdose than methadone.  
Vivitrol: Pharmaceutical company brand name for naltrexone. As previously defined, is an 
opioid antagonist used as the hydrochloride salt in the treatment of opioid or alcohol addiction.  
Recovery: The return to a normal or health condition. Recovery describes the act and process 
of getting off addictive substances. Used in the alcohol and drug addiction treatment field to 
describe the process of being “clean and sober” or drug free and functioning well.  
Sobriety: The state or condition of being sober. Also a term used to describe the state of being 





Harm Reduction: A range of public health policies designed to reduce the harmful 
consequences associated with various human behaviors. In this context the term is used to 
describe the philosophy behind methadone treatment and opioid treatment programs.  
Journey to Wellness: A philosophy of recovery from addiction as defined by the Lummi tribal 
council in 2010. A philosophic approach to treatment that sought better outcomes and higher 
functioning that harm reduction philosophies.  
Abstinence: The process of abstaining from alcohol and other illicit drugs.  
Medical provider: Authorized and trained medical professionals that hold licensure to 
prescribe and oversee clients in treatment. Example includes Physician, Physician assistant, 
and Nurse Practitioner.  
Mid-level provider: Authorized and trained medical professionals that hold licensure to 
prescribe and oversee clients in treatment but such as physician’s assistants and nurse 
practitioners and who are no physicians.  






Chapter II: Literature Review 
 
This critical review of literature in the opioid dependency and treatment field covers the 
range of research that has been conducted in the field.  The literature discussed relates to the 
various forms of treatment for opioid dependence as well as well as the attitudes and beliefs 
about these treatments affect outcomes.    
Treatments 
One focus of this literature review looks at the various methods of treatment for opioid 
dependence, as well as their effectiveness and implications for the future. These treatments fall 
into three broad based categories: (a) no treatment, aging out, or spontaneous recovery; 
(b) psychosocial counseling; and (c) medication assisted treatment.  This last method is by far 
the most cited and researched to date and includes the most up to date and comprehensive 
view and philosophy of modern opioid dependence treatment literature. The treatment of 
choice for opioid dependence as it stands today usually includes a combination of counseling 
with medication assisted treatment in the form of (a) methadone, (b) buprenorphine, and 
(c) naltrexone, although there is not a consensus in the medical community on what constitutes 
the most effective treatment modalities (Amato et al., 2008). 
Natural Recovery or Recovery From Opioid Addiction Without Treatment 
Recovery from opioid addiction without any formal intervention or treatment is not a very 
popular concept in the opioid dependency field for several reasons.  The first reason is the dire 
and life threatening consequences of continuing what has been a well-documented downhill 
course of the disorder. Some question the ethics of advocating following this course of action. 
Given the severity and relapsing tendencies of opioid abuse and dependency, to stand by and 





death. Alternatively, some researchers suggest that opioid addicts simply cannot maintain the 
lifestyle and that the constant stress and energy it takes to continue this behavior will eventually 
lead to negative effects and untreated remission.  
Biernacki’s (1986) work summarizing recovery from opioid addiction is possibly 
outdated. Much has been discovered over the past 27 years, particularly in the field of 
neurobiology, including brain scans and the science behind how opioids change the brain 
pathways.  Biernacki (1986) cites even older work by Winick (1962) that suggests that young 
adults become addicted as a way to deal with life problems encountered during the turbulent 
time of adjustment to young adulthood and that their maladaptive response in the form of using 
opioids was merely a phase that most were able to stop on their own. Robins (1973) in her 
widely cited research on Vietnam War veterans, lent support to this line of reasoning as well. 
Robins was able to demonstrate that most Vietnam veterans that met criteria for opioid 
dependence (20%) were able to return to pre-war rates of societal opioid dependence of less 
than 1% without formal intervention and treatment. Robins made a case for the environmental 
and stress factors that led to the disorder, and showed how once veterans return to their home 
communities where opium was not accessible, where they had the support of family and friends, 
that their opioid dependence disorder went into spontaneous remission. Biernacki’s (1990) work 
was retrospective in nature, included no quantitative information and only three citations, 
possibly limiting its value. The researcher himself noted the limitations of his “relatively small 
sample size” (which was never quantitatively identified) and that the people located for 
discussion on these points came from the “snowballing method.”  In other words the researchers 
sought names of potential study participants from other self-identified opioid addicts who had 





Another prominently cited researcher in this field is Waldorf.  In the 1980s he published 
several articles where he spoke to the social and psychological process of untreated addiction 
and recovery and coined the term “natural recovery.” He also cited Robins’ (1973) research with 
returning Vietnam era opioid dependent soldiers. Waldorf (1983) cites social surveys with larger 
random samples (e.g., Odonelle et al., 1976; Brunswick, 1979) along with evaluations of 
chemical dependency treatment programs (e.g., Burt Associates, 1977; Macro Systems, 1975). 
Waldorf interviewed and surveyed 201 ex-addicts and addressed both the sample selection 
process and the inability to claim that his data were definitive in nature. His sample was not 
randomly selected and therefore caused him to reflect on what population, if any, his findings 
might represent. He spoke of three types of addicts: (a) ghetto or barrio street addict, (b) middle 
class addict, and (c) situational addict. Waldorf did not expand on these definitions nor did he 
classify the types of interview participants that he was citing in his research.  Thus, the 
“maturing out” idea postulated by Winick (1962) was not systematically tested and there were 
only three studies (i.e., Ball & Snarr, 1969; Snow, 1973; Vallant, 1966) that offered any type of 
empirical support to this idea and even these studies found the concept inconclusive.  
Maddux and Desmond (1979) followed up Winick’s (1962) work and made the argument 
that the maturing out thesis was based solely on records from the Federal Bureau of Narcotics 
and was “certainly unrealistically optimistic” (Vaillant, 1973). The general approach to research 
was exploratory and was not set out to test well-defined hypotheses with random samples of ex 
addicts. Data from Waldorf’s (1983) work was garnered from a combination of quantitative and 
qualitative methods.  Half (i.e., 100) of the participants were treated addicts while the other half 





participants were paid $20 to participate. Results showed six patterns of why people quit their 
opioid use that was contrary to the aging out theories that were being hypothesized.   
Opioid Dependence Recovery With Psychosocial Counseling 
“Drug rehabilitation” is the term commonly associated with the process of recovery from 
dependence on psychoactive substances. The term was coined in the 1960s with the formation 
of residential treatment programs, the origins of which date back to the 1930s with the 
publishing of the original self-help twelve step recovery approach used in Alcoholics 
Anonymous (AA). This original mutual aid support network helped lay the foundation for many 
of the concepts utilized in the drug/alcohol rehabilitation centers. These early approaches to 
addiction treatments did not address the medical nature of addictions and were fairly dogmatic 
in their philosophies of a total abstinence model of recovery. This AA phenomenon has spread 
worldwide and is credited by many, including well-respected researchers, to be the most 
effective therapy known for alcoholism and drug dependence (Seiberling, 1985). 
However, when it came to harder drugs, and substances that had a stronger 
physiological dependence like heroin and other opioid narcotic drugs, the positive outcomes of 
traditional approaches such as abstinence-only and non-medical counseling were not as well 
supported by research. The phenomenon of opioid dependence has been widely studied. In a 
search of Psycho INFO, over 18,000 articles were related to the topic (Mayet, Farrell, Ferri, 
Amato, & Davoli, 2004). The need to address the more complex dynamics and severity of 
addiction as it relates specifically to opioid dependence has brought about the entire field of 
medication assisted treatment. Psychosocial approaches of counseling and support toward a 
totally abstinence-based lifestyle have not shown good outcomes for opioid dependence 





been sometimes reported as high as 95%; however, some abstinence-based approaches that 
include psychosocial interventions have shown evidence of support for their effectiveness 
(Amato et al., 2008).  
Electronic searches of the Cochrane Library, MEDLINE (1966–2003), LILACS  
(1982–2003), EMBASE (1980–2003), and Psycho INFO (1872–2003) databases found over a 
thousand articles with these subject lines. The articles were identified and screened to meet 
criteria that conform to modern day treatments for opioid dependence.  It was a difficult task 
to separate pure counseling approaches since many of these studies included both a mixture of 
medication assisted approaches along with counseling and support. Adding to the difficulties 
in trying to make proper comparisons was the heterogenic nature of the population studied 
(inpatient, outpatient, jail settings, etc.). The most comprehensive and up-to-date meta-analysis 
of psychosocial approaches to opioid dependence was undertaken by “The Cochrane 
Collaboration” in 2010.  Their review, found through an exhaustive search of past and current 
literature on this subject matter, produced over 1,024 articles and references; however, using 
the criteria they selected for low bias and adequate allocation concealment, they ultimately 
settled on 16 articles. Their conclusion was that it was unclear if psychosocial treatments alone 
were an effective intervention or better than other approaches that offered both counseling and 
support along with pharmacological interventions. In addition, the diversity of psychosocial 
interventions available in the field of drug and alcohol dependence makes it very challenging to 
draw specific conclusions on the absolute effectiveness of these approaches. Psychosocial 
components of treatment and therapy have long been thought to be a major component of the 
holistic treatment approaches provided in both inpatient and outpatient drug treatment centers.  





settings, making the challenge of isolating effectiveness of the psychological therapy approach 
very difficult to evaluate. The current trend of opioid dependence treatments to involve 
pharmacological approaches is an impediment to evaluating treatments using only traditional 
psychosocial approaches. 
Treatment of opioid dependence is very complex and the range of treatment 
interventions is extensive. Research reviews addressing a combination of pharmacological 
approaches along with psychosocial therapies are far and away the most plentiful (Dawe et al., 
1993; Goldstein, Deren, Kang, Des Jarlais, & Magura, 2002; Gruber, 2000; Katz, Chutuape, 
Jones, & Stitzer, 2002; Zanis, 1996). The results of these studies cannot be pooled or 
summarized as they were very heterogeneous in nature.  
Since the onset of medication assisted treatments it is no longer ethically viable to 
conduct research on counseling-only approaches. With the outcomes so poor, there are serious 
ethical considerations in conducting research where only psychosocial interventions are 
explored. Therefore the following studies of psychosocial approaches were conducted with 
re-engaging or outreaching to dropouts from a methadone maintenance treatment program. 
As previously noted, heroin dependence is a chronic, relapsing illness where 
approximately 70% of all methadone maintenance treatment program clients relapse within one 
year following discharge (Alterman, 1996).  Many clients who have been discharged and 
constitute out of treatment patients resume high risk for various health issues like Hepatitis C, 
HIV infection, as well as criminal behaviors and a host of other dangerous behaviors. It is 
prudent that psychosocial approaches to re-enroll these high-risk users be employed. The 
methods employed in the Alterman article were to identify and reach out to 110 discharged 





identifying 110 former patients from a VA Medical Center’s methadone program that were 
categorized in four discharge types: (a) completed treatment, (b) transferred to other treatment 
programs, (c) voluntarily dropped out of treatment, and (d) involuntarily discharged. Subjects 
who were not re-enrolled in methadone maintenance treatment program services and were deemed 
eligible for the program (41) were randomly assigned to two treatment groups of either enhanced 
outreach counseling, or standard intervention conditions. The study found that after one year 
10% were deceased, 39% were already re-enrolled in treatment, and 7% did now require 
intervention or treatment.  Results were favorable for the enhanced outreach-counseling program 
where 67% were re-enrolled in the program within 2 weeks of the intervention, whereas only 7% 
of those in the standard referral condition were re-enrolled in treatment services. Based on a chi-
square analysis, and adjusted for Yates correction for continuity, the results showed a statistically 
significant difference between the two groups. The limitations of this study affected the ability to 
generalize the findings because of small sample size (110 screened for the study and only 40 
assigned to the two treatment groups).  Most in the sample were male veterans who generally 
have greater access to health insurance and treatment services. There also was no evidence to 
demonstrate the effectiveness this enhanced outreach program approach had at follow-up points. 
The enhanced outreach group was supported as a more effective form of getting clients engaged 
back into methadone medication treatment programs than the standard intervention conditions.  
However the “success” involved patients in forms of medication assisted treatment as well as 
psychosocial forms of opioid dependency treatment.  Thus, again there were few, if any, 
applicable research studies that solely identified and evaluated psychosocial approaches to 





The Katz et al. (2002) study described opioid dependence in the state of Maryland. 
Their study reported that a third of the admissions to substance abuse treatment programs 
were for opioid use.  Also noted in this important and often cited psychosocial treatment 
literature was the acknowledgement of the difficult and often-fruitless efforts of treating 
opioid addiction in a drug free modality because of poor retention and frequent relapse. A 
nationwide Drug Abuse Treatment Outcome Study (DATOS) reviewed retention data from 14 
outpatient drug free programs and showed that clinics only retained 50% of clients for the 
first 90 days, and an even lower 20% over 180 days (Simpson et al., 1997). In an effort to 
address these poor retention rates, the researchers enacted a monetary supported voucher 
system that would offer financial incentives for participating clients. Voucher systems had 
been used extensively for treatment of cocaine abusers (Higgins et al., 1994) and in 
methadone maintenance programs (Silverman et al., 1996). Since these voucher incentive 
programs were effective in previous trials, it was hypothesized that this approach could also be 
effective when used with psychosocial treatment modalities to increase both retention and 
successful outcomes for opioid dependent individuals. The financial incentives were 
significant in that individuals in the voucher treatment group could earn upwards of $1,807 
over three months for submitting urine negative for both opioids and cocaine. The results 
were somewhat disappointing as the researchers found no significant differences between the 
voucher group and non-voucher group on mean days retained in treatment, mean number of 
opioid and cocaine negative urine submitted, duration of continuous abstinence, or for 
percentage of participants abstinent for four weeks. Several rationales were theorized to 
explain the lack of successful outcomes, including that this study targeted users of both 





on single drug use stoppage.  In addition, the lapse and relapse dynamics that affect heroin 
addicts are different from those that affect cocaine abusers. Heroin users find it more difficult 
to abstain because of post-acute withdrawal effects and prolonged physiological cravings for 
the drug. Discussion continued in reference to drug positive urine samples at intake and how 
they were associated with program failure, suggesting that the voucher incentive program may 
be better suited for reinforcing motivation to stay clean, and not for becoming drug free. 
Dawe et al. (1993) also evaluated approaches of psychosocial counseling to opioid 
dependence and looked at a controlled randomized study that followed 186 subjects that 
employed a cue exposure technique. Their research was conducted in a residential treatment 
setting where controls were more tightly administered and controlled. Subjects were randomly 
assigned to one of two treatment settings, one with a drug dependence unit with a special 
10-week program and the other to a 4-week general behavioral treatment unit (control group), 
without cue exposure. Cue exposure is the introduction to stimuli associated with drug activity 
that is designed to elicit reactions that potentially lead to relapse.  In each setting subjects either 
had cue exposure for six sessions over the last three weeks or a control condition. Even though 
both groups did show significant decrement in cue-elicited cravings, withdrawal responses, and 
negative mood, the results did not support the cue exposure treatment modality and the authors 
expressed major reservations that this form of psychosocial treatment was an effective and/or 
practical form of intervention for opioid dependent individuals. 
Mattick, Breen, Kimber, and Davoli (2009) conducted research that attempts to 
validate psychosocial treatments and interventions without adjunctions to medication 
assisted forms of therapy. Retention in methadone maintenance treatment programs is 





et al., 2009). The study attempted to re-engage methadone maintenance treatment program 
patients in treatment using psychosocial approaches employed three approaches: (a) street 
outreach, (b) cognitive behavioral groups, and (c) individual counseling over a 3-month 
period. This study analyzed the impact these three alternative programs had on treatment 
re-entry (Goldstein et al., 2002). The most important study findings suggest that those 
individuals who attended two or more groups of the three interventions (street outreach, 
cognitive behavioral groups, and individual counseling) were more likely to return to 
methadone maintenance treatment programs during the six month follow up, and that it 
was possible to engage 87% of the dropout sample in some portion of the psychosocial 
intervention. The limitations however were that these re-engagement approaches were 
designed to get subjects back into medication assisted treatments using the opioid 
agonist methadone. Even though the designs were psychosocial in nature, the incentive 
and goal was to get subjects back onto a powerful opioid substitution medication, hence 
not a solely psychosocial form of treatment.  
As the comprehensive Cochrane collaboration (Mayet et al., 2004)  review of 
psychosocial treatment effectiveness for opioid dependence points out, there is a lack of 
evidence suggesting that this type of approach is effective for a disorder that has been 
described in the medical literature as a “brain disorder”(Koob & Le Moal, 2008).  In the 
plain language summary Mayet et al. (2004) stated  
Despite its wide use in clinical practice, no systematic review of effectiveness has 
ever been carried out.  My review demonstrates that there is inadequate evidence 
available to prove the effectiveness of psychosocial interventions alone for the 
treatment of opioid dependence or that they are superior to any other type of 






It appears that psychosocial interventions are an important strategy and a critical 
component of opioid dependence treatments, but only when combined with medications 
(Chambless et al., 1998). In critical analysis of the multitude of opioid treatment 
literature, counseling approaches, along with medication, continue to be considered best 
practice. 
Medication Assisted Treatments for Opioid Dependence 
It is well established that opioid dependence has (Louria, Hensle, & Rose, 1967) many 
destructive consequences that include not only medical complications, but also huge 
disruptions to a normal life course. Physiological, psychological, emotional, mental, family, 
and social consequences of this brain disorder (Leshner, 1997) are well documented and well 
researched. The bleak outcomes of traditional counseling approaches have demonstrated the 
unacceptable outcomes that traditional psychosocial counseling alone has provided to those 
afflicted. As a result researchers, doctors, and other healthcare professionals sought more 
effective treatment modalities. The long-term treatment goals began to shift away from the 
total abstinence paradigm toward a more practical, pragmatic, and effective way of treating 
opioid dependence. Outcomes started to become more focused on the importance in reducing 
negative health and social consequences and to improving the well-being and social 
functioning of those affected (Riley et al., 1999).  
 Medication assisted forms of treatment were introduced (Batki, Kauffman, Marion, 
Parrino, & Woody, 2008), originally in a very crude format as compared with the advanced 
therapies of today, back in the early 1900s when physicians used morphine and even heroin to 
alleviate cravings and withdrawal in a doctor supervised setting. The difficulties with these 





morphine. Afflicted patients needed to get a dose of medication every 8 hours. These forms of 
medication assisted treatments did reduce both drug cravings and physiological withdrawal 
symptoms for clients, but faced practical limitations since clinics and their staff could not be 
available 24 hours a day, 7 days a week. Searches for longer acting medications resulted in the 
use of methadone for that purpose. Methadone was developed in Germany back in 1937 in 
WWII because of the need to maintain a reliable source of opioid analgesic (Gerlach, 2004). 
Methadone was introduced into the United States ten years later in 1947 by drug 
manufacturers Eli Lilly and Company. Methadone is a synthetic opioid and acts on the same 
mu opioid receptor sites as heroin and other opioids and mimics the same effects. Methadone 
was found to be useful in the managing of severe and chronic pain because of its long duration 
of action, powerful effects, and very low cost. These three factors led to methadone becoming 
the widely used medication to assist in what is known today as medication assisted treatment. 
 Additional and significant literature in the field of opioid dependence is focused on the 
chemistry of the brain and lays the foundation for scientists and medical specialists to call 
opioid use disorder a “chronic brain disease” (Koob, 2009). The field of neurobiology 
continues to produce studies that demonstrate support for this theoretical orientation that seeks 
to uncover the mechanisms in the brain that are most effected by the use of opioids. Koob’s 
work in the field of neurobiology of emotions works to define what he refers to as the “dark 
side” of compulsivity in addiction. He has written and published numerous articles that help 
explain and understand the opioid dependent individual’s compulsion, obsession, and loss of 
control over their use of opioids. Koob describes the body’s homoeostatic process, where the 
neurological system always attempts and defaults to a place of normalcy. Examples of this 





has been disrupted by the addiction process. His theories include how the use of medications 
used to assist the opioid dependent person feel within this homoeostatic range.   Koob’s 
theories are considered at the leading edge of today’s current views of opioid dependence and 
advocate the use of medications to assist in the recovery process to satiated and repair these 
damages neuro pathways (Koob & Le Moal, 2005; Koob & Volkow, 2010). Another 
recognized leader in the field of opioid dependence treatment and a researcher that lends 
support for the use of medication to assist in the treatment and recovery process is Volkow 
whose body of work includes strategies for identifying and treating opioid use disorder 
(Compton & Volkow, 2006b). Volkow discusses the nature of addiction and points to recent 
advances in neurosciences that offer insight into the biological nature of the disease model 
(Baler & Volkow, 2006) and lends evidence to refute that addiction is simply a moral 
dilemma. The belief that people with opioid use disorder can simply “quit” using if they have 
determination and self-will to recover represents the moralistic view that many people hold as 
true.  McLellan’s work also focuses on mood states, and the underlying triggers for cravings 
and relapse with opioid dependence (CHILDRESS, McLellan, & O'BRIEN, 1986). Effective 
medical treatment for opioid use disorder must contain a component that includes current best 
practice the utilization of medications to assist in the recovery process. 
Today the evolution of additional medications beyond methadone has advanced to a 
more sophisticated and very well researched body of knowledge. Relapse rates of those who 
suffer from opioid dependence are cited at almost 95% with traditional psychosocial 
treatments. Those treated with opioid replacement therapy have shown rates of  
40–65% for maintaining complete abstinence from opioids. There are four medications used 





that all modern day opioid treatment programs around the globe adhere to. These opioid 
treatment program medications include: (a) methadone, (b) LAMM (Levo-alpha acetyl 
methadol), (c) naltrexone, and (d) buprenorphine/naloxone (bup/nal). 
Methadone. Methadone is a pure opioid agonist. It is classified as a synthetic opioid 
and as such is easily produced in a laboratory setting. Of the four medications listed as FDA 
approved for the treatment of opioid dependence methadone is the one that has been studied 
the most. The history of this medication is intriguing as it was synthesized in WWI and came 
into vogue as the preferred method of treatment for the burgeoning heroin addiction epidemic 
from the mid-1960s into the early 70s and spanned several administrations including the 
Kennedy and Nixon presidencies. As stated earlier, the early treatments for this affliction 
were to dose patients on heroin or morphine, but because of the short half-life of the drug, the 
demonstration of increased tolerance to patients, and the perceived public perception of the 
threat to the abstinence based treatments of the time; these trials and clinics were shut down 
by the U.S. Treasury Department through legal pressure, and inspections (Center for 
Substance Abuse Treatment, 2005). The early rationale for research into methadone was born 
out of the societal concerns in the areas of public health and safety, as well as the social 
ramifications of continuing to ignore the negative impact of the growing opioid dependency 
problems. Dr. Vincent P. Dole received a grant to establish the early research and investigate 
the feasibility of opioid maintenance treatment approaches. In preparing for this research, 
Dole read “The Drug Addict as a Patient” (Nyswander, 1956). Nyswander was one of the first 
of her medical colleagues that asserted these patients could be treated under a medical 
treatment modality typically used for patients with chronic diseases. She also forwarded the 





remission state in a short period of time, but rather that they would be more successful if 
maintained on opioid replacement therapy for extended periods. This was born out of her 
experience and work with opioid users who chronically relapsed and failed to make gains 
toward recovery without medication. Other chronic diseases responded to a continued 
reliance on medication, so why not extend that to the treatment of opioid dependence? 
Nyswander joined Dole’s research staff in 1964 and, along with clinical investigator Kreek, 
found that morphine was not a good medication of choice to treat patients because of the 
negative impact on social functioning due to the side effect of sedation, the short half-life of 
the drug that required several injections per day, and the onset of tolerance, thus increasing 
the dosage with no stable platform (Dole & Nyswander, 1980). This early research paved the 
way for methadone since the shorter acting options were eliminated and the focus became a 
longer acting substitute. Methadone also has the benefit of being effectively administered 
orally. The very first study was conducted on two patients who were previously maintained 
on morphine. Once baseline tolerance was established, patients demonstrated the ability to 
function normally without the anxiety of drug cravings, and the absence of self-reported 
withdrawal. The most important findings from the early methadone trials (Dole & 
Nyswander, 1980) were: 
 Patients did not experience euphoric, tranquilizing, or analgesic effects. Thus, they 
were able to more effectively socialize and work normally without incapacitation.  
 At the appropriate dosage methadone reduced or blocked euphoric and 
tranquilizing effects of opioid drugs (morphine, heroin, meperidine, and opium) 
even if patients tried to smoke or inject the drugs.  





methadone. Therefore, a therapeutic dose could be held constant for extended 
periods of time. 
 Methadone was effectively administered orally, eliminating the need for needles 
and demonstrating that patients could administer it one time a day. 
 Methadone took away opioid cravings, which were thought to be a major 
component of most relapses, and eliminated the physiological symptoms of opioid 
withdrawal, which most addicts would go to great lengths to avoid. 
 Methadone caused minimal side effects and researchers indicated that it was 
medically safe and non-toxic. 
The importance of this early and pioneering research cannot be overstated. By 1965 the 
initial research on methadone safety and efficacy was transferred to the Manhattan General 
Hospital in New York. Dole realized that his research would need to be independently 
evaluated and tested. Gearing (1970) was able to verify some of the early finding on methadone 
medication treatment by also demonstrating that once patients were stabilized on a dose of 80 
to 120 mg/day their social functioning improved, and they demonstrated improved 
employment, school attendance, homemaking, and decreased recidivism of legal difficulties. 
The positive effects to the community and larger society by having opioid addicts participate 
in the newly supported forms of medication assistance did not go unnoticed. 
Methadone maintenance treatment was the first widely used opioid replacement therapy 
to treat heroin dependence and remains the best-researched treatment for this purpose (Mattick 
et al., 2009). Even though it is the most widespread treatment in many countries, it remains a 
controversial treatment whose effectiveness has been disputed. The controversy swirls mainly 





medical providers do, or as a form of weak self-willed moral deficiency as many still prefer to 
view it. The Cochrane Collaboration conducted the most comprehensive critical review of the 
methadone treatment research literature in 2009. They concluded that the use of methadone for 
treatment of opioid dependence was effective and represented best practice in the primary 
treatment process for opioid use disorder.  
LAAM.  Longer acting alternatives to methadone were also explored and subject to 
critical review. LAAM (Levo-alpha acetyl methadol) was much like methadone in that it was 
classified as an opioid agonist and also classified as a DEA schedule II controlled substance. 
Thus it was under the same intense scrutiny and regulation for the handling, prescribing, and 
distribution as other schedule II narcotic drugs. LAAM was first developed in 1948 by German 
chemists as an analgesic (Finn & Wilcock, 1997). LAAM mimicked much of the positive 
effects that had been demonstrated by methadone in that it blocked the euphoric effects of 
opioids, suppressed the withdrawal effects, eliminated hunger/cravings for the drug, but also 
had the additional benefit of a longer effective schedule. LAAM can achieve the same effects 
as methadone but maintain that for 48 to 72 hours longer. This longer acting effect captured the 
excitement and imagination of those researching LAAM since its practical application had an 
obvious upside. LAAM demonstrated a longer biological half-life. Medications with a longer 
half-life remain in a patient’s system longer and allow clients to dose less often. This dynamic 
appeared to benefit clients and practitioners.  Patients could reduce their daily visits to clinics, 
as required on the primary treatment regime of methadone medication treatment, replace that 
with LAAM, and only be required to come in for dosing three days a week. This had benefits 
for both providers and patients alike; it reduced the dependence around the clinical model and 





community by eliminating “take home” dosing as is popular in most methadone clinics. By the 
late 1960s research interest in LAAM rose as clinicians saw it as a new alternative to 
methadone maintenance treatment. Between 1969 and 1981, more than 27 studies with over 
6,000 participants established LAAM’s safety and efficacy (Finn & Wilcock, 1997). These 
studies demonstrated LAAM as an effective alternative to methadone maintenance treatment 
and led to FDA approval for treatment in opioid replacement therapy in 1993 (Ducharme & 
Abraham, 2008).  
The entire body of evidence in LAAM research showed that this medication is as 
effective as, or even more effective than, methadone in maintaining abstinence amongst opioid 
addicts (Blaine et al., 1981). LAAM then became the first FDA approved medication that gave 
clinicians and patients a choice between methadone and LAAM as a form of treatment for those 
who were opioid addicted. Since LAAM differed from methadone, clinicians felt this new form 
of opioid treatment program medication could help those that could not be helped by methadone. 
Even though it was not thought of as the treatment of choice for affected patients, clinicians 
could now increase their success rates by identifying people who would benefit most from 
LAAM’s advantages. LAAM and methadone are metabolized differently. The most noticeable 
difference is the delay before the effects of LAAM can be detected and that LAAM remains in 
the body for much longer than methadone does (Fraser & Isbell, 1952). Since this became the 
first new research and discovery in the field of methadone maintenance treatment up until 1993 
for opioid dependency, it is important to note the advantages and disadvantages of LAAM as 
compared to methadone. 
Advantages of LAAM to methadone.  There are several advantages to LAAM, including: 





experiencing commuting problems to the clinic, and frees patients from daily 
dependence on the clinic. 
● LAAM gives a more stable dose across time, thus promoting a more normal 
feeling state than both heroin and methadone. LAAM does not produce the effects 
of euphoria from opioids, while at the same time blocking effects of both cravings 
and withdrawal which are thought to be one of the main precursors to relapse. 
● Federal regulations prohibit take-home privileges for LAAM, and thus it 
eliminates the negotiations between clinician and clients over that privilege. 
● LAAM reduces diversion opportunities. The clinic has tighter controls over the 
medication, which reduces potential harm to the community via abuse or overdose. 
 Disadvantages of LAAM to methadone.  There are several disadvantages to 
LAAM including:  
 LAAM can be difficult to adjust to as it can take up to two weeks for patients to 
reach a steady state. This discomfort can lead to treatment non-compliance and 
relapse. 
● Since it is a long acting opioid agonist, it should never be given more than every 
other day. If LAAM is taken more often than this, the drug will accumulate in the 
body and lethal overdose can occur. 
● Lack of daily contact can be seen as an advantage to some clients, but some 
clients need and benefit from daily contact and structure and for them less than 





● Since LAAM was a new and unfamiliar medication, anxiety at first is increased and 
some clients will need additional support and counseling in order to deal with this 
dynamic. 
● LAAM cannot be given to pregnant women as can methadone and also is forbidden 
for clients under the age of 18. 
Despite its advantages over the shorter acting and preferred treatment of choice, 
methadone, widespread usage was short-lived for LAAM. Even though it still remains an FDA 
approved therapeutic agent for opioid dependence, LAAM was discontinued in Europe in 2001 
due to concerns over life threatening cardiac dysrhythmias (arrhythmia or irregular heartbeat) 
(Jaffe, 2007). The manufacturer Roxane Laboratories discontinued LAAM, branded as Orlaam, 
in the United States in 2003. It was of interest that even though it passed many clinical trials in 
the years 1969–1980, LAAM was ultimately a very short lived alternative, and initial trials 
missed the longer term effects that became evident later. LAAM is no longer being used in 
opioid treatment programs. 
Naltrexone. The two most popular and widely researched medications for treating 
opioid dependence remain methadone and buprenorphine. However, naltrexone, a 
lesser-known medication, is also a form of medication assisted treatment. Researchers picked 
up an interest in naltrexone in the early 1970s and began clinical trials for efficacy and safety 
(Resnick et al., 1991). Naltrexone is an opioid receptor antagonist, meaning that this mediation 
occupies the opioid receptor sites in the brain without activating them. This effectively blocks 
all euphoric effects from the ingestion of opioids, making it meaningless to ingest heroin, 
morphine, demerol, and other narcotics. Naltrexone is the only pure opioid antagonist of those 





Pottash, & Gold, 1984). The primary use of naltrexone never caught on as a mainstream 
treatment due to several notable limitations. Some opioid treatment providers have found that 
naltrexone is useful for highly motivated patients who are detoxified, or no longer under the 
effects of opioids, and in need of additional support. This medication offers some relief from 
drug cravings, but is not helpful for withdrawal, and simply blocks the effects of opioids. 
Treatment compliance has been poor with long-term naltrexone therapy because it offers no 
relief of active symptoms of cravings and withdrawal (Mark, Kranzler, & Song, 2003). 
Naltrexone was also subsequently approved by the FDA in 1995 as a preventative treatment for 
relapse in alcohol dependent individuals (Malerich, 1999), and its use for alcoholics could 
actually be more beneficial than for opioid addiction (Haile, Kosten, & Kosten, 2008). A 
review of more recent research suggests that more studies are needed in order to show 
naltrexone’s effectiveness in treating opioid dependence and to compare it to the more popular 
and widely accepted opioid treatment program medications of methadone and buprenorphine 
(Minozzi et al., 2011). One of the drawbacks and limitation of naltrexone is that with oral 
administration it requires daily dosing. Clients that experience opioid cravings can simply skip 
a day’s dosage before they resume abusing their drug of choice. Clients best suited for this 
medication must be screened and followed carefully. Clinicians found that those who have the 
best chances of success with naltrexone are clients who have a very stable social/living 
situation and are highly motivated to quit the lifestyle and pursue recovery (Tucker & Ritter, 
2000). A critical review of the research on naltrexone was completed in 2000, and published as 
“Naltrexone in the Treatment of Heroin Dependence: A Literature Review” (Tucker & Ritter, 
2000).  The review found 649 articles published in English, however 326 were animal studies 





number of articles located, 91 were review papers while 29 reported on opioid withdrawal (12 
of them research trials). Thirty-seven naltrexone outcome studies, 12 of them controlled and 25 
open trials were found and reviewed. Noted by the authors were the absence of articles that 
dealt with actual patients and data. In addition, concerns were also noted regarding how this 
small amount of research generated so many “review” papers.  Review of this literature found 
several noteworthy issues and concluded that naltrexone is not widely accepted as a form of 
medication assisted treatment for opioid treatment programs and is underused for this purpose 
(O'Brien, Greenstein, & Woody, 1978) and as an opioid antagonist treatment it may only 
appeal to 5-10% of the opioid-dependent population (O'Brien, 1996). Explanations for poor 
patient acceptance rates include fear of withdrawal or the inability to withdraw from opioids, 
the need for an opioid free period prior to dosing of naltrexone, fear of the new drug and 
possible aversive effects, inability to cope with depression during the opioid-free period 
required before active dosing, lack of euphoria-producing properties, and lack of any sincere 
motivation to pursue a drug free lifestyle (Schecter, 1980; Schuckit, Schuckit, & Schuckit, 
1984). Retention rates in drug dependence programs are historically low with the exception of 
methadone maintenance treatment and are described in terms of initial reactions (first 2 weeks). 
Early attrition rates with naltrexone were found to be quite high (Fram, Marmo, & Holden, 
1989). Between 39% and 74% of participants left treatment by the end of the second week. 
Finally, abstinence rates were calculated and varied widely across studies depending on 
treatment regime and were measured by opioid positive urine tests (Hollister, Schwin, & 
Kasper, 1977; Judson, Carney, & Goldstein, 1981). Results and comparisons to other forms of 
methadone maintenance treatment were varied and difficult to ascertain given that the majority 





lean toward positive outcomes as compared with the other three medications reviewed and 
supports more randomized clinical trials for further research. New methods of administration 
and a longer acting form of naltrexone, given to clients with a monthly injection, showed 
promise with the branded “vivitrol” (Krupitsky & Blokhina, 2010), new to treatment specialists 
since 2005.  Research is limited and leans toward preferable treatment for alcohol dependent 
clients (Garbutt et al., 2005); however, some methadone maintenance treatment and opioid 
treatment programs are now examining the efficacy of using this long acting form of naltrexone 
in their treatment programs (Comer et al., 2006). Opioid substitution treatment will continue to 
employ naltrexone as a treatment option both now and in the future. Continued clinical trials 
are indicated and direction should be toward comparison studies with both methadone and 
buprenorphine employing randomized control groupings. 
Buprenorphine. Buprenorphine is a semi-synthetic opioid that was first indicated for 
use to control moderate pain in non-opioid tolerant individuals. Chemists in Britain in 1958 
began working to develop an over-the-counter analgesic through the simulation and 
formulation of a variety of opioid compounds. After years of work by chemists and animal 
trials a compound known as RX6029 began human trials in 1971, and by 1978 buprenorphine 
was released as an injection for pain in the UK with a sublingual pill to follow in 1982 (Martin, 
1979). Widely utilized in Europe as an opioid substitution treatment model in the 1990s 
(Fatseas & Auriacombe, 2007), the newest of the four medications reviewed for opioid 
substitution therapies gained huge and unprecedented support and growth initially in Europe. 
One of the proving grounds for the use of buprenorphine in opioid agonist pharmacotherapy 
was in France. Because of the combination of their open health care system and attitudes 





which covered 100% of the cost of treatment, France become very fertile ground to 
demonstrate the safety and efficacy of buprenorphine. The spike in overdose deaths prompted a 
national response to the offering of buprenorphine treatment by general practitioners. Studies in 
the United States were also noting a significant decline in overdose deaths due to heroin (Olsen & 
Sharfstein, 2014; Schwartz et al., 2013).  Since opioid addiction has become such a widespread 
phenomenon worldwide and many of those afflicted are not receiving or engaged in treatment 
services, ranging by some estimates from 70–85%, (Domingo-Salvany, Hartnoll, Maguire, 
Suelves, & Anto, 1998; Tang, Zhao, Zhao, & Cubells, 2006) any new discoveries in 
medication assisted treatment methods represent progress. By contrast methadone maintenance 
treatments have been in place for over 45 years and the number of patients being treated in 
specialized clinics has remained stagnant while the problem of opioid dependence has 
burgeoned (Inciardi & Harrison, 1999). With the onset of this newest medication the number of 
opioid addicts receiving formalized help has grown by some estimates to 65% of those affected 
(Bickel & Amass, 1995). 
Clinical trials for buprenorphine began in the European bloc countries as an opioid 
substitution therapy over 30 years ago in the 1980s. Since the introduction of buprenorphine the 
increased access to a less restricted form of medication fueled further interest and clinical trials 
in France, and other European communities (Resnick et al., 1991). Researchers recognized the 
potential to those afflicted by this chronic disease, and the advantages that buprenorphine has 
over methadone maintenance treatment, naltrexone, and LAAM (Reed, Glasper, Cornelis, 
Bearn, & Gossop, 2007). The initial and very positive trials on buprenorphine and the 
experiences of many office-based doctors in Europe pushed buprenorphine to the forefront in 





medical doctors in France were being allowed to prescribe buprenorphine for opioid agonist 
treatment without any specialized training. This trend began to challenge the long held and 
preferred method of pharmacological medication using methadone. Buprenorphine offered the 
advantage of being less dangerous for overdose deaths. Since buprenorphine was not a full 
opioid agonist and contained a partial mu antagonist it had a built-in ceiling effect that 
prevented overdose. Since it was also a less controlled medication and was widely and readily 
available, access for opioid addicts to this new form of medication-assisted treatment 
resulted in the number of clients being treated increasing from 15–30% to nearly 65% (San, 
Tremoleda, Olle, & de la Torre, 1989). A medication that was less dangerous to prescribe, 
more accessible to the masses affected by opioid dependence, coupled with favorable outcome 
studies (Giacomuzzi, Kemmler, Ertl, & Riemer, 2006) helped build a body of evidence to 
support buprenorphine as the medication of choice for many doctors, clinicians, and researchers 
(Auriacombe, Fatséas, Dubernet, Daulouède, & Tignol, 2004). 
Advancement and acceptance of buprenorphine in the United States for the treatment 
of opioid addiction was 7–10 years behind the progress of its international colleagues. 
American researchers however were taking note and began clinical trials of their own (Fiellin 
& O'Connor, 2002) that led to the FDA’s approval of buprenorphine for the treatment as an 
opioid substitution treatment in 2002. Another important decision and legislation in the United 
States that cleared the way for the method by which most buprenorphine is prescribed today 
was the Drug Addiction Treatment Act of 2000 (DATA 2000), that allowed the Secretary of 
Health and Human Services to grant waivers to physicians with specific training to prescribe 
and administer Schedule III, IV, or V narcotic drugs for treatment of addiction or 





drug, whereas the more tightly regulated methadone is a Schedule II narcotic. The designation 
asa Schedule III medication is very significant; it entails less stringent guidelines, controls, 
and prescribing ability, as well as increased access to use buprenorphine in both an office 
based and specialized clinic treatment setting. By some estimates the number of clients in 
methadone maintenance has remained stable over the last 10 years at around 200,000 clients in 
the United States whereas buprenorphine, which has only been clinically approved since 
2002, now boast over 650,000 clients engaging in this form of treatment nationwide (Center 
for Substance Abuse Treatment, 2005). 
A critical review of the research demonstrates that buprenorphine is as effective if not 
more so than methadone, LAAM, or naltrexone (Amato et al., 2008; Batki et al., 2008; Bickel 
& Amass, 1995). It represents the newest advancement in the field of medication assisted 
treatment for opioid dependent clients. Buprenorphine has undergone multiple clinical trials, 
double blind studies, and randomized trials beginning in 1986 and continuing today. The body 
of evidence continues to be demonstrated by researchers and clinicians and drug treatment 
policy has reflected this trend. It remains under some debate and scrutiny whether methadone 
or buprenorphine holds the most advantages and is most effective.  Research continues to bear 
out the advantages and disadvantages of each approach and when each medication is best 
indicated for individual clients. 
 Literature Summary 
Table 2.1 shows the major categories of treatment modalities for opioid dependence as 
outlined (no treatment, psychosocial counseling, and medication assisted treatments—
naltrexone, LAAM, methadone, and buprenorphine), the research authors, publication date, 






Research Studies Addressing the Four Opioid Addiction Treatment Modalities 
Type of Treatment Author Title Methods/Findings 
 
No Treatment “Ageing 
out”  
Waldorf, D. 1983 Natural Recovery from 
Opioid Addiction:  Some 
social-psychological 
processes of untreated 
recovery  
Exploratory “in depth” 
study.  Combination of 
Qualitative and 
Quantitative approaches 
with 201 ex-addicts.  
Selected via the snowball 
approach, exploratory 
research. Not 
representative of any 
population, restrictive 
generalization with no 
specific theories or 
hypothesis. Findings are 
“maturing out” concept is 
not sufficient to explain 
variations of opioid 
addiction and subsequent 
results  
Psychosocial Counseling  Katz EC, Chutuape MA, 
Jones HE, Stitzer ML 
Voucher reinforcement for 
heroin and cocaine 
abstinence in an outpatient 
drug free program 
Quantitative and 
Qualitative study involving 
52 participants who were 
Opioid Dependent. 
Randomly assigned to 
voucher or no voucher 
groups and enrolled in an 
outpatient drug free 
program. Participants were 
stratified on three 
variables. All participants 
recently completed 
Inpatient Detox. Findings 
did not improve retention 
or abstinence outcomes.  
Naltrexone (Vivitrol) oral 
or injection Opioid blocker  
Cornish, J. Metzger, D. 
Woody, G. Wilson, D. 
McLellan, T Vandergrift, 
B. O’Brien, C.  
Naltrexone 
Pharmacotherapy for 
Opioid Dependent Federal 
Probationers 
 
Quantitative study with 51 
volunteers randomly 
assigned to 2 groups. 
Limited sample size and 
sampling group. Good 
design, methods, & internal 
validity. Limitation for 
generalization due to 
sampling population being 
respondents on federal 
probation. Results indicate 
that naltrexone (oral) and 
counseling are effective in 
cutting down positive 
Urine drugs screens, and 
re-arrest.  
LAAM (Levomethadyl 
Acetate or Long acting 
Johnson, Rolley E; 
Chutuape, Mary Ann; 
A comparison of 
levomethadyl acetate, 
Quantitative study with 





Methadone) Strain, Eric C; Walsh, 
Sharon L; Stitzer, Maxine 
L; Bigelow, George E 
  
Buprenorphine, and 
methadone for opioid 
dependence 
participating in a single site 
randomized controlled 
study with four treatment 
groups. LAAM as 
compared to Methadone 
(low and high dose) and 
Buprenorphine. Stratified 
according to gender, age, 
marital status, & 
personality. Reviewed and 
cleared by IRB committee.  
Results LAAM along with 
Buprenorphine, and high 
dose Methadone 
substantially reduced use 






The Swedish methadone 
maintenance program: a 
controlled study 
Quantitative and 
Qualitative research study 
of Chronic IV Heroin 
addicts. Small sample size 
N = 34. Randomly 
assigned, however not a 
blind study. Ages of 
respondents only 20-24 
years old, limited ability to 
generalize results. Controls 
were loose. Results 
demonstrate support for 
Methadone for efficacy in 
treating Opioid addiction.  
Buprenorphine (Bup/nal)  Mattick RP, Ali R, White 




therapy: A randomized 
double-blind trial with 405 
opioid-dependent patients 
Quantitative and 
Qualitative study, mixed 
design. N = 405 
respondents in a 13 week 
randomized controlled 
double blind double 
dummy trial. Study took 
place outside US in 
Australia a different 
cultural/geographic 
context. Findings support 
Buprenorphine in its ability 
to suppress Heroin use and 
did not differ in the more 
popular medication 
Methadone, however 
retained 10% fewer 
respondents in the 
Buprenorphine group.  
Conclusion 
 The literature that covers treatment for opioid dependence dates back over 60 years and 
covers three main themes: (a) No treatment, aging out, or spontaneous recovery; 





and (c) Medication assisted  treatment. The field has been evolving since its inception in the 
1940s to the present state it is today. The early forms of intervention, treatment, and research 
included the argument that opioid dependent people would recover on their own with no formal 
intervention. Noted in the research literature of aging out or spontaneous recovery (Biernacki, 
1990) cited earlier work by Winick (1962) that suggested that opioid use was simply a 
maladaptive response and only represented a phase where most people were able to stop on their 
own. In today’s landscape doing nothing and waiting for people who have this brain disorder to 
simply deteriorate represents an unethical practice now that modern literature has noted the use 
of medications to assist in the treatment and recovery process as best practice.  
 The second and most popular mode of treatment for opioid dependent individuals was 
the traditional counseling and cognitive behavior treatments (CBT). These treatments become 
popular in the 1960s and did not address the medical nature of opioid dependence. Psychosocial 
approaches of counseling and support via 12-step support groups originally held great promise as 
had previously happened in the alcoholism recovery movement, however these treatment that 
were based on a totally abstinence-based lifestyle did not produce good outcomes (Flynn et al., 
2003). 
 The most well studied of all treatment approaches for opioid dependence included the 
use of medications to assist in the treatment and recovery process. LAAM (long acting 
methadone) is a medication that is no longer being used, is discontinued and not being 
manufactured due to severe and life threating side effects,  The first and most studied medication 
was methadone which has been studied in many clinical trials since its’ first use in 1947. 
Methadone became the primary medication utilized in the field of medications assisted treatment 





Suboxone® (bup/nal), underwent clinical trials and was approved for use in 2004 in the United 
States. Together methadone and buprenorphine/naloxone, or the term used in this study, bup/nal, 
represents the current accepted practice within the opioid treatment field. Medication assisted 
treatment as it has become known is no longer just a treatment option, but a widely accepted and 
utilized adjunct to most of today’s treatment of opioid dependence. The literature clearly shows 
an evolvement from earlier paradigm’s that did not demonstrate good client outcomes, to the 
current state of medication assisted treatment that utilizes methadone, buprenorphine/naloxone, 








Chapter III: Methodology 
This research project was a comparative mixed methods study with data collection 
focused on attitudes, beliefs, and practices of three groups of participants. These participants 
make up what is referred to as the “three legged stool” in the field of opioid addiction and the 
field of medication assisted treatment (MAT)—the prescribing medical providers, chemical 
dependency professionals (CDPs), and opioid addicted clients in treatment at methadone and 
bup/nal attitudes, beliefs, and practices in the opioid dependence treatment  field.  Analysis 
includes descriptive and comparative ANOVA statistics with post hoc analysis.  Quantitative and 
qualitative data were collected via a survey, and covered a range of research questions that the 
study has formally addressed. The method of research and how data were collected, as well as a 
deeper look into the participants, the survey itself, and how survey responses were analyzed are 
explored below.  
Study Design 
 A mixed method design was utilized for this review as both quantitative and qualitative 
data were collected and analyzed.  Mixed methods research designs offer several important 
advantages, particularly that combining both qualitative and quantitative paradigms strengthen 
the research and creates a stronger theoretical framework by providing two pathways of thought 
and a more robust design. This design also ensures that questions are answered in ways that a 
pure qualitative or qualitative approach would not allow for. The mixed method design is a more 
practical approach and fit for this study because it allows for information on both the frequency 








There are five research questions for this inquiry:  
1. What attitudes, beliefs, and practices do medical providers, chemical dependency 
professionals, and clients have related to medication assisted treatment of opioid 
addiction?    
2. To what degree are the attitudes, beliefs, and practices for the three groups different from 
those of the other groups? 
3. What is the variability on views related to treatment options within each group?  
4. What underlying beliefs and philosophies explain the similar or different views of the 
three groups? 
5. What implications do these differences have for each group of participants in the opioid 
addiction treatment field? 
Participants and Sample Size 
The population that is the focus of this study included medical providers, CDPs, and 
clients in both a methadone and bup/nal opioid treatment program in Washington State. The first 
category of respondents was medical providers, including prescribing physicians and physician’s 
assistants who are working in the field of opioid dependency treatment and medication assisted 
treatment settings throughout Washington State. Traditional training of medical providers leans 
toward a natural tendency to support medication assisted treatment. The scope of medical 
providers’ practice includes prescribing and adjusting medications, and advising clients about 
them. Providers have expressed concern that patients being treated under the current model are 
being negatively influenced by attitudes and perceptions of clients, their peers, and their CDPs.  





marginalized because they are not seen as being in recovery when they are on medications.  Or, 
that they are inherently weak because these have to rely on medications to assist them in the 
recovery process. The medical providers for this study were those who worked in Washington’s 
certified opioid treatment programs, and outpatient office based practices that were credentialed 
under the Federal DATA 2000 program to provide office-based medication assisted treatment.  
These providers are identified through several available databases that include membership in 
Washington state association of opioid treatment professionals, state board certified ASAM 
(American Society of Addiction Medicine) physicians, bup/nal and buprenorphine locater 
websites, and staff that work in methadone and buprenorphine clinics.  There are over 400 
medical providers statewide, with an expectation of between 50 and 75 responses to the survey.  
The second category of respondents were the CDPs, also known as certified addiction 
counselors, that professionally counsel  and oversee each opioid dependent client as well as 
clients with other addictions.  Many CDPs   were trained in an abstinence-only paradigm and this 
study was designed to measure and analyze their current attitudes, beliefs, and practices related 
to medication assisted treatment.  The CDPs in the study were certified in the state of 
Washington and credentialed through the Washington State Department of Health. They are the 
only certified professionals that are recognized and licensed to deliver addiction counseling and 
recovery services to any and all clients enrolled in chemical dependency treatment programs 
throughout the state.  A CDP must be working under the auspices of a state certified chemical 
dependency program as per Washington State Department of Behavioral Health and Recovery 
(DBHR) requirements. There are currently over 1000 credentialed CDPs in Washington State.  
Washington Department of Health (DOH) provided a list of all CDPs licensed in the State of 





status, and email contact information of all Washington State licensed CDPs. This list was used 
to contact CDPs and invite them to take part in the voluntary and anonymous survey sent to their 
email addresses and filled out on line utilizing Survey Monkey.  The goal for this study was to 
have at least 100 CDPs respond and I received over 200 survey responses from this group.   
The third category of respondents was those clients who had been diagnosed as opioid 
dependent and who were participating in one of two opioid treatment programs in Washington 
State. The first   was a methadone clinic where I spent two days collecting over 200 paper and 
pencil surveys. The second was a bup/nal clinic where I also spent two days collecting over 130 
paper and pencil surveys.   Clinic participants were an important element of this study.  Other 
studies have focused on treatment staff and addiction providers, while those that they serve have 
been left out of the study design.   Few studies have sought to collect and analyze data from 
opioid dependent clients about their medication assisted treatment attitudes and beliefs.  At the 
time of the study, there were 4,500 clients who were participating in opioid treatment programs 
statewide.      
Instrument of Measurement Population Survey 
The data collection instrument used for this research projects was a 21- (client) and 
29- (medical provider/CDP) question survey that  covered the topics of: perception/attitudes 
toward current medications, perceived effectiveness of medications, short and long terms goals 
of medication assisted treatment, length of treatment, views on weaning off medication, 
potential  drawbacks of the three primary medications (methadone, bup/nal, vivitrol) utilized in 
opioid treatment, preferred practices, and challenges facing providers and recovering opioid 





Statements related to attitudes, beliefs, and practices about medication assisted treatment 
had 6-point Likert-type response scales, including “strongly disagree” to “strongly agree,” “not 
at all effective” to “very effective,” and “not at all helpful” to “extremely helpful.”  Specifically, 
the issues covered were : respondents’ attitudes toward medication assisted treatment, how 
strongly they believe in the efficacy of current opioid treatments, which medication  is more 
effective, how long treatment should last, the drawbacks of each therapy, long and short term 
treatment goals, which approaches respondents find most helpful, and whether those receiving 
treatments experience shame, judgment or continued marginalization.   There were also several 
open-ended questions designed to encourage respondents to share their stories related to their 
attitudes, beliefs, and practices about medication assisted treatment for opioid dependence.    
Although the same core questions were asked of survey respondents from all three respondent 
groups, additional questions were also asked of each individual group. The survey also collected 
some demographic information, including age, gender, lengthy of time working in the opioid 
addiction field, type of treatment modality, and length of time in recovery.   This survey 
instrument was not limited to the most studied medication, methadone, but also included 
questions related to the most popular medications used currently—methadone, buprenorphine, 
and naltrexone (vivitrol).  
Data Collection Procedures and Participants 
Collection of survey data was completed in one of two ways, either a paper and pencil or 
online version.  Methadone and bup/nal clinic participants were surveyed at their opioid 
treatment clinic locations with paper surveys that were then entered into the statistical database. 
Electronic online surveys were used for both the medical providers and CDPs. Medical 





the two groups.  The survey instrument utilized an automated “skip logic” function to 
differentially move survey respondents into either medical provider or CDP specific questions 
depending on how they responded to this survey item.  In order to utilize electronic collection 
methods survey participants were sent an email with an embedded link giving them the context 
of the survey and inviting them to participate.  
Survey Monkey was used as the electronic collection method for medical providers and 
CDPs.  The medical providers and their emails are listed on a Suboxone® (bup/nal) physician 
locater websites http://www.buprenorphine-doctors.com/suboxone-doctors/Washington-WA.cfm 
and 
http://www.opiateaddictionresource.com/treatment/suboxone_treatment_directory/wa_suboxone. 
In addition, email contacts for medical directors of all Washington State certified opioid 
treatment programs were provided by the Washington State Opioid Treatment Providers 
Association.   The names and email addresses were downloaded unduplicated into an Excel 
spreadsheet and online surveys were sent to all available utilizing Survey Monkey.  
 The CDPs were located by contacting the Washington State Department of Health 
utilizing the public disclosure laws.  The health systems quality assurance public disclosure unit 
of the Washington State Department of Health provided a full database of all CDPs that were 
currently licensed and registered within the State of Washington.  The Department of Health 
provided me the list under their public disclosure policy and gave me permission to use the 
names and email to contact interested participants to fill out the survey. These CDPs were 
contacted in the same way as medical providers, through an email that includes an embedded 





Buprenorphine physicians were located through a public list as noted on the Substance 
Abuse and Mental Health Services Administration (SAMHSA) website locater list. Medical 
providers at state methadone clinics were also listed publicly through a common website and 
were located and contacted through an email survey introduction.  I  also followed up with direct 
phone calls to each Washington State certified opioid treatment program clinic and their medical 
providers to further inform them of this research project and invite them to participate in the 
online survey.  
The third group of participants was active clients in two identified state-certified 
chemical dependency programs.  The two opioid treatment programs supported the collection of 
paper surveys at their clinic sites—one was a methadone treatment center and the other one was 
a bup/nal treatment clinic.  Agency directors were contacted in order to obtain permission for the 
survey to be distributed and collected at each site. Strict confidentiality of all data was ensured as 
no client identifying information were collected or used in this research. Confidentiality and 
anonymity statements were also posted on the survey collection tables and embedded in each 
survey.  All agency IRB policies were followed throughout the collection process.  Collection of 
paper surveys from the clinic clients occurred in each clinic’s waiting room area where clients 
were waiting to be called in to take their medication. A work station with information about the 
research study and informed consents was set up in each clinic starting at 8 a.m. on the data 
collection days.  I spent two full days at each clinic collecting surveys, as my target collection 
was a minimum of 100 responses from each clinic.  Clinic clients were asked to volunteer to 
complete the survey [as they were passing through the waiting room area both before and after 
they received their daily medication.]   Procedures were established and followed that allowed 





without routing it through a third party.  The researcher provided chairs, clipboards, and pencils 
so that volunteers were allowed the time and ease to complete their surveys. Surveys collected by 
the researcher were stored in a locked storage cabinet. Paper and pencil survey data was 
manually entered into a Survey Monkey data file and then downloaded to Statistical package for 
the Social Sciences (SPSS) for analysis.   
This survey was tested by consulting with the Antioch Survey Research Group for clarity 
and general level of reading and understanding.  A pilot study was also conducted with three 
participants in each research group. An email was sent to three identified medical professionals, 
and three CDPs.  Paper client surveys were piloted by three staff members who are recovering 
from opioid dependence and were fully informed as to the purpose of the pilot study and signed 
an informed consent.  
Data Analysis 
Data analysis of all collected responses was undertaken utilizing a concurrent 
triangulation design (Creswell, 2014). The quantitative and qualitative data collection occurred 
concurrently through the survey and analysis began during the data collection phase. Field notes 
were also recorded during the four days of data collection at the two opioid treatment program 
sites.  Clinic participants were very vocal and outspoken in the waiting room areas as they 
awaited their daily medications while filling out surveys.  The data were collected in the same 
instrument, but the quantitative analysis was conducted before the qualitative analysis.  The 
qualitative data were used to help interpret the quantitative findings. Descriptive data were 
presented and analyzed for all closed-end survey questions.  The descriptive statistics included 
frequency and percentage distributions, as well as mean scores and standard deviations.  In 





hoc analysis and t-tests were made for: treatment settings, type of medication utilized in 
treatment, beliefs/attitudes toward medication assisted treatment, long/short term goals of 
treatment, length of time on medications, attitude on recovery status of clients, what forms of 
treatment are considered most effective, and measures of judgment/criticism and marginalization 
of clients receiving medication to assist in opioid dependence treatment and recovery.  
There were three groups in the study—medical providers, CDPs, and clients.  Clients 
were either methadone or bup/nal medication assisted treatment.  Responses from methadone 
clients frequently differed significantly from bup/nal clients.  For this reason, their responses are 
reported separately on the tables. A one way ANOVA with Tukey post hoc analysis was used to 
compare means scores for the medical providers, CDPs, methadone clients, and bup/nal clients.  
For some variables only two groups were compared; in this case a t test was used to test for 
significant differences across means. The tools used to collect and subsequently analyze data 
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Qualitative data were used to help describe and explain the nuances of the similarities 
and/or differences across groups.  Narrative responses to the open-ended questions were coded to 
reflect the major themes.  I coded in six phases in order to create established and meaningful 
patterns. These phases include (a) familiarizing myself with the data, (b) generating codes, 
(c) searching and identifying categories represented by the codes, (d) reviewing the categories 
for themes, (e) naming and defining the themes, and  (f) produce the final report of findings.  The 
Survey Monkey text analysis tool was used to assist in the narrative analysis. 
Key narrative data that add meaning and depth to the quantitative findings are shown in tables 







Chapter IV: Findings of the Study 
 This study investigated the attitudes, beliefs, and opinions of the three primary groups 
involved in the opioid dependence treatment process. Those answering surveys were medical 
providers in both office based practice and state certified (opioid treatment programs, chemical 
dependency professionals (CDP), and clients who were participating in an outpatient methadone 
or bup/nal opioid treatment program. Specifically, this study sought to understand the difference 
in attitudes and beliefs that these three groups held in regards to several key variables in the 
opioid addiction treatment and recovery process.  
 The three groups surveyed were (a) medical professionals (N = 43), including physicians 
and mid-level providers (physicians assistants and nurse practitioner); (b) CDPs licensed in 
Washington State (N = 199); and (c) active clients in either an outpatient methadone clinic 
(N = 199) or an outpatient bup/nal clinic (N = 137).  
Data Preparation  
 Client surveys collected at the methadone and bup/nal clinic sites were sorted and 
reviewed for completeness. Twenty-three (23) methadone client surveys and 14 bup/nal client 
surveys were only partially filled out and were therefore eliminated from the analysis. The online 
surveys submitted by CDPs included 56 that were only partially completed; these CDP surveys 
were also eliminated. All online surveys collected from medical providers were complete.  
 One variable required some recoding.  CDPs were asked to best describe the treatment 
program where they currently worked.  Six surveys were recoded from “other” to the category of 
outpatient treatment with no medication assisted treatment. These six surveys were 
re-categorized based on their narrative responses that indicated they worked in some form of 






 The client surveys were keyed into a digital database from the paper and pencil format.  
Thus, there were two databases—a medical provider and CDP database and a client database that 
included both methadone and bup/nal clients.  ANOVA analyses required having responses to 
similar questions from the different databases in one file.  Thus, data were moved into one 
master file for analysis.  
Demographics   
 The demographic data collected from all three respondent groups included their age 
category and gender. Other demographic data collected varied by group.  Medical providers were 
asked how long they had been providers in the opioid treatment field, their work settings, and the 
types of medications they utilized in their medication assisted treatment practice.  CDPs were 
asked how long they had been practicing in the addiction field as well as their work settings.  
Clients were asked the length of time they had been on methadone or bup/nal and in recovery.   
Age and gender for all three respondent groups. Medical providers were older than 
any of the other groups with over half (54%) reporting their age as 51 years of age or older.  
Medical providers also had a high percentage (28%) in the 60 or older category as compared 
with CDP’s (16%), methadone clients (5%) and bup/nal clients (4%). None of the medical 
providers were under the age of 30 and 46% were between the ages of 31–50 (see Table 4.1).  
The CDPs were somewhat younger than the medical providers, with 61% under age 51, 13% 
between the ages of 21 and 30, 24% between 31 and 40, and 24% between 41 and 50.  About 
39% were age 51 or older, with 16% age 61 or older (see Table 4.1). 
 The methadone clinic clients were fairly evenly spread across the 21 and 60 years old age 
groups, with 21% between 21 and 30, 30% between 31 and 40, 20% between 41 and 50, and 





The bup/nal clinic clients were largely younger with 2% under age 21 and 87% between the ages 
of 21-50.  Only 11% were over age 51 (see Table 4.1). 
Table 4.1 







N = 43 
CDPs 
% 




N = 199 
Bup/nal  
% 
N = 137 
18-20 years old    1.5 
21-30 years old   13.4 20.7 36.5 
31-40 years old  30.2 23.7 30.1 32.1 
41-50 years old  16.3 23.7 20.2 19.0 
51-60 years old  25.6 23.2 23.8 7.3 
61 or older  27.9 16.0 5.2 3.6 
  
 The respondent groups also varied by gender distribution.  The medical providers were 
predominately male (74%), with the other 26% female. The CDPs were more predominately 
female, with 66% females and 34% males.  Both the methadone and bup/nal outpatient client 
groups had more female participants (58% and 56% respectively) than males (42% and 44% 
respectively).  Based on clinic statistics, this is a percentage distribution that closely reflected the 
gender spread at the methadone (50% females and 50% males) and bup/nal (54% female and 










Table 4.2  






N = 43 
CDPs  
% 





N = 199 
Bup/nal  
% 
N = 137 
Female 25.6 66.5 58.0 55.9 
Male  74.4 33.5 42.0 44.1 
 
 Medical provider and CDP professional demographics.  Medical providers were 
asked how long they had been in the opioid treatment field, while CDPs were asked how long 
they had been practicing in the addiction counseling field.  CDPs reported a higher number of 
professionals practicing for less than one year (12%), however, in all other categories of 
experience the percentages were very similar between the two groups (see Table 4.3). 
Table 4.3 
Percentage Distributions for Length of Time as a Medical Professional in Opioid Treatment 
Field or as a CDP   





N = 43 
CDPs  
% 






Less than 1 year 7.0 12.4   
1 to 5 years 30.2 34.0   
6 to 10 years 16.3 19.1   
11 to 20 years 25.6 18.6   
21 years or more 16.3 16.0   
 
 Medical professionals were asked what type of opioid treatment setting they were 
currently working in.  They worked in a cross section of opioid treatment settings, with some 
providers working in more than one setting.  Medical professionals often work in more than one 





outpatient methadone clinic (14%), outpatient bup/nal clinic (62%), detox unit (24%), and other 
settings (23%), such as hospital addiction programs, family practice, residential treatment, pain 
management, and hospital emergency room (see Table 4.4).   
Table 4.4  
Percentages for Medical Provider Respondent Places of Work 
 
Medical providers 
Work setting   
Medical Providers 
% 




Methadone  Bup/nal  
 




   
Office based practice 
Bup/nal/Buprenorphine 
61.9    
Bup/nal program with Physician 
in an outpatient chemical 
dependency program 
23.8    




   
Detox unit 23.8    
Other 23.8    
Note.  Medical Providers often had more than one place of work.   
 Medical providers were also asked to list all the medications used in their current 
practice.  A large majority utilized bup/nal (92%), subutex (81%), and naltrexone/vivitrol (69%), 
while the minority (21%) used methadone in their medication assisted treatment.  Only a few 
medical providers (9%) identified other medications they used in their medication assisted 
treatment practice, such as Zubsolv®, Bunavil®, Butrans®, and Campral® for alcohol abuse. 






Table 4.5  
Percentages for Medications That Medical Providers Use in Their Medication Assisted 
Treatment Practice  
 
Medications  used in 
Medication Assisted Treatment   
Medical Providers 
% 












   
Buprenorphine (subutex) 81.0    




   
Methadone 21.4    
Other 9.5    
 
 CDP respondents worked in a variety of settings and were not limited to traditional 
methadone/bup/nal opioid treatment programs.  The majority (89%) of CDPs were not currently 
employed in a methadone/bup/nal clinic.  They either worked in an outpatient treatment program 
with no medication assisted treatment (29%), in an outpatient center that had a medical provider 
that prescribes bup/nal (30%), or in another chemical dependency treatment setting (31%), such 
as long and short term inpatient chemical dependency treatment programs, detox centers, 
outpatient agencies with co-occurring caseloads, drug courts, private practice, outpatient mental 






Table 4.6  















Methadone Clinic  9.6   
Bup/nal Clinic  2.0   
Outpatient Treatment with NO 




Outpatient Treatment with 





Other   30.8   
* Note.  A few CDPs had more than one place of work.   
 Client demographics.  Clients that were actively attending and participating in the 
medication assisted treatment for opioid dependency were asked about the length of time they 
had been receiving help from their particular clinics. Methadone clients were more than twice as 
likely to have been participating in treatment less than 1 year (56%) as compared with bup/nal 
clients (27%).  The highest percentage (42%) of bup/nal clients had been receiving treatment at 
their clinic for 2–3 years. About one-third of both methadone and bup/nal clients had been 












Table 4.7  
Percentage Distributions for Length of Time as an Active Client in Methadone and Bup/nal 
Treatment Programs  







N = 199 
% 
Bup/nal  
N = 137 
% 
Less than 1 year   56.3 27.0 
A few years (2-3)   12.1 42.3 
More than 3 years   31.7 30.7 
 Methadone clients (30%) were much more likely than bup/nal clients (7%) to be taking the 
medication for 6 or more years. Methadone maintenance treatment has also been used to treat 
opioid dependence for over 45 years. Bup/nal was approved by the FDA in 2004 for use in 
opioid treatment.  However, bup/nal clients (35%) were more likely than the methadone clients 
(20%) to be on their medication for 3-5 years (see Table 4.8). 
Table 4.8  
Percentage Distributions for Length of Time Methadone and Bup/nal Clients Have Been Taking 
Medication for Opioid Dependence    
 
Length of time on medication Medical 
Providers 
 





0–5 months   16.8 21.5 
6 months to 2 year   32.2 37.0 
3 year to 5 years   20.2 34.8 
6 years or more   30.3 6.7 
 
The majority of clients in both the methadone (88%) and bup/nal (98%) clinics identify 
themselves as being in recovery.  The methadone clients were more likely to be only somewhat 
sure (25%) about being in recovery.  Methadone clients were also more likely than their bup/nal 





appeared less clear and certain about their recovery status than did bup/nal clients (see 
Table 4.9). 
Table 4.9  
Percentage Distributions for Clients Belief They Are in Recovery From Opioid Dependency for 
Methadone and Bup/nal Clients    
 






N = 199 
Bup/nal  
% 
N = 137 
Yes, definitely   61.9 85.2 
Yes, somewhat   26.5 13.3 
No   11.6 1.5 
 
 
 Methadone clinic and bup/nal clinic clients were asked about the length of time they had 
been in recovery from opioid dependence.  Bup/nal clients reported being in recovery for longer 
periods of time, with 64% in recovery for one year or more compared to 52% of methadone 
clients.  All bup/nal clients reported themselves to be in some time linked stage of recovery, 














Table 4.10  
Percentage Distributions for Length of Time Methadone and Bup/nal Clients Believe They Have 
Been in Recovery From Opioid Dependence    
 











N = 137 
0–5 months   21.8 18.9 
6 months to 1 year   20.8 17.4 
1 to 2 years   17.8 29.5 
3 years or more   34.5 34.1 
Not in recovery   5.08 0.00 
 
 A large majority (79% and 92% respectively) of methadone and bup/nal clinic clients saw 
the treatment services they were receiving as having helped a lot. No bup/nal participants rated 
the treatment as not helpful and only a small percentage (1.4%) of the methadone clients saw the 
treatment as not helpful at all. Overwhelmingly all clients surveyed viewed their medication 
assisted treatment services as helpful (see Table 4.11). 
Table 4.11   
Percentage Distributions for Methadone and Bup/nal Client Perception of How Helpful 
Treatment Services 
 








N = 199 
Bup/nal  
% 
N = 137 
Helped a lot    79.5 92.7 
Somewhat helped   14.1 7.3 
Helped a little   4.8 0.0 






 As expected, almost all (99% and 98% respectively) clients in the methadone and bup/nal 
clinics surveyed self-reported being exclusively on the medication that their particular clinic 
endorsed.   
Attitudes Toward Medication Assisted Treatment 
 All three respondent groups were surveyed on a variety of opioid treatment issues in 
order to understand the similarities and differences in their attitudes toward medication assisted 
treatment.  The attitudes explored included important treatment issues related to progress in the 
OTP field, effectiveness of medications, length of time clients should be on medications, helpful 
components of treatment, and a variety of other issues as listed in the tables below.  
 The quantitative responses to the survey addressed three research questions about 
attitudes toward medication assisted treatment for opioid addiction.  These were:  
1. What attitudes, beliefs, and practices do medical providers, CDPs and opioid 
dependent, addiction counselors, and clients have related to medication assisted 
treatment of opioid dependence?   
2. To what degree are the attitudes, beliefs, and practices for the three groups different 
from those of the other group?  
3. What is the variability on views related to treatment options within each group? 
 There were significant differences across respondent groups for most variables.  Within 
the client group, the methadone and bup/nal clients also frequently had significantly different 
responses.  Thus, client group responses were broken out in the analyses by methadone and 
bup/nal client group.   
 Overall progress. Medical providers and CPDs were asked about their views on the 





Medical providers (M = 6.33) on a response scale of 1 (no progress at all) to 10 (great deal of 
progress) had a statistically significant more positive view of the progress being made in 
addressing opioid addiction than the CDPs (M = 5.32), t(1,235)  =  3.15, p = .002. Medical 
providers and CDPs were also asked about the effectiveness of the medications currently being 
utilized in the opioid addiction treatment field. Again, on a scale of 1 (not at all effective) to 10 
(very effective), medical providers (M  = 7.55) rated the effectiveness significantly higher than 
the CDPs (M = 6.08), t(1,235) = 5.8, p = .000 (see Table 4.12). Methadone and bup/nal clients 
were not asked these two overall rating questions. Results were statistically significant that CDPs 
rated both progress in the field and effectiveness of medications lower than the medical 
providers.  
Table 4.12  
Mean, Standard Deviation, and t-Test Results for Overall Progress and Medication Effectiveness 
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Supporting group response to opioid dependence issues.  Medical providers, CDPs, 
and methadone and bup/nal clients were asked to assess how well various supporting groups 





1(not at all well), 2(somewhat okay), 3(okay), 4(well), and 5(extremely well).  ANOVA results 
showed there were statistically significant differences across respondent groups for each 
supporting group, F(3,557) = 33.2, p = .000.  Post hoc analysis identified the specific respondent 
group differences at the p < .05 level.  With respect to how the physicians were doing in 
responding to needs of clients, bup/nal clients (M = 3.89) were most likely to see this group as 
doing well as compared  to methadone clients, CDPs, and physicians.  
Respondent groups were also asked how the counselors were doing at responding to the 
needs of opioid dependent individuals. ANOVA results showed there were statistically 
significant differences across groups F(3,545) = 18.3, p = .000.   Post hoc analysis showed that 
when it came to rating the counselors on the same response scale at the p = .000 level of 
significance the bup/nal clients (M = 4.03) were again more likely to view them as doing well 
compared to the methadone clients responses (M = 3.31) and the medical providers responses 
(M = 3.21).  At the same time, medical providers (M = 3.21) were significantly less likely than 
CDPs (M = 3.83) and bup/nal clients (M = 4.03) to see counselors as doing well. Medical 
providers did not rate the counseling as effective as did other groups, this has implications 
toward integrated care.  
Respondent groups were also asked how they felt their local communities were doing in 
responding to the needs of opioid dependent individuals. The mean scores for support from local 
communities for all groups were lower than for any other supporting group.  ANOVA results 
showed there was also a statistically significant difference across respondent groups 
F(3,550) = 13.0, p = .000.  Post hoc analysis showed that at the p < .05 level both methadone 
(M = 2.24) and bup/nal (M = 2.29) client groups responded more positively than either CDPs 





responding to their needs. Medical providers and CDPs did not have a good regard for how their 
local communities were doing in responding to the needs of affected individuals, suggesting a 
need for improvement in shared responsibility.  
 Respondent groups were also asked how the clients themselves were doing at responding 
to the needs of opioid dependent individuals.  ANOVA results showed there was statistically 
significant across groups F(3,544) = 32.7, p = .000.  Post hoc analysis again showed at that the 
p = .000 level of significance methadone (M = 3.06) and bup/nal (M = 3.42) clients were more 
likely to see clients responding better to the problem of opioid dependence as compared to the 
hired professionals.        
Respondent groups were also asked how family and friends were doing at responding to 
the needs of opioid dependent individuals  ANOVA results showed there was a statistically 
significant difference across respondent groups F(3,551) = 50.5, p = .000.  Post hoc analysis 
showed that at the p = .000 level of significance bup/nal (M = 3.46) clients reported higher mean 
scores on the family and friends response to the needs of opioid dependent individuals, than 
medical providers (M = 2.39), CDPs (M = 2.07), and methadone (M = 2.81) clients were less 
positive about the support of family and friends. Methadone clients were also significantly more 
positive about the support of family and friends than medical providers and CDPs. The medical 
providers and CDPs did not differ on this item. It appears that both sets of paid professionals 









Table 4.13  
Mean, Standard Deviation, and ANOVA Results for Overall Progress in Addressing Opioid 
Dependence Problems for Medical Providers, CDPs, and Methadone and Bup/nal Clients  
 
How Supporting Group 





(N = 43) 
CDPs 
(N = 199) 
M(SD) 
Clients ANOVA 
Results Methadone  
N = 199 
Bup/nal  






















































Length of time clients should use methadone or bup/nal.  Respondents were also 
asked about the length of time clients should use methadone or bup/nal to assist in the recovery 
process.  Medical providers, CDPs, and methadone clients were asked this question with respect 
to methadone.  Response options ranged from detox (less than 1 week) to as long as needed.  
Methadone clinic participants that were actively taking methadone as part of their treatment for 
opioid dependence, overwhelmingly (84%) responded that they should be allowed to take 
methadone for as long as needed. Only (3%) of methadone respondents answered that it was 
appropriate to take the medication less than 6 months.  Medical providers also largely (70%) 
supported that clients should be allowed to take methadone as a part of their treatment regime for 
as long as it was needed.  A much lower percentage (26%) of CDPs felt that methadone should 





the majority of CDPs (63%) thought methadone should be used for a shorter period of time, such 
as detox, or less than 1 week (13%), or stabilization, 1 week to less than 6 months (26%). CDPs 
consistently favored the use of medications for stabilization purposes only, whereas both the 
clients and their medication provider’s felts medications should be used for as long as needed 
(see Table 4.14). 
Table 4.14  
Percentage Distributions for Length of Time Clients Should Be on Methadone to Assist in Opioid 
Treatment for Medical Providers, CDPs, and Methadone Clients 
  
Length Time on methadone Medical 
Providers 
% 
N = 43 
CDPs 
% 




N = 199 
Bup/nal  
 
Detox (1 week or less) 7.0 13.4 1.0  
Stabilization < 6 months 2.3 25.8 2.0  
6 months to 2 years 7.0 24.2 9.2  
3 to 5 years 4.7 5.7 4.1  
For as long as needed 69.8 25.8 83.7  
No Experience  9.3 5.2 0  
 
Medical providers, CDPs, and bup/nal clients were asked the same length of time 
question with respect to bup/nal treatment of opioid dependence.  Again the response categories 
ranged from detox (1 week or less) to “for as long as needed.” Both medical providers (81%), 
and bup/nal clinic participants (83%) felt that it would be appropriate to utilize bup/nal to assist 
in opioid dependence treatment for as long as needed.  A much lower percentage (27%) of CDPs 
felt that bup/nal should be used for as long as needed.  CDPs were more likely to suggest bup/nal 
should be used for 6 months to 2 years (31%), stabilization—less than 6 months (25%), or 
detox—one week or less (10%). When the detox, stabilization < 6 months, and 6 months to 2 





bup/nal clinic participants’responses, and 57% of CDP responses.  CDP responses again favored 
stabilization only, whereas medical providers and clients felt medication use should be for as 
long as needed (see Table 4.15). 
Table 4.15  
 
 Percentage Distributions for Length of Time Clients Should Be on Bup/nal to Assist in Opioid 
Treatment for Medical Providers, CDPs, and Bup/nal Clients  
 
 




N = 43 
CDPs 
% 







N = 137 
Detox (1 week or less) 2.3 10.3  0 
Stabilization (less than 6 months) 0 25.4  4.5 
6 months to 2 years 14.0 31.4  10.7 
3 to 5 years 2.3 1.5  1.5 
For as long as needed 81.4 26.8  83.3 
No Experience  0 4.6  0 
 
Medical providers and CDPs were also asked about vivitrol, an opioid blocker, a third, but less 
frequently used medication in the treatment of opioid dependence treatment.  Medical providers 
and CDPs were asked about the length of time vivitrol should be used.  Methadone and bup/nal 
clinic participants were not expected to have a working knowledge of vivitrol. The same five 
categories were given as possible survey responses, ranging from detox—1 week or less to for as 
long as needed.  About 12% of the medical providers and 21% of the CDPs indicated that they 
had no experience with vivitrol.  Of those with experience with vivitrol, medical providers were 
most likely to support its use for longer periods of time, with 31% responding that 6 months to 2 
years was appropriate, and 52% indicating they indicating  that it could be used or as long as 
needed. A much smaller percentage of CDPs thought the longer time periods of 6 months to 2 





CDPs were more likely than medical professionals to respond that vivitrol should be used for 
less than 6 months, (34%) compared to (5%).  Even for naltrexone (vivitrol) that is a non-opioid 
medication that blocks the effects of opioids, CDPs did not favor its use for other than 
stabilization purposed.  Medical providers and clients again felt that this medication like all 
others should be used for as long as needed in the treatment and recovery process (see 
Table 4.16).  
Table 4.16  
Percentage Distributions for Length of Time Clients Should Be on Vivitrol to Assist in Opioid 
Treatment for Medical Providers and CDPs 
 
Length on Vivitrol Medical 
Providers 
% 
N = 43 
CDPs 
% 





Detox (1 week or less) 0 6.2   
Stabilization (less than 6 months) 4.8 27.8   
6 months to 2 years 31.0 17.0   
3 to 5 years 0 1.5   
For as long as needed 52.4 26.8   
No Experience  11.9 20.6   
 
The fourth medication that both medical professionals and chemical dependency 
professionals were asked to rate was buprenorphine (subutex). Subutex is basically the same 
medication as bup/nal without the mu partial agonist “naloxone” added.  Not surprisingly, since 
buprenorphine and bup/nal are very similar compounds, the results for this medication mirrored 
the responses groups gave about bup/nal. CDPs were more likely to agree to shorter use for 
detox (9%), for stabilization (29%) and for 6 months to 2 years (23%), compared to 5%, 12%, 
and 19% respectively of medical providers.  At the same time, medical providers were more 





(65%) whereas only 23% of CDPs thought that for as long as needed was appropriate.  All 
medical providers had experience with buprenorphine (subutex), while 14% of CDPs indicated 
they had no experience with this medication. Again identical results as compared to the other 
three medications surveyed, CDPs favored stabilization only. These consistent results have major 
implication in the treatment field (see Table 4.17). 
Table 4.17  
Percentage Distributions for Length of Time Clients Should Be on Buprenorphine (Subutex) to 
Assist in Opioid Treatment for Medical Providers and CDPs  
 





N = 43 
CDPs 
% 







Detox (1 week or less) 4.7 9.3   
Stabilization (less than 6 months) 11.6 28.9   
6 months to 2 years 18.6 22.7   
3 to 5 years 2.3 2.1   
For as long as needed 62.8 22.7   
No Experience  0 14.4   
 
Effectiveness of medications.  Medical providers and CDPs were also asked to rate the 
effectiveness of the four medications that are currently being utilized in medication assisted 
treatment for opioid dependence. The response scale was: 1(not at all effective), 2(not to 
effective), 3(somewhat effective), 4(effective), 5(very effective).   Medical providers were more 
likely than CDPs to view the two most frequently utilized medications, methadone (M = 3.98) 
and bup/nal (M = 4.44), higher in effectiveness. Medical providers (M = 3.98) were significantly 
more likely than CDPs (M = 2.99) to view methadone as effective, t(1,235) = 2.8, p = .000.  
Medical providers (M = 4.44) were also more likely than CDPs (M = 3.67) to view bup/nal as 





medications lower than did the medical providers. The only medication that CDPs were more 
likely than medical providers (M = 3.86) to view as effective was also the only opioid antagonist 
(blocker) and non-opioid medication, vivitrol, but the differences were not statistically 
significant. CDPs did not rate the currently available and widely used medications as effective 
compared with all other groups (see Table 4.18). 
Table 4.18  
 












(N = 199) 
M(SD) 






How effective is: 
Naltrexone (Vivitrol) 
3.86 (1.21) 4.15 (1.38)   .171 
How effective is: 
Methadone 
3.98 (1.28) 2.99 (1.31)   .000 
How effective is: 
Bup/nal 
4.44 (0.82) 3.67 (1.20)   .000 
How effective is: 
Buprenorphine 
(subutex) 
4.21 (0.80) 3.86 (1.42)   .126 
 
Who should be involved in decision to get off medications?  Survey respondents were 
asked how much they agreed that physicians, counselors, clients, or families should be involved 
in decisions related to getting off medications.  The response scale was: 1(strongly disagree), 
2(disagree), 3(somewhat disagree), 4(somewhat agree), 5(agree) and 6(strongly agree).   There 
were statistically significant differences of opinion about whether each of these supporting 
groups—physicians, counselors, clients, and family—should be involved in decisions about 





across responding groups about whether physicians should be involved in the decision, 
F(3,551) = 21.1, p = .000.  Post hoc analysis showed that at the p < .01 level of significance 
methadone clients (M = 3.35) had the statistically lower level of agreement about whether 
physicians should be involved in the decision to stop medications when compared to the other 
respondent groups—medical providers (M = 4.95), CDPs (M = 4.42), and bup/nal clients 
(M = 4.11). Methadone clients felt that they should be the ones to determine when they 
discontinue the use of methadone (see Table 4.19). 
With regard to counselors’ input into the decision to get a client off medications, there 
were again statistically significant differences across groups, F(3,535) = 12.3, p = .000.  Post 
hoc analysis showed that at the p = .000 level of significance the methadone clients (M = 3.42) 
were less likely than bup/nal clients (M = 4.20), medical providers (M = 3.85) and CDPs 
(M = 4.28) to agree that counselors should be involved in the decision to stop medication. Again 
methadone clients were most likely to favor their own input in deciding when to discontinue the 
use of methadone (see Table 4.19). 
Medical providers (M = 5.02), CDPs (M = 4.57), methadone (M = 5.20), and bup/nal 
(M = 5.07) clients groups all had their highest level of agreement that clients should be involved 
in the decision to stop medications.   Although they all agreed that clients should be involved in 
the decision, ANOVA results again showed statistically significant differences across groups, 
F(3,546) = 6.5, p = .000.  Post hoc analysis showed that at the p < .01 level of significance 
CDPs (M = 4.57) were less likely than the methadone (M = 5.20) and the bup/nal (M = 5.08) 
clients to agree that clients should be involved in the decision to stop medications. CDPs agreed 
that clients should be involved in the decision to discontinue medication but as statistically 





Medical providers (M = 2.60), CDPs (M = 2.34), methadone (M = 2.35) and bup/nal 
(M = 3.20) clients all tended to disagree that family members should be involved in the decision 
to stop medication.  Again, however, ANOVA results showed statistically significant differences 
across groups, F(3,506) = 9.6, p = .000 .  Post hoc analysis showed that at the p = .000 level of 
significance bup/nal clients (M = 3.20) were more likely than the other groups to agree that 
family should be involved in the decision. Bup/nal clients demonstrated a higher level of trust 
involving their families in decision about their medications (see Table 4.19). 
Table 4.19  
Mean, Standard Deviation, and ANOVA Results for Who Should Be Involved in Decision to Get 
Client Off Medications for Medical Providers, CDPs, Methadone and Bup/nal Clients  
Decision to taper off Medical 
Providers 
(N = 43) 
M(SD) 
CDPs 








(N = 199) 
M(SD) 
Bup/nal  
(N = 137) 
M(SD) 
Physician  4.95 (1.13) 4.42 (1.39) 3.35 (1.74) 4.11 (1.59) .000 
Counselors 3.85 (1.45) 4.28 (1.33) 3.42 (1.63) 4.20 (1.31) .000 
Clients in treatment 5.02 (1.30) 4.57 (1.42) 5.20 (1.56) 5.07 (1.36) .000 
Family members 2.60 (1.36) 2.34 (1.25) 2.35 (1.59) 3.20 (1.58) .000 
 
Helpfulness of treatment options.  Attitudes of all survey respondent groups about their 
perceptions of various components of the treatment process and their helpfulness was collected 
and summarized. The scale included the response options of: 1(not at all helpful), 2(not helpful), 
3(somewhat helpful), 4(helpful), 5(very helpful), and 6(extremely helpful).  ANOVA results 
showed there were statistically significant differences in opinions across respondent groups 
about how they viewed the helpfulness of various components of the opioid treatment process, 
F(3,555) = 25.4, p = .000.  Post hoc analysis identified which groups had significantly different 





Medical providers rated medications (M = 5.11) and a combination of medications, urine 
analysis, and counseling as very or extremely helpful (M = 5.53).  Medical providers also viewed 
involvement with 12 step support (M = 4.34) and counseling (M = 4.40) as helpful components.  
CDPs viewed counseling (M = 5.05) and the combination of counseling, medications, and urine 
analysis (M = 5.50) as very or extremely helpful.   CDPs rated medications alone (M = 4.44) a bit 
lower, but still helpful.  Methadone (M = 5.29) and bup/nal (M = 5.35) clients rated the use of 
medications as the single most helpful component of their treatment programs, followed by 
counseling, M = 4.13 and M = 4.97 respectively, and combinations of medications and 
counseling, M = 4.64 and M = 4.98 respectively. Methadone clients rated the 12 step (M = 2.83) 
support as the least helpful. 
Looking at each of the treatment options, with respect to counseling, overall ANOVA 
results showed there was a statistically significant difference across groups, F(3,563) = 22.9, 
p = .000.  Post hoc analyses showed there were several significant between group differences at 
the p < .01 level of significance. Methadone (M = 4.13) clients rated counseling as less helpful 
than the CDPs (M = 5.05) and bup/nal (M = 4.97) clients. Medical providers (M = 4.40) viewed 
counseling as less helpful than the CDPs (M = 5.05). Bup/nal (M = 4.97) clients rated counseling 
as more helpful than the medical providers (M = 4.40). Bup/nal clients and CDPs did not differ 
significantly with respect to the helpfulness of counselling. Medical providers and methadone 
clients saw the counseling components of treatment as less helpful than the counselors 
themselves.  
Medication. Overall, ANOVA results showed a statistically significant difference across 
groups on the helpfulness of medication, F(3,555) = 25.4, p = .000.  Post hoc analysis 





(M = 5.35), and methadone (M = 5.2) clients groups all rated the use of medications in the 
treatment process as more helpful than did the CDP (M = 4.44) group at the p < .01 level of 
significance. There were no significant differences between the medical providers and their 
clients with respect to the helpfulness of medications. CDPs again saw the use of medications as 
less helpful than the medical providers and the clients who used them to assist in treatment and 
recovery. Results are consistent with CDP attitudes and beliefs against the use of medications  
(see Table 4.20). 
Twelve step support and urine analysis drug screens. Overall, ANOVA results showed a 
statistically significant difference across groups on the helpfulness of 12-step supports, 
F(3,530) = 45.1, p = .000.  Post hoc analysis showed that at the p = .000 level of significance 
methadone clients (M = 2.83) viewed 12 step supports as a less helpful treatment component than 
medical providers (M = 4.34), CDPs (M = 4.45), and bup/nal clients (M = 4.13).  Post hoc 
analysis ratings on helpfulness of the urine drug screens were identical to the results noted for the 
12 step support. Methadone (M = 3.51) clients rated the drug screens statistically significantly 
lower in the helpfulness than did the medical providers (M = 4.79), CDPs (M = 4.75), and 
bup/nal clients (M = 4.71). Methadone clients did not see accountability via urine drug screens or 
attendance at 12 step support group meetings as helpful components of treatment (see Table 
4.20). 
Combination of counseling and medication. Overall, ANOVA results showed a 
statistically significant difference across groups on the helpfulness of the combination of 
counseling and medication F(3,545) = 8.1, p = .000.  Post hoc analysis showed that at the p < .05      






counseling and medication than medical providers (M = 5.09), CDPs (M = 5.20), and bup/nal clients 
(M = 4.98) (see Table 4.20). 
Combination of counseling, medication, and urine drug screen. Overall, ANOVA results 
showed a statistically significant difference across groups on the helpfulness of the combination 
of counseling, medication, and urine drug screens, F(3,542) = 50.1, p = .000.  Post hoc analysis 
showed that at the p < .05 level of significance both medical providers (M = 5.53), and CDPs 
(M = 5.50) viewed the combination of medication, counseling and accountability as more helpful 
than did both the methadone clients (M = 4.04), and bup/nal clients (M = 4.94).  The paid 
professionals see the combination of all forms of the treatment process as more helpful than did the 
clients who were the receivers of these services (see Table 4.20). 
Table 4.20  
Mean, Standard Deviation, and ANOVA Results for Components of Treatment That Are Helpful 





(N = 43) 
M(SD) 
CDPs 
(N = 199) 
M(SD) 
Clients ANOVA 
Results Methadone  
(N = 199) 
M(SD) 
Bup/nal  
(N = 137) 
M(SD) 
Counseling  4.40 (1.03) 5.05 (.99) 4.13 (1.53) 4.97 (1.02) .000 
Medication 5.11 (.73) 4.44 (1.25) 5.29 (1.09) 5.35 (.87) .000 
Accountability 
UA 
4.79 (.91) 4.75 (1.14) 3.51 (1.52) 4.71 (1.27) .000 
















Other client issues.   All survey respondents were asked about clients who are involved 
in the treatment process being negatively judged or not, being seen as not motivated. The rating 
scale was as follows: 1(strongly disagree), 2(disagree), 3(somewhat disagree), 4(somewhat 
agree), 5(agree), and 6(strongly agree).  
Negatively judged.  The respondent groups demonstrated a high level of agreement that 
people on medication for opioid dependence are negatively judged by others.  While there was 
concurrence that clients were negatively judged, there was also a statistically significant 
difference across respondent groups, F(3,565) = 15.2, p = .000.  Post hoc analysis showed that at 
the p < .05 level of significance methadone clients (M = 5.16) were more likely than medical 
providers (M = 4.65), CDPs (M = 4.61), and bup/nal clients (M = 4.30) to strongly agree that 
they were negatively judged. Methadone client’s felts more negatively judged than all other 
groups, and this is consistent with narrative responses as well.  
Opioid dependence a chronic disease.  ANOVA analysis showed a statistically 
significant difference across respondent groups on the issue of whether opioid dependence is a 
chronic disease, F(3,565) = 5.4 p = .001. Post hoc analysis showed that at the p < .01 level of 
significance medical providers (M = 5.83) were statistically significantly more likely than the 
CDPs (M = 5.32), methadone clients (M = 5.31), and bup/nal clients (M = 5.11) to strongly agree 
that opioid dependence is a chronic disease. All groups had strong agreement with this item, 
however medical providers strongly agreed at a higher rate.  
Client motivation to get clean.  All groups disagreed that people on medication for 
opioid dependency are not motivated to get clean.  ANOVA results showed statistically 
significant differences across respondent groups on the issue of motivation to get clean, 





medical providers (M = 1.74) more strongly disagreed that people on medications are not 
motivated than CDPs (M = 2.43). CDPs appear to question clients motivation to get clean more 
so than the medical professionals and clients themselves (see Table 4.21). 
Table 4.21  
 
Mean, Standard Deviation, and ANOVA Results Feeling Judged for Being on Medications for 













Results Methadone  
(N = 199) 
M(SD) 
Bup/nal  
(N = 137) 
M(SD) 
People on medication 
are negative judged 
4.65 (1.04) 4.61 (1.12) 5.16 (1.20) 4.30 (1.33) .000 
Opioid addiction is a 
chronic disease 
5.83 (.43) 5.32 (.98) 5.31 (1.12) 5.11 (1.04) .001 
People of medication 
are not motivated 
1.74 (1.07) 2.43 (1.30) 2.21 (1.54) 2.36 (1.44) .026 
 
Issues related to medication assisted treatment. There were also a variety of issues 
addressed related to the process of medication assisted treatment and recovery from opioid 
dependence. The response scale for this set of statements was: 1(strongly disagree), 2(disagree), 
3(somewhat disagree), 4(somewhat agree), 5(agree), and 6(strongly agree).   
Whether clients receiving medication assisted treatment are clean. ANOVA results 
showed statistically significant differences across respondent groups on the issue of whether 
clients on medication assisted treatment are clean, F(3,557) = 9.7, p = .000.  Post hoc analysis 
demonstrates that at the p < .05 level of significance CDPs (M = 3.91) were less likely to agree 
that clients who are on medication assisted treatment are clean when compared to the medical 
providers (M = 4.67), methadone clients (M = 4.46), and bup/nal clients (M = 4.62). CDPs did 





reflects a consistent belief about the role of medications in the process of opioid treatment and 
recovery.  
Whether medication assisted treatment should be time limited.  All groups were asked 
to rate their level of disagreement or agreement on the view that medication assisted treatment 
should be time limited. The rating scale was as follows: 1(strongly disagree), 2(disagree), 
3(somewhat disagree), 4(somewhat agree), 5(agree), and 6(strongly agree).  ANOVA results 
showed statistically significant differences across respondent groups on the issue of whether 
medication assisted treatment should be time limited, F(3,554) = 68.9, p = .000.  Post hoc 
analysis showed that at the p<.05. level of significance medical providers (M = 2.11), methadone 
clients (M = 2.12), and bup/nal clients (M = 2.90) were more likely to disagree and the CDPs 
(M = 4.27) were more likely to agree with the notion that medication assisted treatment should 
be time limited. CDPs as in other survey responses to items related to length of time on 
medications, again validated their belief that medications should be time limited and used for 
stabilization purposes only.     
Whether the long-term goal of medication assisted treatment should be to be off all 
drugs and medications.  The next statement asks for level of disagreement or agreement that the 
long term goal of medication assisted treatment should be to be off both illicit drugs and all 
medications. The rating scale was as follows: 1(strongly disagree), 2(disagree), 3(somewhat 
disagree), 4(somewhat agree), 5(agree), and 6(strongly agree). ANOVA results showed 
statistically significant differences across respondent groups on the issue of the long term goal of 
medication assisted treatment, F(3,548) = 22.4, p = .000.   Post hoc analysis shows that at the 
p < .01 level of significance medical providers (M = 2.48) were more likely to disagree with this 





(M = 3.93).  There was also a statistically significant difference at the p<.01 level between 
methadone clients (M = 3.70) and bup/nal clients (M = 3.93) as compared to CDPs (M = 4.53).  
Similarly, CDPs were also much more likely to agree with the assertion that the long term goal 
of medication assisted treatment is to be off both all illicit opioids and the medications used to 
assist in the treatment process. Methadone and bup/nal clients were are more likely to agree that 
the long term goal should be to be off medications as well, however at a significantly lower rate 
than the CDPs. Medical providers (M = 2.48) stand alone in their disagreement that the long term 
goal should be to be off all medications.   
Whether it is okay to stay on medication assisted treatment for life.  All groups were ask 
their agreement/disagreement on the statement that it is ok for clients to stay on medications for 
life if need be. The rating scale was as follows: 1(strongly disagree), 2(disagree), 3(somewhat 
disagree), 4(somewhat agree), 5(agree), and 6(strongly agree). ANOVA results showed 
statistically significant differences across respondent groups on the issue of whether it is okay to 
stay on medication assisted treatment for life, F(3,560) = 30.0, p = .000.   Post hoc analysis 
showed that at the p<.01 level of significance medical providers (M = 5.20)  that oversee and 
prescribe the use of medications for the treatment of opioid dependency agree that clients should 
be able to stay on medications for life if they need it as compared to CDPs (M = 3.64). 
Methadone clients (M = 4.92), and bup/nal clients (M = 4.37) also differed statistically 
significantly from CDPs (M = 3.64) on whether clients should be able to stay on medications for 
life if need be. Medical providers lead the way when it comes to beliefs about the use of 
medications and utilizing them for as long as needed and even for the rest of the client’s lives if 






Whether they support medication assisted treatment.  All groups were asked their 
disagreement/agreement about the assertion that they support medication assisted treatment. The 
rating scale was as follows: 1(strongly disagree), (disagree), 3(somewhat disagree), 4(somewhat 
agree), 5(agree), and 6(strongly agree). ANOVA results showed statistically significant 
differences across respondent groups on the issue of whether they support medication assisted 
treatment, F(3,557) = 22.1, p = .000 .  Post hoc analysis showed that at the p<.01 level of 
significance medical providers (M = 5.74), methadone clients (M = 5.66), and bup/nal clients 
(M = 5.32) agreed on their support of medication assisted treatment as compared to the 
somewhat lower level of agreement from the CDP group (M = 4.88). CDPs demonstrated less 
overall support for medication assisted treatment. These results continue to point to major 
differences in beliefs and philosophies between the CDPs and all other groups.  
Whether clients should be considered clean if they are off all medications.  Another 
survey item was rating the attitudes of all respondents on their opinions of clients in medication 
assisted treatment programs and whether those clients should be considered clean only if they are 
off ALL medications. The rating scale was as follows: 1(strongly disagree), (disagree), 
3(somewhat disagree), 4(somewhat agree), 5(agree), and 6(strongly agree). ANOVA results 
showed statistically significant differences across respondent groups on the issue of whether 
clients should be considered clean if they are off all medications, F(3,555) = 3.1, p < .05.  Post 
hoc analysis showed that at the p < .01 level of significance the bup/nal client group (M = 3.12), 
as compared to medical providers (M = 2.21), CDPs (M = 2.89), and methadone clients 
(M = 2.90). 
 Whether clients should be given a chance to get clean without medication.  The last 





dependence should be given the chance to get clean with the use of medications. The rating scale 
was as follows: 1(strongly disagree), (disagree), 3(somewhat disagree), 4(somewhat agree), 
5(agree), and 6(strongly agree). ANOVA results showed statistically significant differences 
across respondent groups on the issue of whether clients should be given the chance to get clean 
with the use of medications, F(3,547) = 26.2, p = .000.  Post hoc test results indicate that at the 
p < .05 level of significance CDPs (M = 4.83) had a higher level of agreement that clients should 
be given the chance to get clean without medication than medical providers (M = 4.18), 
methadone clients (M = 3.68), and bup/nal clients (M = 3.67). CDPs again appear to favor 



























Table 4.22  
 
Mean, Standard Deviation, and ANOVA Results Attitudes on Issues Related to Clients in Opioid 




(N = 43) 
M(SD) 
CDPs 
(N = 199) 
M(SD) 
Clients ANOVA 
Results Methadone  
(N = 199) 
M(SD) 
Bup/nal  
(N = 137) 
M(SD) 
Clients in MAT are 
clean 
4.67 (1.20) 3.91 (1.54) 4.46 (1.38) 4.62 (1.08) .000 
MAT should be time 
limited 
2.11 (1.36) 4.27 (1.75) 2.12 (1.42) 2.90 (1.46) .000 
Long term goal is to be 
off illicit opioids AND 
all medications  
2.48 (1.46) 4.53 (1.65) 3.70 (1.68) 3.93 (1.34) .000 
Okay for clients to stay 
on medications for life  
5.20 (.88) 3.64 (1.66) 4.92 (1.39) 4.37 (1.36 .000 
I support medication 
assisted treatment 
5.74 (.53) 4.88 (1.26) 5.66 (.78) 5.32 (.95) .000 
Clients should only be 
considered clean if off 
ALL medications 
2.21 ((1.56) 2.89 (1.72) 2.90 (1.82) 3.12 (1.58) .026 
Clients who seek 
treatment for opioid 
dependence should be 
given chance to get 
clean without meds 
4.18 (1.38) 4.83 (1.26) 3.68 (1.64) 3.67 (1.43) .000 
 
 
Challenges faced by clients.  Respondents were also asked about their perceptions of the 
challenges faced by those who are involved in the treatment and recovery process for opioid 
treatment. There were six possible responses: 1(not at all a challenge), 2(not too much of a 
challenge), 3(somewhat of a challenge), 4(a challenge), 5(a big challenge), 6(a huge challenge).   
Dependence on medication.  ANOVA results showed statistically significant differences 





p = .000.  Post hoc test indicate that at the p<.05 level of significance CDP’s (M = 4.71) saw being 
dependent on the medications as more challenging that both clients groups, methadone (M = 4.22) 
and bup/nal (M = 3.62), and medical providers (M = 4.16).  
Feeling shame.  Feeling shame by clients is an important factor in the opioid treatment and 
recovery process, so all groups were asked how much of a challenge shame is for clients on 
medication assisted treatment. The rating scale was as follows: 1(strongly disagree), 2(disagree), 
3(somewhat disagree), 4(somewhat agree), 5(agree), and 6(strongly agree).  ANOVA results 
showed statistically significant differences across respondent groups on the issue of whether 
clients feel shame, F(3,555) = 40.9, p = .000.  Post hoc analysis showed that at the p < .01 level of 
significance methadone clients (M = 3.52) and bup/nal clients (M = 2.97) saw shame as less 
challenging than both the medical providers (M = 4.32) and the CDPs (M = 4.58).  
 Not being trusted.  Respondent groups were also asked about how much of a challenge not 
being trusted was for clients on medications assisted treatment. The rating scale was as follows: 
1(strongly disagree), (disagree), 3(somewhat disagree), 4(somewhat agree), 5(agree), and 
6(strongly agree). ANOVA results showed statistically significant differences across respondent 
groups on the issue of clients feeling of being trusted, F(3,555) = 25.4, p = .000.  Post hoc 
analysis, again showed that at the p<.01 level of significance both groups of clients, methadone 
(M = 3.60) and bup/nal (M = 3.07), rated not being trusted as less challenging than did their 
medical providers (M = 4.16) and CDPs (M = 4.45). Further analysis revealed that bup/nal 
clients (M = 3.07) saw not being trusted as less of a challenge than methadone clients (M = 3.60), 
medical providers (M = 4.16), and CDPs (M = 4.45), p < 000.   
 Not being understood.  Respondent groups were also asked about how much of a challenge 





follows: 1(strongly disagree), (disagree), 3(somewhat disagree), 4(somewhat agree), 5(agree), 
and 6(strongly agree).  ANOVA results showed statistically significant differences across 
respondent groups on the issue of clients not being understood, F(3,556) = 23.2, p = .000.  Post 
hoc analysis showed that at the p = .000 level of significance methadone clients (M = 4.11) and 
bup/nal clients (M = 3.32) were less likely than medical providers (M = 4.33) and CDPs (M = 4.64) 
to agree with this statement. Bup/nal clients (M = 3.32) also differed at significant than did medical 
providers (M = 4.37), CDPs (M = 4.64) and methadone clients (M = 4.11) (see Table 4.23). 
Being criticized. The last statement that respondent groups were asked about was how much 
being criticized was a challenge for clients on medications assisted treatment. The rating scale was 
as follows: 1(strongly disagree), (disagree), 3(somewhat disagree), 4(somewhat agree), 
5(agree), and 6(strongly agree). ANOVA results showed statistically significant differences 
across respondent groups on the issue of clients being criticized, F(3,553) = 16.2, p = .000.  Post 
hoc analysis again showed that at the p < .05 level of significance bup/nal clients (M = 3.63) 
were less likely to agree that being criticized was as much of a challenge when compared to the 
methadone group (M = 4.09) and the CDPs (M = 4.73). Both clients groups, methadone 
M = 4.09, and bup/nal (M = 4.09) were less likely than CDPs (M = 4.73) to agree about the 






Table 4.23  
 
Means and Standard Deviations for Challenges That Participating Clients in Opioid 
Dependence Recovery Face for Medical Providers, CDPs, and Methadone and Bup/nal Clients 







(N = 43) 
M(SD) 
CDPs 







(N = 199) 
M(SD) 
Bup/nal  
(N = 137) 
M(SD) 
Being dependent on 
medication 
4.16 (1.15) 4.71 (1.10) 4.26 (1.41) 3.62 (1.18) .000 
Feeling shame 
 
4.32 (1.01) 4.58 (1.08) 3.52(1.60) 2.97(1.50) .000 
Not being trusted 4.16 (1.21) 4.45 (1.21) 3.60 (1.67) 3.07(1.50) .000 
Not being understood 4.37 (1.15) 4.64 (1.15) 4.11 (1.60) 3.32 (1.48) .000 
Being criticized 4.28 (1.11) 4.73 (1.09) 4.09 (1.66) 3.63 (1.56) .000 
 
Views on medication assisted treatment.  Medical provider and n CDP respondents 
were also asked about their views on medication assisted treatment. A few (5%) CDPs stated 
they were against it.  The starkest difference however is that the CDPs have a much higher 
percentage of reservations (36% versus 13%) than the medical providers and medical providers 
have a much higher rate of complete support (80%) compared to the CDPs (43%). Medical 
















Table 4.24  
 
Percentage  Distributions for Level of Support for Medication Assisted Treatment for Medical 
Providers and CDPs 
 
Statements on MAT  Medical 
Providers 
% 











I am against using medications to 
assist in treatment 
0.00 5.53   
I used to be against MAT but now 
mildly support it 
0.00 3.02   
I used to be against MAT but now 
strongly support it 
6.67 6.53   
I am still unsure if I support the use of 
methadone/bup/nal for opioid 
dependence treatment 
0 5.03   
I support MAT but still have 
reservations 
13.33 36.18   
I totally support MAT for treatment 
of opioid dependence 
80.00 43.72   
 
Consistent with this view, CDPs also encourage their clients who are engaged in opioid 
dependence treatment to get off medications at higher rates than the medical providers that 
administer and/or prescribe these medications. More than one-third of the CDPs (38%) almost 
always or usually encourage clients to get off all opioid replacement medications.   Conversely, 
almost two-thirds (65.91%) of the medical providers only occasionally or almost never 
encourage their patients to stop their medications. CDPs encourage clients to consider 
discontinuing medications at much higher rates that those who are responsible for the medication 
decisions-the medical providers. Medication decision is outside the scope of the CDPs practice 






Table 4.25  
Percentage Distributions for Encouraging Clients to Get Off Medication for Medical Providers 
and CDPs 
 





N = 43 
CDPs 
% 






Yes, I almost always do this 11.36 16.58   
Yes, I usually do this 4.55 21.11   
Yes, I sometimes do this 18.18 13.07   
Yes, I occasionally do this 18.18 16.58   
No, I almost never do this 47.73 32.66   
 
  
 Pressure to get off medication.   Getting off of medications is a very central issue in the 
treatment process for bup/nal clients. Clients were asked if they experienced pressure to get off 
their medications. The rating scale was as follows: 1(strongly disagree), (disagree), 3(somewhat 
disagree), 4(somewhat agree), 5(agree), and 6(strongly agree).  
Pressure Bup/nal clients felt pressure to get off medication.  Bup/nal clients agreed on 
some level that they experienced pressure to get off their medications from family members 
(54%), followed by their medical providers (43%), friends (43%), and counselors (37%), They 
reported less pressure to get off medications by their CPS workers (36%) and probation officers 
(34%) when applicable. Bup/nal clients faced significant pressure to get off their medications by 








Table 4.26  
Mean, Standard Deviations, and Percentage Distributions for Bup/nal Clients Experiencing 
Pressure to Get Off Their Medications 
 














N = 126 
3.20 
(1.40) 
12.7 23.8 19.8 24.6 11.9 7.1 
My Counselor 
N = 127 
3.28 
(1.50) 
18.4 35.6 9.2 16.1 13.8 6.9 
Family 
Member 
N = 128 
3.40 
(1.50) 
13.3 18.8 14.1 31.3 14.1 8.6 
Probation 
Officer 
N = 87 
2.80 
(1.50) 
25.3 23.0 17.2 18.4 12.6 3.4 
CPS Worker 
N = 89 
   2.82 
(1.50) 
    25.8 23.6 14.6 21.3 7.9 6.7 
Friends 
N = 111 
3.14 
(1.60) 
18.0 23.4 15.3 21.6 12.6 9.0 
 
Pressure methadone clients felt to get off of medications.  Methadone clinic participants 
were asked if they had experienced pressure to get off their medication that was aiding them in 
the recovery process. Methadone clients agreed on some level that they felt pressure to get off 
their medications from family members (66%), followed by their friends (52%). To a lesser 
degree methadone clients also felt some pressure from medical providers (46%) and their 
counselors (37%) as well.  About half of the methadone clients had a probation officer (52%) or 
CPS worker (47%) and of those who did have these service workers about half (49% and 46% 
respectively) agreed on some level that they felt pressure from them to get off their medication. 





maintain abstinence from opioids is noted by the majority of methadone clinic participants. It is 
of interest that the two groups that have no input into the client’s treatment, family (66%) and 
friends (52%) are rated as the most likely to pressure methadone clinic participants to get off 
their medication. Methadone clients faced significant pressure to get off their medications by all 
groups (see Table 4.27). 
Table 4.27  
Mean, Standard Deviation, and Percentage Distributions for Methadone Clients Experiencing 
Pressure to Get Off Their Medications      
 












Provider       
    N = 174 
3.19 
(1.60) 
15.1 29.7 6.9 21.7 12.6 12.0 
My Counselor   
   N = 174 
2.92 
(1.50) 
18.4 35.6 9.2 16.1 13.8 6.9 
Family 
Member      
  N = 166 
3.97 
(1.70) 
9.6 19.3 4.8 19.3 24.1 22.9 
Probation 
Officer 
      N = 90 
3.29 
(1.70) 
20.0 20.0 11.1 20.0 17.8 11.1 
CPS Worker     
   N = 82 
   3.17 
(1.70) 
    22.0 26.8 4.9 12.2 26.8 7.3 
Friends     
 N = 162 
3.47 
(1.60) 
11.1 24.7 12.3 21.0 19.8 11.1 
 
Pressure medical providers felt to get their clients off medication.  Medical providers 
are the central figure that coordinate care and provides for methadone and bup/nal to be 
administered to clients who are in treatment for opioid dependence.  They appear as the most 





they experience a significant pressure from clients (69%) as well as family members (81%), 
counselors (42%), CPS workers (39%), and insurance providers (78%) to get patients off 
methadone and bup/nal.  Of interest is that medical providers feel the most pressure from family 
members and insurance providers to get their clients off medications. Medical provides faced 
significant pressure to get their clients off medications that were helping them in the treatment 
and recovery process by all outside non clients groups (see Table 4.28). 
Table 4.28  
Mean, Standard Deviation, and Percentage Distributions for Medical Providers Experiencing 
Pressure to Get Their Patients Off Medications That Assist in the Treatment of Opioid 
Dependence (Methadone, Bup/nal, Vivitrol) 
 
Groups That  











Clients   
   
3.71 
(.94) 






















4.8 14.3 2.4 19.0 45.2 14.3 
 
Philosophies and Beliefs on Medication Assisted Treatments                                                                    
Methadone has been a longstanding medication for treating opioid dependence and dates 
back to approval for use in the United States in 1947. There remain both downsides and benefits 
of the use of this well-known and well researched medication for its use in the opioid treatment 





4. What underlying beliefs and philosophies explain the similar or different views of the 
four groups?  
5.  What implications do these differences have for each group of participants in the 
opioid dependence treatment field? 
Downside of medication assisted treatment. Narrative responses shed light on the 
respondent group views on each medication.  There is some overall consensus on the harmful 
side effects, including the dependency caused by daily dosing and safety issues like overdose.  
Methadone.  With respect to the downsides of methadone, medical professionals’ focus 
is related to safety issues, side effects and difficulty in withdrawing the medication. One medical 
doctor summed it up by stating, “Most methadone patients are dosed daily at clinics with clientele 
who are frequently involved in drug abuse and crime, and they display drowsy and drugged behavior 
and it is very hard to taper them off.”   CDPs express more concern for its long term use, lack of 
plans to taper clients off, impairment, functioning level, and lack of what they believe is true 
“recovery.” CDPs overall reported more negative attitudes toward methadone. A CDP reported, 
“I have not seen clients achieve much of anything except staying high.  Methadone is a joke and I 
have not seen one client at these clinics that wasn’t using.”  Methadone clients focus mostly on the 
detrimental physical/medical effects, and on how it impacts them personally as they have the 
most firsthand knowledge of methadone’s side effects. They also felt the dependence on both the 
medication and the clinics made them feel like they were in a “Liquid handcuffs, I don’t feel like I 
am in recovery and it is more addictive than heroin.”  Bup/nal clients have minimal respect for 
methadone and rate it as ineffective when they did express their opinions on methadone it was 





heroin except I know what is in it, and the withdrawal is worse than heroin. I don’t think it works and 
to me it is just a free high” (see Table 4.29).  
The themes identified below are a result of content analysis, grouping responses and  that 
included word repetitions and searching for key-words-in-context (KWIC). The resulting 
grouping of responses were then categorized and recorded in the table below.   
Table 4.29  





















Social stigma  





Dependent on clinic & 
medication  
Cognitive impairment 
Loss of teeth 
Weight gain 
Intoxicating effects 
Cross addiction  
Clients should taper off  
Not treatment or 
recovery  






Makes sleepy  
Cognitive impairments 
Decreased libido 
Loss of teeth  
Memory loss  
Difficulty getting off —
withdrawal  
Feeling judged   
Stigma.  
Not in recovery  
Ball and chain dependency 
Makes you sleepy  
Very difficult to get 
off methadone  
Withdrawal  
Overdose risk  
Not recovery  







On the positive and beneficial side of the methadone spectrum, medical providers cite 
wealth of research data, best practice and the benefits of methadone in keeping patients alive, 
and engaged in treatment services. They appeared more scientific in the explanation of 
methadone’s benefits by reporting “Methadone maintenance is well established and has shown 
clear evidence of its effectiveness. It helps people stay clean and avoid relapse. It gives them their 
lives back.”  CDPs see some similar benefits in that it cuts down the death rate, keeps clients 
engaged in treatment and cuts the spread of communicable diseases while being under medically 
managed care. They do understand and list the benefits of methadone maintenance treatment and 
recognize its place in their field of practice. A CDP displayed the reality that “Methadone 
maintenance is well established and has shown clear evidence of its effectiveness. It helps people 
stay clean and avoid relapse. It gives them their lives back.”  Methadone clients report gratitude for 
how medication has positively impacted them, as some see it as a lifesaving service.  It came as 
little surprise that the methadone clients surveyed were overall the most positive about the 
medication as they were participating in something that many felt not only improved their 
situations, but actually saved their lives. There were many positive sentiments expressed by 
methadone clients including, “I don’t use anymore, it has helped me out a lot and I would be dead 
without it,” and “It saved my life, I don’t use heroin or inject myself. I don’t have to wake up sick or 
be in the rat race that is heroin addiction.”   Bup/nal clients do not report many positives in regards 
to methadone nor did they see the value of methadone. As one bup/nal client stated “To me there 








Table 4.30  




























Medically managed  
Cuts heroin use  
Stops spread of Hep C and HIV 
Decreases ER visits 
Reduces crime 
Reduces relapse  
Evidenced based  
Lowers death rate 
Keeps clients engaged in treatment 
Saves lives  













May help some 
  
 
Bup/nal.  Bup/nal has only been used for opioid dependence in the United States since it 
received FDA approval in 2004. Since that time this newer medication has been widely utilized 
in the field of opioid dependence and is now a more widely used medication than methadone. 
Medical providers, CDPs, methadone clients, and bup/nal clients gave narratives on their views 
of both the downsides and benefits of bup/nal as used to combat opioid dependence.  
Medical providers were mostly concerned with the diversion, cost, and access to bup/nal, 
while promoting positive views on its effectiveness, safety, and the growing body of evidence 





destructive lifestyle to recovery. A bup/nal doctor said “It’s not perfect, but it is far and away the 
best we’ve got, it is too bad there are not more doctors willing to get on board with this needed 
treatment.” While another pointed out “there is just a growing body of evidence for bup/nal 
effectiveness and I am really amazed at the transformative effects it has on my clients.”  
CDPs report more negative views than the other three groups, and are quick to point out 
the issues of  lack of recovery, the inability of clients to taper off medications, poor collaboration 
between themselves and medical providers, and what they feel is just switching one drug for 
another or cross addiction. “Some people think it is a panacea and addiction is deeper and more 
complex than just taking a pill to make you feel okay.  People get hooked on bup/nal too, and so 
it just becomes another substance that my patients get addicted to.”  CDPs do see the benefits of 
bup/nal treatment and rate it higher than methadone maintenance therapy in the areas of 
functioning level, safety, and ability to fit nicely with CDP treatment services.  “Bup/nal fits 
nicely with treatment” stated one CDP and he went on to say, “I have seen the greatest benefit 
with bup/nal.  People are able to engage in employment, counseling, parenting, etc. without 
being as sedated as with methadone.”   
Methadone clients mostly did not respond to the open ended question about bup/nal, but 
did note some drawbacks related to bup/nal use, including cost, taste, and ineffectiveness, while 
also reporting that bup/nal did help by blocking the opioid effects and being a safe and 
manageable medication.  One respondent stated, “I don’t trust Suboxone® [bup/nal] . . . it makes 
me sick, terrible side effects, it’s like poison.”  On the positive side, however, current methadone 
clients like the notion of getting more flexible take home privileges, and how bup/nal helps with 
cravings and withdrawals.  A methadone medication treatment client reported “[With Suboxone®] I 





Bup/nal clients noted some minimal negative side effects, including daily dependence on 
the medication and that it blocks the opioid effects, but they also touted the benefits, for example 
saying, “It’s great I can’t even get high if I wanted to, but with Suboxone® I don’t even think 
about using. I really don’t believe there are any downsides, what took them so long to discover 
this drug.” Most bup/nal clients touted the benefits that they have experienced in being on the 
medication.  These benefits included a more normalized life, where they were able to get back to 
a functioning life that included important things like family, jobs, and freedom from the stress of 






Table 4.31  
Narrative—Downsides and Benefits of Bup/nal for Medical Providers, CDPs, and Methadone 
















Cost & access 
Not enough 
providers 
Cost &  access 
Street value 
Diversion 




Lacks acceptance in CDP 
field 
Stigma 
CDPs won’t work with 
clients on bup/nal 
Poor collaboration with 
medical providers 
Clients not motivated 
Harm reduction is not 
treatment 
Withdrawal--trading one 
addiction for another cross 
addiction 
Treats symptoms not cause 







Don’t like the way it 
makes me feel 
No relief from 
cravings and 







NO drawbacks to 
bup/nal 
Being dependent on 
clinic & meds 
Having to take daily 









Helps with detoxing 
Cravings 























evidence  of 
effectiveness 
Prevents overdose 
Works well with treatment 
Flexibility/freedom no daily 
visits 
Feel normal 
Higher functioning level 
Stabilizes 
Better treatment and success 
Medically managed 
Ease of dosing 
Cuts down criminal behavior 




Can get from doctor 
without clinic 
Don’t have to come to 
clinic  daily 
Freedom 
Can’t get high 
Blocker 
Easier to kick 





Relieves obsession  & 









s comments (lots of 
those) 
 
Naltrexone Injectable (Vivitrol).  Although naltrexone is not an opioid like its 
methadone and bup/nal counterparts, it is used in both oral and injectable forms to occupy the 
opioid receptor sites and block the effects of opioid ingestion. As such vivitrol is also used as a 
medication to assist in opioid dependence treatment. Vivitrol is starting to gain some traction in 
the opioid treatment field, but as noted in the narrative responses lags in the shadows of the more 
popular methadone and bup/nal medications.  All three respondent groups were asked about the 
downsides and benefits of vivitrol.  
Medical providers cited painful shots, possible tissue injury, as well as the lack of 
research literature on efficacy as their main concerns about vivitrol.  They reported that “Most of 





using it as I have when I use suboxone.”  Providers did embrace the positive sides of this once a 
month opioid blocking injection, pointing out that “It’s great and there is little risk of abuse or 
diversion, and its opioid free so I don’t have to concern myself with withdrawals or overdosing.” 
Medical providers also liked the benefits of once a month injections, the non-addictive nature, 
and the absence of any withdrawal effects.   
All groups cited the lack of information, knowledge and experience with vivitrol as a 
current hindrance to full acceptance and use in the opioid treatment field.  CDPs saw difficulties 
with patients being off opioids long enough as a barrier, along with lack of follow through, and 
the absence of counseling/treatment services to coincide with the monthly shots. “There just is 
not enough evidence to justify the cost and I have just not experienced that much success with 
those that got the shot.”  CDPs did embrace the lack of diversion potential, blocking of opioid 
effects, and the removal of opioid cravings as positives.  Vivitrol is viewed more positively by 
CDPs as compared to both the medical providers and active clients on methadone and bup/nal. 
Some CDPs felt “it is the best treatment out there, and it really helps with cravings as well as 
taking away the option to use opioids.” This mindset by CDPs that vivitrol is preferred 
medication to its opioid counterparts most likely reflects the consistent and persistent mindsets 
that CDPs adhere to in abstinence-based paradigms that reflects their education and training.  
Methadone and bup/nal clients were mostly unknowledgeable or inexperienced with vivitrol as a 
medication assisted treatment. There were only a few narrative responses focused on this drug. 
Overall there appears to be a lack of both education and experience related to vivitrol by current 







Table 4.32  
Narrative—Downsides and Benefits of Vivitrol (naltrexone) for Medical Providers, CDPs, and 
Methadone and Bup/nal Clients  
 
Medical Providers CDPs Clients 
Methadone  Bup/nal  
Downsides 
Painful shots 
Tissue injury at injection 
site 
Risk of OD once off 
Difficulty in starting due to 
window off opioids needed  
Patients don’t like  
Not effective  
Lacking evidence to 
support 
Cost 
Patients not as committed 
to recovery process  
Poor follow up on shots  
Side effects 
Cost 
Lack of research  
Poor follow through/no 
second shot 
Switch to non-blocked drugs 
(meth, cocaine)  
Increased chance of over dose 
when discontinued 
Not popular with clients 
Doesn’t address addiction 
issues 
Not effective or popular 














this medication  
Benefits 
Non addictive 
No diversion potential 
No high Infrequent dosing-
once a month 
Prevents relapse  
Minimal side effects 
Patients more committed 
and motivated 
Good  after detox 
Removes cravings  
Blocks opioids 
Once a month dosing 
Cannot be manipulated 
No street value 
Low diversion potential 
Reduces OD Stabilizes 
Best option/best treatment 






Once a month 
dosing 
Good as a backup 
plan 






Medication assisted treatment.  Medical providers, CDPs, and methadone and bup/nal 
clients also addressed questions about their beliefs, philosophies, and feelings about the use of 
medications to assist in the treatment of opioid dependent people. There was some agreement 
that more needs to be done to help those affected. The bup/nal client group reported a more 
positive experience and outlook than did their methadone counterparts who felt more judged, 
criticized and looked down upon. The methadone clients reported more marginalization of their 
lives and circumstances by all involved. Medical providers appeared to embrace medication 
assisted treatment as an effective and viable evidence based practice, while the CDP were more 
critical of medications, and their use in the treatment process.  CDPs were very outspoken in 
both their cynicism and criticism of the opioid treatment process that utilizes methadone and 






Table 4.33  
Narratives––Other Thoughts About the Use of Medications to Assist in the Treatment of Opioid 







Methadone  Bup/nal  
Wish I had magic bullet 
Need public education 
Access and ease to 
treatment 
Counseling not effective 
MAT effective so treat 
as a CHRONIC disease 
Medications good, 
access and delivery lag 
Medications are 
short term solutions 
Need counseling for 
best outcomes  
Substituting, not 
getting to cause 




be time limited 
Outpatient treatment 





Medications not the 
answer, must be 
abstinent.  
Use heroin legally  
Feel judged, losers, 
homeless junkies, 
uneducated, stigma 
Cure is worse than 
addiction 





Side effects bad 
 long term effects 
unknown 
Gratitude, saved my 
life, would be dead 
without it 
Need to expand access 
Saves lives, brings 
families together 
Has helped with alcohol 
and other drugs 
Works, stops cravings, 
blocks opioids 
Need a timeline to get 
off medication 
Safe alternative 
Educate public more 
 
 Recovery.  All survey participants were asked to define what “recovery” meant to them 
as it relates to opioid dependence. There were a lot of similarities and differences across groups. 
Medical professionals and CDPs tended to have lengthier definition that included better overall 





complexities of the recovery process and they included a variety of holistic and individualized 
set of circumstances that included wellness, and functionality. The methadone and bup/nal 
clients who were involved in the process of recovery, saw things on a more personal and intimate 
scale. Their answers were much shorter and succinct and included many of the very basic tenants 
of recovery of being clean and rebuilding their broken spirits and self-worth. Several methadone 
clients noted that some use of opioid was acceptable (see Table 4.34). 
Table 4.34  
Narrative––What Does “Recovery” as It Relates to Opioid Dependence Mean for Medical 
Providers, CDPs, and Methadone and Bup/nal Clients  
 
Medical Providers CDPs  Client 
Methadone  Bup/nal 
Having a happy, 
productive life 
Free from illicit drugs, 
working steps, recovery 
Job, education, family 
higher functioning 
Control cravings, stabilizes 
life medically 
Acceptance of medications  
Need more than 
medications 
Behavioral adaptation, 
spiritual journey with love, 
forgiveness, and discovery.  
Living life without 
illicit drugs 
Functioning to best of 
ability, reach 
individual potential 
Process of change in 





Returning to healthy, 
stable life, without 
obsession & 
compulsion  
No one right answer 
 
 
Off heroin  
Of streets, no illegal 
Harm reduction, so 
irregular use is 
recovery 
Path of progress and 
change, not 100% 












Being a normal civilized 
human, not using any 
opioids 
Getting my life back, able 
to function 
Family, job, no legal 
problems. 
Self-worth and growth in 
all life areas.  
New lifestyle, values, 
morals, attitude  
Free and less stress 
Change in all areas of life 
Being clean, body, mind, 







 Any additional thoughts.  A final open ended question asked for any additional thoughts 
about medication assisted treatment. Medical providers had very thoughtful comments about 
their reflection on where the field is at, the limitations, and the areas of needed expansion. They 
acknowledge that they are a long way from effectively treating all of those in need or negatively 
impacted. CDPs also clearly saw the limitation of medication assisted treatment, some embraced 
the help it produces, while other remained skeptical about using an opioid to address the 
problem. CDPs see this as an epidemic and report the need for more resources and tools to help 
their clients overcome this chronic disorder. Methadone clients add in a mix of complaints about 
the negative effects of the medications and the methadone medication treatment process, while 
also seeing how methadone absolutely saved their lives and helped them on their road to 
recovery. Bup/nal clients appeared much more positive about the help they were receiving and 
the progress they had made in recovery from opioid dependence that all the other groups. They 
expressed much less concern and reported fewer negative opinions they did their methadone 






Table 4.35  
Narrative—Additional Thoughts About Medication Assisted Treatment for Medical Providers, 







Methadone  Bup/nal  
Good success for some 
not a silver bullet 
Trying to find the best 
option for everyone, 








Only a start, more 
advances needed 
Cost and insurance is a 
limitation.   
Expand research on 
vivitrol, and newer 
medications.  
Office based MAT 
good option with other 
treatment components 
 
U.S. behind advances 
in other countries.  
MAT needs to be 
between the provider 
and client & 
individualized 
New paradigms that 
include MAT 
Counselors under 
resourced and pay 
Need FULL MAT 
acceptance, still new 
Epidemic, treat earlier 
and as chronic  
MAT works well if 
done correctly, but 
pros and cons 
Need public education 
and acceptance 
 Get tougher on 
clients,  
Medications do not 
work 
Policies need to 
work toward treating 
illness not punish 
No time limits on 
treatments/meds 
Hope and success 
Methadone is a bad 
drug. 
Opioid addiction is 
complex 




to change is key 
Positive experience  
Support and 
understanding great.  
Never felt Judged 
More help, people in 
family still dying 
Never let MAT stop. 





support and counseling 
all together for best 
outcomes.  
New clean and sober 
life, bup/nal saved my 
life.  
 
 Table 4.36 presents a quick overview of the detailed findings discussed above.  The table 





medical provider, CDP, methadone and bup/nal client respondent.  That is, where over half of 
the responses were in the stated category.  A discussion of findings follows in Chapter V.   
Table 4.36  
Summary—Typical Responses for Medical Providers, CDPs, Methadone and Bup/nal Clients  
Summary Medical 
Providers 
CDPs  Methadone 
Clients 
Bup/nal Clients 
Age Majority older, 
no under 30,  
Younger group, 




group, under 50 
Gender Majority male Majority female Majority female Majority female 
Work setting Majority 
outpatient 
bup/nal 
 N/A N/A 









than 1 year 
Majority 2-3 
years or more 
Medications used Majority 
bup/nal 
   




years or more 
Majority 2 
years or less 
In Recovery?  
N/A N/A 











years or less 
Perception of treatment 


















Okay Okay Okay Well 
Progress by 
Counselors 
Well Well Well Very Well 
Progress by 
Communities 
Not very well Not very well Not very well OK 
Progress by 
Clients 
OK OK Well Well 
Progress by 
Family and friends 
OK OK Well Very Well 




Stabilize only Long as needed N/A 
Length time on bup/nal Long as 
needed 
Stabilize only N/A Long as needed 
Length time on vivitrol Long as 
needed 
Stabilize only  N/A N/A 






























Effective N/A N/A 
Involved in decision to 







Involved in decision to 









Involved in decision to 






Involved in decision to 
get off meds 
Family 
Disagree Disagree Disagree Agree  
Helpfulness of  
counseling 









Very Helpful Very Helpful 
Helpfulness of  12 step 
support 
Helpful Helpful Not to helpful Helpful 









Helpfulness of  
combination of  
counseling and 
medications, UA’s and 
12 step support 





Suffer judgment Agree Agree Strongly agree Agree 
Seen  as chronic disease Strongly 
agree 
Agree Agree Agree 
Clients not motivated Strongly 
disagree 
Disagree Disagree Disagree 






Issues about treatment 
Time limited 
Disagree Agree Disagree Disagree 
Issues about treatment 
Long term goal off 
meds 




Issues about treatment 





Strongly agree Agree 
Issues about treatment 






Strongly agree Agree 
Issues about treatment 









Issues about treatment 









Challenges clients face 
Dependent on 
medications 







Challenges clients face 
Shame 
A challenge A big challenge 
Somewhat of a 
challenge 
Not much of a 
challenge  
Challenges clients face 
Not being trusted A challenge A challenge 
 
Somewhat of a 
challenge 
 Somewhat of a 
Challenge  
 
Challenges clients face 




Somewhat of a 
Challenge 
Challenges clients face 




 Less of a 
Somewhat of a 
Challenge 
Current views on 
medication assisted 
treatment 




Current views  
encouraging clients to 
get off medications 
Don’t 
encourage to 
get off meds 
Somewhat 
encourage to 
get off meds 
N/A N/A 
Pressure to get off 
medications 
Feels pressure   N/A 
Lots of 
pressure  







Chapter V: Discussion of Findings 
The field of medication assisted treatment has been around for over 60 years; however, 
the practice was primarily limited to methadone clinics in the United States until 2004 when 
buprenorphine/naltrexone, under the brand name Suboxone, was approved by the FDA for use in 
the treatment of opioid dependence. In the subsequent years the adoption and use of medications 
to assist in treatment services has jumped dramatically to an unprecedented level. The number of 
clients being treated for opioid dependence has burgeoned from only 250,000 nationwide to over 
700,000 today (United Nations Office on Drugs and Crime, 2010). Medical providers and 
treatment programs have struggled to keep up with advancements in the field. This steep rise in 
both the breadth and scope of the problem has left a gap in how clients are addressing their 
opioid dependence and highlights the emergence of how both medical providers and CDPs 
address the issues associated with medications. Medication assisted treatment outside of the 
traditional methadone clinics was virtually unknown before this decade. Therefore counselor, or 
CDP, knowledge and scope of practice with these clients was limited. There was also a shortage 
of medical providers working outside of methadone clinics that fully understood the implications 
and effectiveness of medication assisted treatment. Thus, this research study was designed to 
collect, understand, summarize, and analyze the present attitudes, beliefs and practices within the 
field from the perspective of the medical providers, CDPs, and opioid dependent clients.  
Opioid dependence and addiction remains a threat to public health in the United States as 
well as around the world. This public health crisis has been labeled as an “epidemic” by many of 
our national leaders, including the President of the United States. The use of prescribed 
pharmaceutical medications as well as illicit opioid related drugs (heroin, morphine, etc.) 
continues to marginalize many in our society. These powerful drugs and medications that were 





pain and suffering for those affected, their communities, their families, and our modern day 
society.  
 Much of the previous research in this field focused on the efficacy of available 
medications utilized in medication assisted treatment for opioid dependence (Volkow, Frieden, 
Hyde, & Cha, 2014a).  Methadone is one of the most well-known and studied medications.  
Bup/nal has undergone many research trials and double blind studies in order to more recently 
gain FDA approval (Kosten, Schottenfeld, Ziedonis, & Falcioni, 1993). Naltrexone (Vivitrol) has 
also been studied and all of these mediations continue to be evaluated by treatment professionals, 
pharmaceutical companies, and researchers (Fram et al., 1989). This study was designed to 
uncover issues that are not well studied and to add to the body of knowledge in the opioid 
dependency treatment field by taking a deeper look into the complex dynamics that take place 
with the three primary player groups in the treatment and recovery process. Medical providers, 
CDPs, and the clients they serve make up the crux of the recovery platform and more research 
focus on the beliefs and attitudes toward the treatment process for these parties could benefit 
those who suffer. It is imperative that the process of change involved in the treatment and 
recovery from opioid dependence be better understood and evaluated. It starts with identifying 
the attitudes and beliefs that these three groups hold.   In addition, the research design and data 
are meant to add to the body of knowledge within the opioid dependence, recovery, and 
treatment field especially as it relates to the new and widening best practice of medication 
assisted treatment. Opioid replacement medications and the field of addiction medicine continue 
to undergo important changes as medical science works to understand the physiology and 
pharmacology of what the medical field calls a chronic brain disorder. The traditional paradigms 





dependence and recovery. This study examines professional and client views of length of time on 
medications, decision on weaning off, effectiveness of the currently utilized medications, 
benefits and drawbacks of each medication, helpful components of the treatment process, 
defining recovery, as well as a variety of other important treatment issues.  
The research questions were addressed and findings related to research questions 1, 2, 
and 3 about the existence and nature of differences in opinions about medication assisted 
treatment issues across provider and client groups were explored.  Statistically significant 
differences in attitudes were found on most issues, including  length of time on medications, 
effectiveness of medications, helpful components of the treatment process, decisions about 
discontinuing medications, long term goals of medication assisted treatment, and the overall 
progress of the field of medication assisted treatment showed different attitudes and beliefs 
among the groups.    Research question 4 about what underlying beliefs and philosophies and 
research question 5 about the implications of these differences were also explored and discussed 
below.   
Methods and Procedures  
This research utilized a comparative mixed methods study with survey data collection 
focused on attitudes, beliefs, and practices of the three participant groups—the “three legged 
stool” in the field of medication assisted treatment for opioid dependence and recovery. Analysis 
included descriptive and comparative t-test and ANOVA statistics with post hoc analysis. 
Quantitative and qualitative data were collected via a survey. 
This study was designed to identify differences and similarities across the three legs of 
the stool in the field of medication assisted treatment—medical providers, CDPs, and clients. It 





treatment (Volkow et al., 2014b)  is preferable to not receiving these services. It is important to 
point out that “one size does not fit all” when it comes to treating this complex brain disease.  
Participants and Sample Size 
The study population included 45 medical providers, 199 CDPs, 199 methadone clients, 
and 137 bup/nal clients.  Medical providers included prescribing physicians, and physician’s 
assistants that worked in opioid dependency and medication assisted treatment settings 
throughout Washington State. CDPs, also known as addiction counselors, counsel and oversee 
each opioid dependent client. Client respondents had been diagnosed as opioid dependent and 
were participating in one of two opioid treatment programs in Washington State—one 
methadone and one bup/nal clinic.  
Demographics  
 Medical providers were on average older than both the CDP and client respondent 
groups. The methadone and bup/nal client groups were younger than both of the professional 
provider groups. The bup/nal group was the youngest of all participant groups, with the majority 
of client participants between the ages of 21 and 40.  Over half (55%) of the clients respondents 
and about two-thirds of the CDPs were female, which was similar to the CDP gender distribution  
statewide.  The opposite was true for the medical provider group which was largely male. This 
was somewhat higher than statewide, where 52% of practicing physicians are male (Washington 
State Health Services Research Project Research Brief #66). The sample of medical providers 
was a good cross representation of those working in the outpatient treatment practice field. There 
are 22, primarily methadone, outpatient treatment practices in Washington State, whereas there 
are several hundred doctors who engaged in office based bup/nal practices. The survey sample 





 The CDPs are much like many other helping professions in that this work draws more 
interested female professionals (i.e., nursing, social work, counselors). Interestingly, even though 
statistics show that (Unger, Jung, Winklbaur, & Fischer, 2010)  more males are diagnosed with 
opioid dependence in the general population, the majority of those seeking help and enrolled in 
opioid treatment programs are female participants. It can be theorized that females go for 
professional help at higher levels than their male counterparts. This certainly holds true for 
gender access to other medical services (Bertakis, Azari, Helms, Callahan, & Robbins, 2000)  as 
well. The medical provider group continues to be a male. Although this trend is changing (Allen, 
2005)  it appears to hold for the older group of medical providers surveyed in this research. The 
length of time in the opioid treatment field for medical providers and CDPs appeared evenly 
spread from one year to 21 years of service or more; however, the CDP group did have more 
professionals with fewer years of experience.   
 The work setting of medical providers and CDPs was important to this research in order 
to understand the context of experiential knowledge in the opioid dependence treatment field. 
Medical providers were predominantly from bup/nal programs with inpatient, detox, and mostly 
outpatient office based practice providers. Only a small group of the medical provider 
respondents worked in methadone clinics. Medical providers in this study for the most part 
perceived bup/nal as their medication of choice and only about one-fourth of providers treated 
clients with methadone. Methadone is a tightly regulated schedule 2 narcotic and controlled 
substance, so its use in the medication assisted treatment field is limited to federally and state 
licensed opioid treatment programs. The majority of CDP respondents worked in outpatient 
settings, with about half of each of those either having services that provide medications to assist 





work settings that included detox, methadone clinics, and inpatient treatment programs. Overall 
the CDP respondent group was a good representation of treatment settings across Washington 
State. The CDP survey respondents were a very good cross sample of professionals currently 
working in the field of substance abuse counseling. Their work settings, and time in the field 
demonstrated a variety of settings where they practiced. These were not just professionals 
working in primarily methadone outpatient treatment practices, or but represented a range of 
CDP positions in Washington State.   The clients were selected from two licensed and state 
certified opioid treatment programs—a methadone clinic in the inner city of Seattle, Washington, 
and a rural area bup/nal clinic located on a Native American reservation in the Northwest 
Washington area. There were some distinctive cultural differences that could account for some of 
the client research findings. The methadone group was from a large ethnically diverse urban, 
primarily Caucasian and African American, in the Seattle, Washington area. The bup/nal clients 
were representative of a smaller, more rural and tightknit Native American community.  Ethnic 
background was not collected in the survey; however, ethnic differences were clear given the 
locations of the clinics and observation during the survey collection process. My research field 
experience during clinic survey data collection in the methadone and bup/nal clinics represented 
contrasting treatment delivery models. The methadone clinic had a more harried and sterile feel 
toward the delivery of medicaitons, and the bup/nal clinic was smaller in nature and provided a 
more nurturing environment.  
The majority of methadone client participants had been participating in clinic services for 





two to three years. Bup/nal is a fairly new medication in the field of study as compared to 
methadone. The bup/nal clinic participants have only had access to medication assisted treatment 
since 2006 and their particular clinic setting has only been in operation since 2013.  
 Methadone clinic participants primarily self-reported themselves as being in recovery 
from opioid dependence; however, some were ambivalent about their recovery status as nearly 
one-fourth of them chose the yes, somewhat versus yes, definitely in recovery option.  Bup/nal 
clinic participants overwhelmingly had the self-perception that they were in recovery, with 
almost all of them responding that they were definitely in recovery.  Bup/nal clients also 
self-reported being in recovery for longer periods of time than their methadone counterparts.  
Both groups of client participants self-reported that the clinic services they were receiving were 
helpful. This sample was a good cross representation of Washington State OTP clinic 
participants that number 4,500 (SAMHSA—Substance Abuse and Mental Health Services 
Administration brief 2015).  
Survey Instrument  
The data collection instrument used for this research project was a 21–29 question survey 
that covered the topics related to medication assisted treatment.                                                                               
Statements related to attitudes, beliefs, and practices about medication assisted treatment 
had 6-point Likert-type response scales, including strongly disagree to strongly agree, not at all 
effective to very effective, and not at all helpful to extremely helpful.  Specifically, the issues 
covered were: respondents’ attitudes toward medication assisted treatment; how strongly they 
believe in the efficacy of current opioid treatments; effectiveness of medications; how long 
treatment should last; the drawbacks of each therapy; long and short term treatment goals; 





judgment, or continued marginalization.   There were also several open-ended questions 
designed to encourage respondents to share their stories related to their attitudes, beliefs, and 
practices about medication assisted treatment for opioid dependence. Although the same core 
questions were asked of survey respondents from all three respondent groups, additional 
questions were also asked of each individual group. The survey also collected some demographic 
information, including age, gender, length of time working in the opioid addiction field, type of 
treatment modality, and length of time in recovery.  
Major Findings  
Three categories of major findings are discussed below.  These include (a) differences 
between provider groups (medical providers and CDPs, (b) differences between methadone and 
bup/nal (buprenorphine/naloxone) clients, and (c) cross differences across all respondents 
groups.  There were statistically significant differences for almost all of the issues addressed by 
the survey questions.  
 Overall progress and effectiveness of medication.  The use of medications in the 
treatment process for opioid dependence is a key advancement in the field and thus why, in 
today’s opioid treatment field, best practice is noted as medication assisted treatment (Center for 
Substance Abuse Treatment, 2005).  With relapse rates noted as high as 95% with traditional 
psychosocial treatments that involve cognitive behavioral approaches, the implementation of 
adding medications to assist in the treatment and recovery for opioid dependent individuals has 
been key. Medical providers and CDPs were asked about the overall progress in the field of 
medication assisted treatment and the effectiveness of medications. They had significantly 
different points of view.  These results are consistent with findings patterned throughout this 





the medical providers. These findings contradict current research that clearly demonstrates the 
effectiveness of medications that are currently being used and accepted as best practice by the 
medical professionals and leading researchers (Compton & Volkow, 2006a; Koob, 2009; Koob 
& Le Moal, 2005; Koob & Volkow, 2010). 
  With the ever changing landscape, national focus, and advancements in medications, this 
study first looked at how medical providers and CDPs perceived overall progress in the field. 
Medical providers noted more progress being made in addressing the problem of opioid 
dependence than did their CDP counterparts.  What factors possibly account for these 
differences? When one looks at the education and training differences between groups, it must be 
noted that medical providers undergo extensive and rigorous training in order to get licensed as a 
physician. They are traditionally trained to prescribe medication to assist them in the daily job 
duties as a helping professional and are accustomed to utilizing medications for many different 
forms of recovery from injuries and illnesses. CDPs have a much lower threshold of both 
educational and internship/training requirements in order to obtain licensing. Chemical 
dependency training programs are mostly conducted by two-year community college programs 
where the curriculums require no classes in medication assisted treatment. Thus, these two 
groups have different backgrounds, professional experiences, and educational requirements in 
order to become licensed and considered experts in their fields. CDPs and medical providers not 
seeing the same level of progress in the opioid treatment practice field has huge implications for 
those who are undergoing treatments and working to get into recovery. CDPs have much more 
face time and one-on-one contact with those in treatment, and by implication, greater influence 
on their clients, and possibly a more in-depth view of how clients, their families, and 





Medical providers and CDPs also had different views on the effectiveness of current 
medications. Medical providers have the responsibility to understand the current research about 
the effectiveness of each of the three primary medications studied. Methadone, 
buprenorphine/naloxone (Suboxone®), and naltrexone (Vivitrol) are all medications that have 
undergone double blind clinical trials in order to be shown as effective in the treatment of opioid 
dependence. Medical providers must have firsthand working knowledge of these studies and 
what is considered best practice in their fields. They undergo additional training in these 
medications in order to certify themselves as opioid treatment providers. Workshops, trainings, 
and continuing education all keep medical providers informed on the latest information about 
this complex field and the challenges they face with clients who suffer from opioid dependence. 
Utilizing medications to assist in the treatment and recovery process is part of the medical 
providers’ scope of practice.  It is for these reasons that medical providers are on the cutting edge 
of how these medications are working or not working with the clients they are responsible to 
serve. Do no harm is the Hippocratic Oath undertaken in medical school and played out in daily 
practice. Many have studied and been exposed to the harm reduction model of addiction 
treatment services and use this way of thinking and being as they navigate opioid treatment 
services.  
 CDPs take a curriculum of courses that make up their chemical dependency educational 
requirements, and participate in a 1500–2500 hour internship at a Washington State certified 
treatment agency as trainees before they become fully licensed. Some CDPs have come into the 
field because of personal firsthand experience as a recovering alcoholic/addict. Because of their 
experience and training, the focus and goal of recovery has primarily been to be completely 





influenced their attitudes toward medications.  This mindset is in direct contrast to the medical 
providers in the field.  The burgeoning field of medically treating opioid dependence and the 
rapid advancement that accompanied it left a gap for the CDPs to fill. They are professionals that 
counsel and guide clients into the recovery process and typically have more one-on-one face time 
and have developed a deeper level of trust, rapport, and discourse with affected clients. The 
licensing process for CDPs has not changed in decades and remains in this state much the same 
as it did when I was certified 28 years ago—all pre-medication assisted treatment. There are no 
formal classes or educational requirements that are mandated as a part of CDP licensing for 
medication assisted treatment. Many CDPs have had to learn this new paradigm of treatment by 
workshops or firsthand experience and on the job training. CDPs approach their chosen 
profession with a lot of heart and passion for what they do. They adhere to a guiding principle to 
help others. They have their clients’ best interests in mind as they guide, teach, and counsel them 
to rebuild their shattered lives. CDPs are very important and primary participants in the treatment 
and recovery process since they spend the most time face to face with recovering clients in 
opioid treatment programs and therefore have a lot of emotional equity and influence with opioid 
treatment participants. CDPs are also asking the more difficult and far reaching questions that 
many times are overlooked by the medical professionals as they take a wider and more holistic 
approach to their work, helping clients navigate in the larger, not just physical, world.  
Methadone and bup/nal client group differences.  Originally this study was focused on 
medical providers, CDPs, and clients who were active participants in opioid treatment programs 
in Washington State. However, because of the design of the two clinics where I collected 
surveys, I had two distinct opioid treatment respondent groups—199 surveys from methadone 





group results emerged. These included views on the treatment components, their own feelings, 
who should be involved in making the decision to get off medications, the long term goal of 
medication assisted treatment, and the downsides and benefits.   
Treatment components. When looking at components of treatment that were helpful, 
methadone clients were less likely than bup/nal clients to view counseling as helpful. Methadone 
clients also viewed the 12 step support self-help meetings as less helpful than did their bup/nal 
counterparts. This pattern of differences continued when respondents were asked about 
accountability via observed urine drug screens—methadone clients again saw this component of 
the treatment process as less helpful than the bup/nal clients.  In terms of the combination of 
counseling and medications, once again methadone clients found these significantly less helpful 
than did the bup/nal clients. Much of the previous literature does not break out the various 
components of treatment as was addressed in this inquiry.    
 Client feelings. When it came to feelings of being marginalized (judged, criticized, seen 
as not clean, feeling shame, being misunderstood, etc.) the methadone clients were significantly 
more likely to agree that they felt negatively judged by others while they were on the 
medications that were helping them gain and maintain recovery. Methadone clients viewed 
feelings of shame more of a challenge than did bup/nal clients. There were similar findings for 
feelings of being dependent on the medications, not being trusted, being criticized, and being 
misunderstood.  
Who should be involved in making decision about getting off medications. Bup/nal 
clients were more likely than methadone clients to agree that family members could be involved 
in the determination of their getting off medication. Methadone clients mostly disagreed with this 





perspectives.  This was beyond the scope of this inquiry; however, the why could have important 
implications for successful treatment.    
Long term goal of medication assisted treatment.  Methadone clients also were more 
likely to disagree that the long term goal of medication assisted treatment was to get off all the 
medications used for opioid treatment. Again, methadone clients were more likely than bup/nal 
clients to agree that it is okay if they stay on medication assisted treatment for life if need be.  
Downsides and benefits.  On narrative responses that inquired about the positives and 
downsides of both bup/nal and methadone, the methadone clients had a longer list of the medical 
and physical issues related to methadone, including constipation, weight gain, and decaying 
teeth. Overall they reported more complaints about the medication and did not report the level of 
gratitude and positive effects of the medications and treatments as did their bup/nal counterparts. 
Both methadone and bup/nal groups did report the treatment they were receiving as being 
helpful.  
 Across providers (medical and CDP) and client (methadone and bup/nal) group 
differences.  There were several issues related to medication assisted treatment on which opinion 
varied across both provider (medical and counseling) and client (methadone and bup/nal) groups. 
 Support. All respondent groups were asked how various supporting groups (physician 
and medical providers, counselors, local communities, clients themselves, family and friends) 
were doing in meeting the needs of people who suffer from opioid dependence. Bup/nal clients 
were more likely than methadone clients and CDPs to respond that their physicians and medical 
providers were doing well at addressing their needs.   
Both the CDPs and the bup/nal clients perceived the counselors in a better light than the 





the treatment process higher and bup/nal clients tended to agree. Bup/nal clients rated their 
family and friends more positively than did all other groups, although methadone clients also 
rated their family and friends as doing better than did the medical providers or CDPs did. 
 Both methadone and bup/nal clients were united with a higher assessment of how clients 
themselves were responding than the paid professionals (medical providers and CDPs).   Each 
group rated themselves the highest in responding to the needs of those affected. Counselors felt 
counselors responded better, medical providers thought medical providers responded better, and 
clients felt they did better. A natural bias is demonstrated.   
Helpfulness of treatment component. Opioid treatment programs have other components 
besides just medication dosing and medication management, so respondents were also surveyed 
about various components of the treatment process and asked how helpful they were. Those 
components identified and surveyed included medication, counseling, accountability via 
monitored urine drugs screens, 12-step support, and combinations of the four components listed. 
All respondent groups were asked about the helpfulness of the various components of the 
treatment process.   
Counseling. Counseling was viewed as helpful by all respondent groups. However, 
methadone clients and medical providers saw counseling as significantly less helpful than both 
the bup/nal clients and CDPs.  
Medications. All groups rated medications as helpful or very helpful.  However, the 
CDPs mean scores for helpfulness of medications were significantly lower than those of the 
medical providers and both the methadone and bup/nal clients.  
The 12-step support and accountability urine analysis. The 12-step support and 





clients viewed these two treatment components as less helpful than medical providers, CDPs, 
and bup/nal clients.   Methadone clients did rate accountability with urine drug screening as 
somewhat helpful, but this was significantly lower than the medical providers, CDPs, and 
bup/nal clients. These differences may be related to how methadone clients more frequently felt 
judged, criticized or stigmatized at self-help support groups.  
Urine drug screens and 12-step support both had methadone clients as lower in 
helpfulness than the other three groups. Methadone clients felt urine drug screens and 12-step 
support groups were less helpful than the bup/nal clients and the two professional groups. 
Methadone clients in particular reflected a view that 12-step support groups were not helpful. 
The traditional 12-step support groups of Alcoholics Anonymous, Narcotics Anonymous, 
represent the primary self-help support that many clients in substance abuse treatment programs 
attend as a part of their treatment program. Probation officers and the legal systems that clients 
are involved with often mandate attendance at these AA/NA meetings. Even though clinicians 
and providers see them as helpful components of recovery, methadone clients have reported 
feeling negatively judged, criticized, and generally marginalized at these self-help meetings.  
Component combinations. When the 12-step support and urine analysis accountability 
were combined to include counseling and medications, all groups rated the pairing of these 
components as helpful; however, the methadone group again differed from the other three groups 
with a lower helpfulness rating. The last treatment option combined counseling, medication, and 
accountability via urine drug screens, and these results indicated that both methadone and 
bup/nal groups viewed this combination as less helpful than the CDP and medical provider 





 Communities. The lowest ratings for all groups related to how respondents felt their local 
communities were doing at responding to their needs. The two professional groups, medical 
providers and CDPs, saw the local community response to this epidemic as not doing very well. 
The methadone and bup/nal groups’ perception of community response was only slightly higher, 
leaving a lot of room for improvement in their community’s response.  
My experience has been that those outside the field of study continue to judge and 
marginalize those who are afflicted, especially for clients in methadone.  This is evidenced by 
the lack of understanding of the disease process, and conservative approaches that tend to 
moralize opioid dependence as a “choice.” Communities are resistant to allowing opioid 
treatment programs to get licensed, and public hearings in this process bring out the opposition to 
an expansion of services that are meant to help. Professionals in the field understand and 
experience this lack of community support   
Considered clean on medications.  One statement asked if clients should be considered 
“clean” or drug free if they were on opioid replacement medications like bup/nal and methadone. 
While medical providers, methadone clients, and bup/nal clients agreed to this notion at mean 
scores that were consistent with each other, the CDP group was less likely to agree that people 
on these medications were clean. Although clients use these terms in responding to themselves, 
narrative responses made the point that the clean and dirty terms were words that only 
marginalized clients seeking treatment and recovery and that some thought these terms should be 
abolished from use in the field of medication assisted treatment. Results were also consistent 
with the thinking that medication assisted treatment participants were somehow not fully seen as 
successful because of the use of medication to aid in this process. CDPs were, however, less 





clients. People who are not in the substance abuse treatment field might agree with this 
statement; however, for trained addiction treatment specialists to hold these beliefs and attitudes 
toward clients on medication is troubling. Is this how clients are looked at while following their 
approved treatment regimens? The results suggest that the substance abuse counselor continues 
to agree to language that marginalizes and judges clients as they are trying to help in the 
recovery from opioid dependence. If the CDPs do not believe in the efficacy of the medication 
and continue to see their clients as not being in recovery when they are on medication, then one 
has to wonder what impact this has on clients who are using their counselors as guides in the 
recovery process. 
Length of time and time limits.   Medical providers and CDPs were asked whether opioid 
dependent clients should be allowed to stay on medications as long as needed and this was 
followed by a question about whether medication assisted treatment should be time limited. 
Medical providers, methadone clients, and bup/nal clients disagreed with the statement that 
medication use in opioid treatment should be time limited, whereas CDPs agreed with this 
statement.  These groups consistently appear to be on opposite ends of the spectrum—clients in 
treatment and their medical providers voice strong sentiment that clients should be on 
medications for as long as the need, while CDPs’ attitudes are the polar opposite and 
demonstrate support for medications being strictly time limited.  
 Each medication was also addressed separately. The first was methadone. Bup/nal clients 
were not asked their opinions on methadone, and methadone clients were not asked for input on 
bup/nal as it was thought best for clients to respond only to the medications they were currently 
utilizing in their treatment programs.  Both methadone clients and their prescribers 





The opposite trend was noted by the CDPs; their responses generally indicated that methadone 
was good for detox, stabilization, and periods of time up to two years. Only a minority of CDPs 
saw the need to allow clients to be on methadone for as long as they needed. 
The identical pattern of response was noted for bup/nal. Clients and medical providers 
overwhelmingly responded “for as long as needed,” whereas CDPs were looking for the use of 
bup/nal in a time limited fashion, for detox or shorter term stabilization. Buprenorphine, a third 
medication which is a variant of bup/nal, recorded the same patterns of response. A fourth and 
less frequently used medication, naltrexone (Vivitrol), was also put to the length of time inquiry. 
A word of note here is that a naltrexone injection, which lasts for 30 days but can also be taken 
as a daily oral medication, is a pure opioid blocker and possesses no opioid properties. 
Methadone and bup/nal clients had little working knowledge of this medication and therefore 
were not polled. Again a majority of medical providers supported naltrexone’s use for as long as 
needed in the recovery process while CDPs continued their consistent response rates that 
included stabilization.  A good portion of CDPs had no working experience with naltrexone and 
a small percentage even responded that it could be used for detox purposes, a use that naltrexone 
is contra indicated for.  
Responses to time limits highlight the biggest threat to successful client outcomes. 
Narrative responses also were consistent as many CDPs continued expressing concern over 
medications and their beliefs that clients over the long run needed to be off all medications in 
order to properly and fully recover. I do understand the CDPs’ thinking process on this measure 
as they want complete and full “recovery” from this disease.  However they differ in their views 





This length of time issue represents the most controversial and often discussed question 
from not only medical professionals, CDPs, and clients but other professionals, the general 
public, and family members. Many times I have heard challenges and negative comments on 
how long clients should be able to stay on the medications that many times are helping them gain 
and maintain their recovery from opioid dependence. It seems everyone has a strong opinion on 
this issue and are willing to express and give free and often times unsolicited advice. Many 
analogies have been offered, but when was the last time anyone asked you how long you had to 
be on insulin for your diabetes, or blood pressure medication? The issues about the length of 
time clients should take their medication is complex and not easily solved.  Clients in medication 
assisted treatment are individuals that have different pathways into addiction as well as different 
pathways into recovery. Medications and medication management fall under the licensure and 
scope of practice of medical professionals, but that does not stop friends, family members, 
spouses, and clients’ counselors from sharing their opinions and expertise.  
 This finding supports the need for CDPs to get additional training on available 
medications that are currently being utilized in the field of opioid dependence treatment services.   
Long term goal of medication assisted treatment.  The statement that the long term goal 
of medication assisted treatment should be that clients are free from illicit opioids and all 
medications used in the treatment process had the least support from medical providers.  Both 
methadone and bup/nal clients as well as CDPs were significantly more likely to agree that the 
long term goal should be for clients to be off all medications. The CDP group agreed with this 
way of thinking at levels significantly above all other groups.   
Support for medication assisted treatment.  There was across the board support for 





concept of medication assisted treatment at significantly higher levels than the CDP group.   
CDPs also had higher levels of agreement that clients should be given the chance to get clean 
without the use of medication.   These results are consistent with the lower level of CDP support 
for medication assisted treatment.  
 Who should be involved in making decisions about getting off medication. Another 
primary issue is related to the views about who should be involved in the decision for clients in 
opioid treatment programs to get off their medications. One might initially think that this 
decision should be solely between the medical provider and the clients who are taking the 
medications; however, other views were clearly possible.  When asked for their level of 
agreement about who should be involved in the decision to discontinue mediations from the 
standpoint of physicians, counselors, clients in treatment, and family members the results were 
curious.  Methadone clients were less likely than medical providers, CDPs, and bup/nal clients 
that physicians should be involved in the decision. CDPs were significantly less likely to agree 
that counselors should have a say in discontinuing their medication.   Methadone clients 
consistently answered lower on several scales related to time on medications, and decisions to 
get off medications. It appears that methadone clients sought more control and less outside 
interference (even with their prescribing physicians) when it came to these central issues related 
to time on medications. Further inquiry into this dynamic is worth noting and is a 
recommendation for further research.  
The highest level of agreement between all respondent groups was noted when asked 
about clients having a say about when they should get off their medications. The CDP group had 
less agreement than the clients that clients should be involved in the decision.  Why would 





clients about their input into discontinuing medication? This appears to reflect the attitudes and 
beliefs held by CDPs that clients should only utilize mediations for shorter time periods, such as 
for detox and stabilization.  
Medical providers, CDPs, and clients in opioid treatment programs did not support family 
member input into the decision of when to get off medications, although curiously bup/nal clinic 
participants were more agreeable to family input.  
Client feelings.  As expected, clients, medical providers, and CDPs indicated they 
thought that clients who participated in medication assisted treatment for opioid dependence are 
negatively judged until they discontinue the use of medications. All groups had high levels of 
agreement, however methadone clients had higher levels of agreement that they felt negatively 
judged and marginalized for being on methadone.  There remains a lot of work to be done by 
providers and professionals in the field to advocate and educate others to combat these pervasive 
and divisive attitudes that remain a daily constant to clients who are attempting recovery from 
opioid dependence. If opioid dependence is truly an epidemic in this country and other places in 
the world, then solutions will certainly include a wide acceptance of what researchers and 
providers consider best practice. All surveyed groups, especially medical providers, view opioid 
dependence as a chronic disease. Chronic disease by definition lasts for long periods of time, if 
not for the lifetime. However a very pervasive attitude and many analogies and metaphors 
indicate beliefs that opioid dependence is an acute condition.   
Motivation to change.  Another popular belief held by many hinges on the change 
dynamic and motivation to change. Respondent groups were posed a statement that people on 





to that statement with the medical providers indicating stronger disagreement. Interestingly 
however the CDP group disagreed less heartily.  
Long term goal.  Medical providers highly disagreed while CDPs highly agreed that the 
long term goal of mediation assisted treatment was to be free from both illicit drugs and all 
medications that assisted them in the process. It is clear that the attitudes and beliefs of the 
professionals involved do not align and have implications for the clients they serve are 
concerning. Imagine yourself a client in this scenario where your prescribing physician 
encourages and supports you to continue your course of treatment and consults with you about 
how the medications are working, with no mention of stopping or titrating off, but then as you go 
into your counseling session your CDP asks about your long term goals, and asks how long you 
think you need to stay on the medication, or worse yet, encourages you to discontinue taking it.  
Clients may find themselves confused and uncertain about their recovery status. This small 
scenario highlights the dilemma of having two professionals with very different attitudes about 
one’s treatment and recovery program.  
 All groups shared agreement that they supported medication assisted treatment. CDPs 
demonstrated lower levels of agreement. When asked whether clients should be allowed to get 
clean without the use of medications, there were moderate levels of agreement by all groups, but 
again the CDP group was more likely to agree with this statement. The implications are 
enormous since it is the CDPs who must first assess for opioid dependence and then discuss 
treatment options with clients before they are referred to the medical providers. In order to be 
eligible for medication assisted treatment clients must have an official diagnosis by their CDP; 
however, if the CDP holds the belief that the client should first have the chance to go to a 





receive the proper treatment. This in turn could have negative consequences and in some cases 
cause more harm than good. Determining which client is a good candidate for medication is a 
difficult task.  I would not want to be the CDP responsible for this decision and would prefer to 
consult with a medical provider who has more training in medications. Scope of practice 
continues to be an important part of this critical dialogue, and “staying in your lane” is an 
important teaching when dealing with decisions that can affect a person’s health and wellbeing. 
Conclusion 
 Opioid abuse and dependence is a public health threat and epidemic here in the United 
States and requires a dedicated focus and leadership among health care providers. One aspect of 
this battle deals with the solution driven practices that attempt to help those affected to overcome 
their dependence on opioids. Medication assisted treatment services are well researched and 
documented and this body of knowledge in the field of opioid dependence has been adopted as 
best practice by the leading practitioners and agencies that are experts in the field (Volkow et al., 
2014b).   The American Medical Association, Substance Abuse and Mental Health Services 
Administration, and The American Society of Addiction Medicine have all adopted medication 
assisted treatment as cutting edge accepted treatment practices in today’s landscape.  
 This study sought to shed light on the complexities of the treatment practices that take 
place between the three primary participants in this important work. Research designed to 
unpack the underlying beliefs and attitudes that guide best practice is important. The deep and 
complex treatment practices that help medical providers, CDPs, and opioid dependent clients 
require inquiry to help aid in this epidemic. Research findings that add to the body of knowledge 
in the field of medication assisted treatment can be beneficial to all involved and lead to changes 





 Findings of this study help open the dialogue and bring professional discourse into the 
continued conversations about opioid dependence and recovery. The challenge lies in making the 
study findings aid all participants in the opioid treatment and recovery process and to examine 
and reflect on their approaches in treating this chronic medical disease.   
 Medical providers represent leaders in the field in the fight to achieve recovery. Their 
experience and education continues to evolve as they advocate for the use of new and advancing 
medications in the struggle to overcome insidious dependence on opioid drugs and the personal 
and societal harm inflicted by misuse, abuse, and dependence of both prescribed pharmaceuticals 
and illicit opioids. Medications are only one tool that medical providers have at their disposal, 
and even though research validates medication effectiveness, it cannot be viewed as the panacea. 
Complicated issues never come with easy solutions, and medical providers must continue to 
remain open in their thinking to counseling, 12-step support, spiritual guidance, and other helpful 
components that clients and CDPs identify as helpful pathways into recovery. Medical providers 
as leaders in the field must continue to work with other professionals to communicate, 
collaborate, and cooperate in the opioid treatment and recovery process. As long as they continue 
the conversation in a professional and respectful manner they will lead by example and work to 
be part of the solution.  
 CDPs and addiction counseling specialists across the United States also play a critical 
role in the well documented struggle for viable opioid treatment services and recovery from the 
disease. CDPs have a leadership role that cannot be minimized or downplayed as they have been 
tasked as professionals in their chosen field of study to have a major impact with clients who 
suffer. CDPs often times have the most “face time” through one-on-one counseling relationships, 





medication assisted treatments. Their vital and important impact on clients and the recovery 
process requires continued vigilance, study, and a way to keep updated to best practices and stay 
on top of the ever changing landscape of valid and credible treatment practices. This study’s 
findings point to adopting some changes in beliefs, attitudes, and practice for CDPs as they are 
challenged to move forward with solution driven services. Understanding their own experiences 
and bias that they have internalized is crucial to their advocacy for recovery with their clients and 
how they communicate with other professionals in the field of medication assisted treatment. 
Full recovery cannot take place without CDPs recognizing their strengths and limitations. CDPs 
have been educated and trained philosophically toward abstinence based paradigms. These 
traditional paradigms are undergoing strain and stretching the understanding of CDPs who 
struggle to meet the challenges that the use of opioid based medications plays in the recovery 
process adds to the recovery dynamic. There remains much work to be done for CDPs to fully 
accept the new landscape of opioid dependence, medication treatment, and recovery. As with the 
medical providers, CDPs must continue to work with an open mindset and stay engaged in 
professional discourse in order to collaborate and cooperate with other addiction specialists and 
especially with the clients that are the core focus of their chosen profession.  
 Clients who suffer from this debilitating disease can teach us a lot about the pathways 
into and out of opioid dependence. It is their voices, beliefs, and attitudes that require intense 
focus and understanding because they have the most to gain and lose in the process of treatment 
and recovery. The importance of client driven data cannot be overstated. Clients make up a 
group of affected individuals whose struggles impact families, communities, and the greater 
society.  They must continue to be seen and treated as individual human beings. As such they 





experiences and voices from opioid dependent individuals point to the negative judgment, 
labeling, criticizing, blame, and debilitating marginalization by society. Clients are in need of 
effective and helpful treatment and recovery services, and have embraced medications as a part 
of the solution to their personal dilemmas. It is time for all providers to listen carefully to client 
experience and opinion as they seek solutions to rebuild the shattered spirits, personal dignity, 
and worth that many times opioid dependency has taken from them. Clients have a personal 
responsibility in this process and must be open to guidance by those that have both received 
education and training and also “been there done that.” They must also continue to communicate, 
collaborate, and cooperate with the treatment professionals and take an active role in their 
personal recoveries. It is only through working together that all parties will experience the rich 
and rewarding experience of freedom and recovery.  
Study Implications 
 The current study findings have far reaching and serious implications for all involved in 
the field of medication assisted treatment and opioid dependence recovery. Opioid use disorder 
constitutes a national health problem and continues to represent a current epidemic in the U.S 
and around the world.  The implications for each of the study groups are discussed below.  
 Medical providers. Medical providers face many challenges as they treat this complex 
and progressive brain disorder. As a group they are at the forefront of the treatment process for 
opioid dependent individuals. This study demonstrated the challenges that they as medical  
providers face in their daily work. They often times are criticized for not getting clients off 
medications, feel pressure from addiction counselors to reduce dose amounts, or discontinue 
medication if clients are not in compliance with counselor or other components of the treatment 





work with in order to justify current best practice. Medical providers need to understand that it is 
up to them to educate others involved with the treatment process about the importance of 
properly assessing the valid use of medications throughout the treatment and recovery process. 
They need to recognize the amount of misinformation that others have about the use of 
medications in the treatment process and the amount of resistance and skepticism that their 
clients face when involved in medication-assisted treatment. The implications this study holds 
for medical professionals as well as the clients they serve and the counselors who guide the 
recovery process is a model of fully integrated care. All groups need to understand and be open 
to their own bias and be willing to challenge themselves to set these aside for the best interest of 
the clients who suffer. The importance of having these groups work collaboratively cannot be 
overstated. Medical providers   need to ask far reaching questions about long term recovery and 
how that is defined with or without medications. Medications do have limitations and they are 
only one component of successful recovery; they are not a sliver bullet and the only pathway into 
recovery. Medical providers are in a leadership role in this important and often times life 
threatening illness, and as such have a responsibility to educate, advocate, and work with clients 
and all who are involved in the treatment and recovery process.  
 Chemical Dependency Professionals (CPDs).  CPDs and other substance abuse 
counselors providing direct psychosocial counseling and support services to opioid dependent 
clients represent a huge piece of the puzzle for opioid dependent individuals who are seeking 
relief and recovery. CDPs have a significant influence on the clients they serve and as such must 
recognize their scope of practice, role, experience, and expertise in the recovery spectrum. This 
study demonstrated the divergence in attitudes that CDPs have with regards to the medications 





research indicating the neuroplasticity of this chronic brain disease to fully comprehend the 
complexities of opioid dependence and the proper and legitimate use of medications that help 
clients achieve recovery. Based on study findings, CDPs could benefit from additional training 
and education about both the effects, and effectiveness of available medications, as well as on 
the nature of the addicted brains and the damage created by opioid abuse. A focus toward the 
best interest of their clients, possibly in some cases, less reliance on their own personal 
experiences of recovery could help bridge the gap that is evident between CDPs and medical 
providers. CDPs have a substantial impact with clients and much to offer the field of medication 
assisted treatment.  They must work toward a more integrated care model of treatment and 
recovery. Their role needs to be better understood and respected by the medical field as they help 
clients work toward long term goals, to cope with the negative responses they experience, and to 
a full and successful recovery. CDPs are helpers and as such want the best for their clients, they 
see recovery potential in each person they work with, and must recognize each individual’s 
pathways into recovery vary. A possible fourth leg of the stool recognizes the importance of 
family being involved in the education, treatment and recovery process and future research could 
provide some focus and recommendations in this important arena. Full acceptance of medication 
to assist and treat opioid dependence appears a lofty challenge to all CDPs, however continued 
insistence on dogmatic approaches that include complete and total abstinence as the criteria for 
recovery in the light of medical research findings are dangerous and destructive for some clients. 
CDPs must challenge themselves to new ways of thinking and familiarize themselves with 
current research literature on opioid dependence, in order to break free from the limitations of 
their original training and experience that includes complete and total abstinence as the criteria 





 Clients recovering from opioid dependence. Client voices and their recovery from opioid 
dependence remain the most important single factor in this dialogue. This study demonstrated the 
importance of giving clients their voice as it relates to their own individual recovery. They 
literally are in the middle of the divergent approaches to help from the professionals.  At the 
same time they experience negative responses from their family members, friends, and others.  
Clients who suffer from opioid dependence are clearly helped by medications, with the aim of 
healing their damaged brains. They are the ones that need to be at the center of the discussion 
about what works best for each individual’s success. Clients who have been and continued to be 
negatively judged and marginalized for having this substance use disorder sometimes have 
difficulty acting confidently or competently enough to act in their own best interest. However it 
is in the clients’ best interests that they are factual and honest in their presentation to themselves, 
providers, and friends/family. It remains a tall order for recovering people to take personal 
responsibility in their recovery process, including their medications, counseling, and other forms 
of support in order to fully recover. Diversion of medications, continued relapse with 
pharmaceutical medications, and illicit drugs, are all issues that clients must face and overcome 
in order to demonstrate integrity in their personal recoveries and gain the trust of their providers.  
Study Limitations 
There are several limitation to this study. It was difficult to identify, contact and get 
medical providers to respond to the survey.  Thus, the sample size of N = 43 fell short of the 
study goal. Medical providers’ work settings were primarily outpatient bup/nal providers and 
more methadone clinic providers could have made results more robust, providing for the 
possibility of comparing bup/nal and methadone medical providers. The survey instrument had 





reflect a particular demographic area of the United States and may not generalize to other areas, 
countries, or cultures.  
The sample population was from the Pacific Northwest geographic region of the United 
States, specifically, Washington State, and thus might not be representative of other geographical 
areas. Since the survey was designed and first tested in this study, reliability and validity are yet 
to be established until the current study is replicated. There also remains the possibility of 
missing data as some participants carefully considered and answered all questions while others 
may have been hasty in their responses.  
Future Research  
Future research is indicated in several key areas of medication assisted treatment for 
opioid dependence. Clinical trials of medications continue to dominate the landscape of research 
in the field; however, what is lacking is deeper understanding of clients, CDP, and medical 
provider attitudes and bias as they relate to opioid treatment and recovery. What is indicated is 
further inquiry into how the clients and providers (both medical and psychosocial) view the 
process of treatment solutions and define what recovery means and what it looks like in today’s 
landscape. An additional and important area of inquiry would be to study family members, 
friends, and community attitudes about medication assisted treatment. Families and communities 
can play an important role in supporting and contributing to clients’ treatment and recovery.  
More qualitative inquiry could enhance deeper understandings of both the challenges and 
solutions by any of these three groups. Each supported finding is worthy of independent study. 
Issues related to length of time on medications, goals of opioid treatment and recovery, helpful 
components of the treatment process, and especially negative attitudes held about opioid based 





studies in order to add to the ever growing body of knowledge in the mediation assisted 
treatment field.   
Families and community members also have a role to play in addressing the opioid 
dependency epidemic.  Survey research for these groups, similar to the study of medical 
providers, CDPs, and clients would also add to the conversation and help in the search for 
solutions. 
Recommendations 
 The recommendations that come from the current study are not confined to a simple set 
of criteria; however, the complexities of both the process that leads to a very negative impulsive 
and compulsive use of opioids and the process leading to change and recovery are evident. It is 
important that each of these three important groups that is involved in solution based activities 
come together to practice integrated care. No groups have the one right answer, but collectively 
they possess the power, knowledge, and experience necessary to overcome this devastating 
conditions that effects millions. Easy solutions to complex problems rarely exist, and in the field 
of opioid dependence recovery utilizing medications to assist in the process constitutes the 
biggest advancement in the field over the past 60 years. With the addition of newer medications 
recently approved and adopted for practice, the recommendations for continued study, analysis, 
and shifting of paradigms for the “old” way of doing things in the addiction treatment field is 
paramount. We must keep focus on best practice and successful client outcomes to truly inform 
how providers, clients, and substance abuse counselors continue to move forward in the field of 
medications assisted treatment. This will only happen through treatment outcome data as  
providers and the programs they work for track client success and the components of care that 





 Scientists and researchers also need to help in this challenge by continuing their 
dedicated work in the fields of pharmacology, neurobiology, and brain chemistry in order that 
they lead the way and inform the field of addiction medicine as to best practices.  
Recommendations going forward from this research study include but are not limited to: 
 Mandated education classes as part of any core curriculum for the certification of 
chemical dependency licensing on “medication assisted treatment”; 
 Required continuing education (CEUs) for medical providers, chemical dependency 
counselors, and other professional working in the social science fields on opioid 
dependence, recovery, and medication assisted treatment; 
 More research focused on the deeper qualitative dynamics of the opioid treatment and 
recovery process; 
 Continued advocacy and voice at the policy level for substance abuse prevention and 
treatment, especially as it relates to opioid abuse and dependence; 
 Community education campaigns that help educated the general public about the field 
of medication assisted treatment, overcoming myths and misconceptions, and 
advocating for the expansion of opioid treatment programs and services for those that 
suffer from this chronic disease process; 
 Work to mandate a true “integrated care” model of medication assisted treatment 
between medical provides, CDPs, and the clients they both serve; and 
 Continue the medical and scientific work and research in order to understand the 
neuropathways involved in the addiction process, and how the brain is in effect 






My role as a leader in the area of substance abuse treatment and counseling was evident 
to me from the very first year that I entered personal recovery from substance abuse over 29 
years ago. My journey was to not only help myself overcome the demons and life shattering 
experiences that I encountered but also to leave the treatment and recovery field better than I 
found it. I felt that sharing my story, and personal experience, strength, and hope would 
demonstrate leadership by modeling. I knew through personal experience that leadership in those 
I admired, respected, and followed was a style that was more modeled by example than by 
words. Respect is a huge part of leadership and being able to gain that with family members, 
peers, and other leaders was how I carried myself. At the time I did not realize what I know 
today and that is the journey to both my personal healing and recovery and my leadership ability 
and focus represented a side-by-side process of change. During my life’s darkest time, something 
others describe as an emotional, physical, and spiritual bottom, I was consoled by a future 
mentor and leader who reassured me that change was simple and that all I would have to do was 
change ONE thing, and I thought what a relief I can do that, but after a long pause he said 
“everything.”  A change in my thinking, my feeling, and my entire way of being was indicated if 
I was to undergo the transformation from a broken drug addict to a true leader. The leadership 
potential was a value system that was embedded in me from my early upbringing in a small rural 
Nebraska community. Those that came before me taught and inspired me to be an independent 
thinker, to never give up, and to be interested in others, to give back, and to be a lifelong learner.   
My PhD in Leadership and Change began not as a professional goal and a stepping stone 
to enhance my professional career, but rather as a deep personal goal to validate my potential and 





as stated above I had undergone a personal transformation over the previous 20 years and as a 
result experience the personal freedoms associated with the promises of recovery. A personal 
mantra that ensued was taken directly from one of my guiding references, the Big Book of 
Alcoholics Anonymous, which stated: 
If we are painstaking about this phase of our development, we will be amazed before we 
are halfway through. We are going to know a new freedom and a new happiness. We will 
not regret the past nor wish to shut the door on it. We will comprehend the word serenity 
and we will know peace. No matter how far down the scale we have gone, we will see 
how our experience can benefit others. That feeling of uselessness and self-pity will 
disappear. We will lose interest in selfish things and gain interest in our fellows. 
Self-seeking will slip away. Our whole attitude and outlook on life will change. Fear of 
people and economic insecurity will leave us. We will intuitively know how to handle 
situations which used to baffle us. We will suddenly realize that God is doing for us what 
we could not do for ourselves. (pp. 83–84) 
 
And so the promises were personally manifested in my life, which led me to pursue my doctoral 
degree in this program at Antioch University in leadership and change.  
 While working in the substance abuse field I occupied many important leadership 
positions within a local Native American reservation as the Lummi people adopted me into their 
ways and practices. They allowed me to humbly direct youth leadership treatment and recovery 
programs, help build and enhance residential programs like the Lummi youth academy and the 
Se>eye>chen youth residential treatment program, as well as my current position as Director of 
the Lummi Healing Spirit Clinic. I have been allowed the honor of supervision and leading staff 
teams that included from 20–45 professionals. In my certification as a CDP I also aspired to 
leadership roles in my educational and scholarly pursuits. Most CDPs do not go beyond a two 
year associate degree in their training and certification process. I set my goals in leadership to 
gain a PhD as a CDP, which is something very few do. I felt that this would position me to be 
able to make the most impact in my field on inquiry and place me in a leadership role and 





afforded me all of those opportunities and more. My hopes and dreams as I graduate from this 
program is to humbly and respectfully carry the message to those who still suffer from not only 
substance abuse problems but life challenges as well. There is strength in change, and personal 
fulfillment in leadership. Many thanks for those individuals that inspired, motivated, supported, 




















































































































































































Appendix D: HSC Permission 
    LUMMI COUNSELING SERVICES 
Dr. Adam Kartman M.D. Medical Director 
2616 Kwina Road, BELLINGHAM, WA 98226 
(360) 380-7121      FAX: (360) 384-2350 
Antioch IRB                                                                                                           August 11, 2015 
RE: Healing Spirit clinic OTP Survey     
 
Dear Sir or Madam: 
 
Opiate dependence is a local, state and national problem. The number of opiate related deaths has 
tripled over the past 3 years. In Washington State it represents the number one cause of death for the 
age group 21-39.  
 
I have been working in the opiate treatment field for the past decade and have personally witnessed the 
devastation the affliction of opiate dependence causes individuals, their families and the community  
 
Traditionally Opiate Treatment Program (OTP) clinics have utilized the medication methadone, however 
with the recent approval of other medications the field of opiate dependence treatment has been 
expanding. Buprenorphine/Naloxone (Suboxone) was approved by the FDA in 2004 for OTP clinics and 
office base practice as well. Lummi’s OTP providing Buprenorphine/Naloxone and Naltrexone, but not 
methadone is unique.  
 
Many past and current research designs have documented positive outcomes due to the use of 
medications in opiate treatment programs. It is now considered best practice to utilize medications to 
assist opiate addicts in their recovery process. The addition of medication to counseling therapy is 






However in the field of opiate treatment there still remains controversy and concern among patients, 
their families and counselors about medication assisted treatment. There is work to be done to inform 
and educate people to the benefits of combining patient accountability through drug testing, counseling 
and medication assisted treatment. 
 
I fully support conducting a survey of opiate dependent clients in our clinic in order to learn more about 
underlying attitudes and beliefs about treatment services and medication. This information can be a 
benefit in improving services. As long as the information collected is anonymous and confidential, there 
should be no risk of harm to anyone. Clinic counselors will be available to talk with any survey 
participants as the need arises in case of any negative feelings or reactions.      
 




Dr. Adam Kartman M.D 
Lummi Healing Spirit Medical Director 
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